

Box 500

A

Atty Dkt No. 6064.US.P1
0200-0006.20

APPLICATION TRANSMITTAL LETTER

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

☒ "Express Mail" Mailing Label No. EM 336 912 047 US, Date of Deposit MARCH 31, 1998.
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed
to the Assistant Commissioner for Patents, Washington, D.C. 20231.

PATRICIA K HIMENES
(Typed or Printed Name of Person Mailing Paper or Fee)

Patricia K Himenes
(Signature of Person Mailing Paper or Fee)

Transmitted herewith for filing is the patent application of Patricia A. BILLING-MEDEL, Maurice
COHEN, Tracey L. COLPITTS, Paula N. FRIEDMAN, Julian GORDON, Edward N. GRANADOS, Mark
HAYDEN, Steven C. HODGES, Michael R. KLASS, Jon D. KRATOCHVIL, Lisa ROBERTS-RAPP,
John C. RUSSELL and Stephen D. STROUPE for REAGENTS AND METHODS USEFUL FOR
DETECTING DISEASES OF THE GASTROINTESTINAL TRACT, which is a continuation-in-part of
U.S. application serial no. 08/828,489, filed March 31, 1997.

Enclosed are:

8 sheet(s) of X formal ___ informal drawing(s).

___ A claim for foreign priority under 35 U.S.C. § 119/363 in
___ a separate document ___ the declaration.

___ A claim for priority under 35 U.S.C. § 119(e)(1) in
___ a separate document ___ the declaration.

___ A certified copy of the priority document.

___ Verified Statement(s) Claiming Small Entity Status.

X Other: Sequence Listing in paper form (pp. 90-100) Sequence Listing in computer readable
form; and Statement to Support Filing and Submission in Accordance with 37 C.F.R.
§§ 1.821-1.825.


The declaration of the inventor X is enclosed X unsigned.

The fee has been calculated as follows:

A. Basic Application Fee		\$790.00
B. Total Claims 39 - 20 = 19	x \$22.00	418.00
C. Independent Claims 20 - 3 = 17	x \$82.00	1394.00
D. If multiple dependent claims present, add	\$270.00	0.00
E. Total Application Fee (Total of A, B, C, & D)	=	2602.00
<hr/>		
F. If verified statement of small entity status is enclosed, reduce Total Application Fee by 50%		NA
G. Application Fee Due (E - F)	=	2602.00
<hr/>		
H. Assignment Recording Fee of \$40.00 if assignment document is enclosed	\$40.00	NA
<hr/>		
I. TOTAL FEE (G + H)		\$2602.00

Respectfully submitted,

Date: 3/31/98

By: 
Roberta L. Robins
Registration No. 33,208
Attorney for Applicants

ABBOTT LABORATORIES
100 Abbott Park Road
Abbott Park, IL 60064-3500
Telephone: (847) 937-0378
Facsimile: (847) 938-2623

Atty Dkt 6064.US.P1
PATENT

"Express Mail" Mailing Label No. EM 336 912 047 US
Date of Deposit MARCH 31, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

PATRICIA K HIMENES
Typed or Printed Name of Person Mailing Paper or Fee

Patricia K Himenes
Signature of Person Mailing Paper or Fee

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

BILLING-MEDEL et al.

Serial No.: CIP of 08/828,489

Group Art Unit: Unassigned

Filing Date: on even date herewith

Examiner: Unassigned

Title: REAGENTS AND METHODS USEFUL FOR DETECTING
DISEASES OF THE GASTROINTESTINAL TRACT

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The undersigned hereby states that the content of the attached papers and the computer-readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Date: 3/31/98

By: Roberta L. Robins
Roberta L. Robins
Registration No. 33,208
Attorney for Applicants

ABBOTT LABORATORIES
100 Abbott Park Road
Abbott Park, IL 60064-3500
Telephone: (847) 937-0378
Facsimile: (847) 938-2623

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"Express Mail" Mailing Label No. EM336912 047 US
Date of Deposit MARCH 31, 1998
I hereby certify that the enclosed material was deposited with the United States Patent and Trademark Office (USPTO) at the United States Patent and Trademark Office, 400 ...
-1-
PATRICIA K. HEMES
Patricia K. Hemes

Atty Dkt No. 6064.US.P1
PATENT

5

REAGENTS AND METHODS USEFUL FOR DETECTING
DISEASES OF THE GASTROINTESTINAL TRACT

Cross-Reference to Related Application

- 10 This application is a continuation-in-part of U.S. application Serial No. 08/828,489, filed March 31, 1997, from which priority is claimed pursuant to 35 U.S.C. §120 and which is incorporated herein by reference in its entirety.

Background of the Invention

- 15 The invention relates generally to detecting diseases of the gastrointestinal tract organs, and more particularly, relates to reagents such as polynucleotide sequences and the polypeptide sequences encoded thereby, as well as methods which utilize these sequences, which are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining predisposition to
20 diseases and conditions of the GI tract such as cancer.

- The organs of the GI tract include the esophagus, stomach, small and large intestines, rectum and pancreas. Of the approximately 225,900 new cases of GI tract cancer projected for the United States during 1996, 131,200 will be due to colorectal cancer. Further, GI tract cancers will account for
25 approximately 127,070 related deaths (American Cancer Society statistics). In addition to its high incidence, GI tract cancers can be extremely lethal; for example, greater than 97% of pancreatic cancer patients will die of the disease. H.J. Wanebo, et al., Cancer 78:580-91 (1996).

- Generally, the early detection of GI tract cancers at a pre-invasive stage
30 dramatically reduces disease-related mortality. However, only few GI tract cancers are detected at this stage. For example, only 37% of colorectal cancers are detected at this stage by screening for premalignant polyps which can be removed before they progress to cancer. The primary methods used for colorectal cancer screening are fecal occult blood testing (FOBT) and flexible
35 sigmoidoscopy. A. M. Cohen et al. In: Cancer: Principles and Practice of

Oncology, Fourth Edition, pp. 929-977, Philadelphia, PA: J/B. Lippincott Co. (1993). Although FOBT is noninvasive, simple and inexpensive, its sensitivity is low; for example, sensitivity for detecting colorectal cancer was only 26% in one study. D.A. Ahlquist et al., JAMA 269: 1262-1267 (1993). Further,
5 although flexible sigmoidoscopy is highly sensitive for detecting early cancer and precursor polyps, it is invasive, costly, and too technically demanding to be used for routine screening. D.F. Ransohoff, et al., JAMA 269: 1278-1281 (1993). In addition, only eight percent (8%) of pancreatic cancers and eighteen percent (18%) of stomach cancers are detected at a pre-invasive stage (American
10 Cancer Society statistics). Thus, the need exists for improved screening methods for detection of GI tract diseases such as cancer.

The standard procedures currently used for establishing a definitive diagnosis for a GI tract cancer include barium studies, endoscopy, biopsy and computed tomography (CT). These procedures are invasive and costly.
15 Moreover, an erroneous diagnosis can result from any of these procedures due to technical reasons, the subjective interpretation of results, or lack of sensitivity of the procedure. M. F. Brennan, et al. In: Cancer: Principles and Practice of Oncology, Fourth Edition, pp. 849-882, Philadelphia, PA: J.B. Lippincott Co. (1993).

20 After the diagnosis of a particular GI tract cancer is confirmed, staging is performed to determine the anatomic extent of the disease. Staging is performed by a pathologist on tissue obtained by biopsy and/or surgery. Accurate staging is critical for predicting patient outcome and providing criteria for designing optimal therapy. Inaccurate staging can result in poor therapeutic decisions and
25 is a major clinical problem in colorectal cancer. A need therefore exists for more sensitive diagnostic procedures for staging GI tract cancers.

While surgical resection of the affected organ is typical therapy for a majority of patients diagnosed with GI tract cancers, some patients undergo radiation and/or chemotherapy. All of these patients need to be monitored in
30 order to evaluate their response to therapy and to detect persistent or recurrent disease and distant metastasis. A variety of markers including CEA and CA 19-9 can be assayed and the assay results used to monitor a patient's progress in conjunction with radiological procedures and colonoscopy. E.L. Jacobs, Curr. Probl. Cancer 15 (6):299-350 (1991). These monitoring techniques, however,

have failed to provide an accurate and effective means to monitor the progress of these patients.

Assays based upon the appearance of various disease markers in test samples such as blood, plasma or serum obtained by minimally invasive techniques, could
5 provide low-cost and accurate information to aid the physician in diagnosing disease such as cancer, in selecting a therapy protocol, and in monitoring the success of the chosen therapy. Such markers have been placed into several categories. The first category contains those markers which are elevated in disease. Examples include human chorionic gonadotropin (hCG) which is elevated in testicular cancer and
10 trophoblastic disease, and alpha fetoprotein (AFP) which is elevated in hepatocellular carcinoma (HCC). E.L. Jacobs, supra. The second category includes qualitatively altered mRNA or protein markers in disease. Examples include mRNA splice variants of CD 44 in bladder cancer and mutations in p53 protein in lung and colorectal cancer. Y. Matsumura et al. Journal of Pathology 175(Suppl): 108A
15 (1995); W.P. Bennett, Cancer Detection and Prevention 19 (6): 503-511 (1995). The third category includes those protein markers which are normally expressed in a specific tissue, organ or organ system but which appear in an inappropriate body compartment. For example, prostate specific antigen (PSA) is a normal protein which is secreted at high levels into the seminal fluid. PSA is present in very low
20 levels in the blood of men with normal prostates but markedly elevated in the blood of patients with diseases of the prostate, including benign prostatic hyperplasia (BPH) and adenocarcinoma of the prostate. At high levels in the blood, PSA is a strong indicator of prostate disease. P.H. Lange et al., Urology 33 (6 Suppl): 13 (1989). Similarly, carcinoembryonic antigen (CEA) is a normal component of the
25 inner lining of the colon which is present in blood at low levels in people without colon disease. E. L. Jacobs, supra. However, the CEA concentration is markedly elevated in the blood, plasma or serum of many patients diagnosed with colon disease including inflammatory bowel disease and adeno-carcinoma of the colon, and is used as an indicator of colorectal disease.

30 There are yet other examples of detecting disease markers in an inappropriate bodily compartment. In the case of metastatic cancer, the blood, bone marrow or lymph nodes may contain cells which have originated from the primary tumor and which may express mRNA or protein markers representative of the primary tumor. For example, CEA and PSA have been demonstrated immunohistochemically in
35 lymph nodes or bone marrow of patients with metastatic colorectal cancer and

prostate cancer, respectively. B.R. Davidson, et al., Cancer 65:967-970 (1990); J.L. Mansi, et al., J. Urol., 139:545-548 (1988). In addition, RT-PCR has detected CEA and PSA mRNAs at distant sites in patients with colon and prostate cancer, suggesting the presence of metastatic cells. M. Gerhard, et al., J. Clin. Oncol. 12:725-729 (1994); A.E. Katz, et al., Urology 43:765-775 (1994). Other
5 compartments in which the inappropriate appearance of normal gene products may be indicative of disease include but are not limited to, whole blood, urine, saliva, and stool. Currently, no universally acceptable marker(s) exist(s) for the early detection of pancreatic, stomach, and esophageal cancers. Further, improved
10 markers are needed to detect colorectal cancer.

It therefore would be advantageous to provide specific methods and reagents for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining predisposition to diseases and conditions associated with the GI tract or to indicate possible predisposition to these
15 conditions. Such methods would include assaying a test sample for products of a gene which are overexpressed in GI tract diseases and conditions such as cancer. Such methods may also include assaying a test sample for products of a gene alteration associated with the GI tract disease or condition. Such methods may further include assaying a test sample for products of a gene whose
20 distribution among the various tissues and compartments of the body have been altered by a GI tract-associated disease or condition such as cancer. Useful reagents include polynucleotide(s), or fragment(s) thereof which may be used in diagnostic methods such as reverse transcriptase-polymerase chain reaction (RT-PCR), PCR, or hybridization assays of mRNA extracted from biopsied tissue,
25 blood or other test samples; polypeptides or proteins which are the translation products of such mRNAs; or antibodies directed against these proteins. Drug treatment or gene therapy for diseases or conditions of the GI tract then can be based on these identified gene sequences or their expressed proteins, and efficacy of any particular therapy can be monitored. Furthermore, it would be
30 advantageous to have available alternative, non-surgical diagnostic methods capable of detecting early stage GI tract disease such as cancer.

Summary of the Invention

The present invention provides a method of detecting a target CS141
35 polynucleotide in a test sample which comprises contacting the test sample with at

least one CS141-specific polynucleotide and detecting the presence of the target CS141 polynucleotide in the test sample. The CS141-specific polynucleotide has at least 50% identity with a polynucleotide selected from the group consisting of SEQUENCE ID NO 1, SEQUENCE ID NO 2, SEQUENCE ID NO 3, SEQUENCE ID NO 4, SEQUENCE ID NO 5, SEQUENCE ID NO 6, SEQUENCE ID NO 7, SEQUENCE ID NO 8, SEQUENCE ID NO 9, SEQUENCE ID NO 10, SEQUENCE ID NO 11, SEQUENCE ID NO 12, SEQUENCE ID NO 13 ("SEQUENCE ID NOS 1-13"), and fragments or complements thereof. Also, the CS141-specific polynucleotide may be attached to a solid phase prior to performing the method.

The present invention also provides a method for detecting CS141 mRNA in a test sample, which comprises performing reverse transcription (RT) with at least one primer in order to produce cDNA, amplifying the cDNA so obtained using CS141 oligonucleotides as sense and antisense primers to obtain CS141 amplicon, and detecting the presence of the CS141 amplicon as an indication of the presence of CS141 mRNA in the test sample, wherein the CS141 oligonucleotides have at least 50% identity to a sequence selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof. Amplification can be performed by the polymerase chain reaction. Also, the test sample can be reacted with a solid phase prior to performing the method, prior to amplification or prior to detection. This reaction can be a direct or an indirect reaction. Further, the detection step can comprise utilizing a detectable label capable of generating a measurable signal. The detectable label can be attached to a solid phase.

The present invention further provides a method of detecting a target CS141 polynucleotide in a test sample suspected of containing target CS141 polynucleotides, which comprises (a) contacting the test sample with at least one CS141 oligonucleotide as a sense primer and at least one CS141 oligonucleotide as an anti-sense primer, and amplifying same to obtain a first stage reaction product; (b) contacting the first stage reaction product with at least one other CS141 oligonucleotide to obtain a second stage reaction product, with the proviso that the other CS141 oligonucleotide is located 3' to the CS141 oligonucleotides utilized in step (a) and is complementary to the first stage reaction product; and (c) detecting the second stage reaction product as an indication of the presence of a target CS141 polynucleotide in the test sample. The CS141 oligonucleotides selected as reagents in the method have at least 50% identity to a sequence selected from the group

consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof. Amplification may be performed by the polymerase chain reaction. The test sample can be reacted either directly or indirectly with a solid phase prior to performing the method, or prior to amplification, or prior to detection. The detection step also
5 comprises utilizing a detectable label capable of generating a measurable signal; further, the detectable label can be attached to a solid phase. Test kits useful for detecting target CS141 polynucleotides in a test sample are also provided which comprise a container containing at least one CS141-specific polynucleotide selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or
10 complements thereof. These test kits further comprise containers with tools useful for collecting test samples (such as, for example, blood, urine, saliva and stool). Such tools include lancets and absorbent paper or cloth for collecting and stabilizing blood; swabs for collecting and stabilizing saliva; and cups for collecting and stabilizing urine or stool samples. Collection materials, such as papers, cloths,
15 swabs, cups, and the like, may optionally be treated to avoid denaturation or irreversible adsorption of the sample. The collection materials also may be treated with or contain preservatives, stabilizers or antimicrobial agents to help maintain the integrity of the specimens.

The present invention also provides a purified polynucleotide or fragment
20 thereof derived from a CS141 gene. The purified polynucleotide is capable of selectively hybridizing to the nucleic acid of the CS141 gene, or a complement thereof. The polynucleotide has at least 50% identity with a sequence selected from the group consisting of (a) SEQUENCE ID NOS 1-9, SEQUENCE ID NO 12, SEQUENCE ID NO 13, and complements thereof, and (b) fragments of
25 SEQUENCE ID NOS 1-9. Further, the purified polynucleotide can be produced by recombinant and/or synthetic techniques. The purified recombinant polynucleotide can be contained within a recombinant vector. The invention further comprises a host cell transfected with the recombinant vector.

The present invention further provides a recombinant expression system
30 comprising a nucleic acid sequence that includes an open reading frame derived from CS141. The nucleic acid sequence has at least 50% identity with a sequence selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof. The nucleic acid sequence is operably linked to a control sequence compatible with a desired host. Also provided is a cell transfected with
35 this recombinant expression system.

-7-

1 The present invention also provides a polypeptide encoded by CS141. The
polypeptide can be produced by recombinant technology, provided in purified form,
or produced by synthetic techniques. The polypeptide comprises an amino acid
sequence which has at least 60% identity with an amino acid sequence selected from
5 the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25,
SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and
fragments thereof.

Also provided is an antibody which specifically binds to at least one CS141
10 epitope. The antibody can be a polyclonal or monoclonal antibody. The epitope is
derived from an amino acid sequence selected from the group consisting of
SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26,
SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof. Assay kits
for determining the presence of CS141 antigen or anti-CS141 antibody in a test
15 sample are also included. In one embodiment, the assay kits comprise a container
containing at least one CS141 polypeptide having at least 50% identity with an
amino acid sequence selected from the group consisting of SEQUENCE ID NO 24,
SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27,
SEQUENCE ID NO 28, and fragments thereof. Further, the test kit can comprise a
20 container with tools useful for collecting test samples (such as blood, urine, saliva,
and stool). Such tools include lancets and absorbent paper or cloth for collecting
and stabilizing blood; swabs for collecting and stabilizing saliva; and cups for
collecting and stabilizing urine or stool samples. Collection materials such as
papers, cloths, swabs, cups, and the like, may optionally be treated to avoid
25 denaturation or irreversible adsorption of the sample. These collection materials also
may be treated with or contain preservatives, stabilizers or antimicrobial agents to
help maintain the integrity of the specimens. Also, the polypeptide can be attached
to a solid phase.

Another assay kit for determining the presence of CS141 antigen or anti-
CS141 antibody in a test sample comprises a container containing an antibody which
30 specifically binds to a CS141 antigen, wherein the CS141 antigen comprises at least
one CS141-encoded epitope. The CS141 antigen has at least about 60% sequence
similarity to a sequence of a CS141-encoded antigen selected from the group
consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO
26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof. These
35 test kits can further comprise containers with tools useful for collecting test samples

(such as blood, urine, saliva, and stool). Such tools include lancets and absorbent paper or cloth for collecting and stabilizing blood; swabs for collecting and stabilizing saliva; cups for collecting and stabilizing urine or stool samples.

Collection materials, papers, cloths, swabs, cups and the like, may optionally be
5 treated to avoid denaturation or irreversible adsorption of the sample. These collection materials also may be treated with, or contain, preservatives, stabilizers or antimicrobial agents to help maintain the integrity of the specimens. The antibody can be attached to a solid phase.

A method for producing a polypeptide which contains at least one epitope of
10 CS141 is provided, which method comprises incubating host cells transfected with an expression vector. This vector comprises a polynucleotide sequence encoding a polypeptide, wherein the polypeptide comprises an amino acid sequence having at least 50% identity with a CS141 amino acid sequence selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO
15 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof.

A method for detecting CS141 antigen in a test sample suspected of
containing CS141 antigen also is provided. The method comprises contacting the test sample with an antibody or fragment thereof which specifically binds to at least one epitope of CS141 antigen, for a time and under conditions sufficient for the
20 formation of antibody/antigen complexes; and detecting the presence of such complexes containing the antibody as an indication of the presence of CS141 antigen in the test sample. The antibody can be attached to a solid phase and may be either a monoclonal or polyclonal antibody. Furthermore, the antibody specifically binds to at least one CS141 antigen selected from the group consisting of SEQUENCE ID
25 NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof.

Another method is provided which detects antibodies which specifically bind to CS141 antigen in a test sample suspected of containing these antibodies. The method comprises contacting the test sample with a polypeptide which contains at
30 least one CS141 epitope, wherein the CS141 epitope comprises an amino acid sequence having at least 50% identity with an amino acid sequence encoded by a CS141 polynucleotide, or a fragment thereof. Contacting is carried out for a time and under conditions sufficient to allow antigen/antibody complexes to form. The method further entails detecting complexes which contain the polypeptide. The
35 polypeptide can be attached to a solid phase. Further, the polypeptide can be a

recombinant protein or a synthetic peptide having at least 50% identity to an amino acid sequence selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof.

5 The present invention provides a cell transfected with a CS141 nucleic acid sequence that encodes at least one epitope of a CS141 antigen, or fragment thereof. The nucleic acid sequence is selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof.

10 A method for producing antibodies to CS141 antigen also is provided, which method comprises administering to an individual an isolated immunogenic polypeptide or fragment thereof, wherein the isolated immunogenic polypeptide comprises at least one CS141 epitope. The immunogenic polypeptide is administered in an amount sufficient to produce an immune response. The isolated, immunogenic polypeptide comprises an amino acid sequence selected from the
15 group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof.

20 Another method for producing antibodies which specifically bind to CS141 antigen is disclosed, which method comprises administering to an individual a plasmid comprising a nucleic acid sequence which encodes at least one CS141 epitope derived from an amino acid sequence selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof. The plasmid is administered in an amount such that the plasmid is taken up by cells in the individual and expressed at levels sufficient to produce an immune response.

25 Also provided is a composition of matter that comprises a CS141 polynucleotide of at least about 10-12 nucleotides having at least 50% identity with a sequence selected from the group consisting of (a) SEQUENCE ID NOS 1-9, SEQUENCE ID NO 12, SEQUENCE ID NO 13, and complements thereof, and (b) fragments of SEQUENCE ID NOS 1-9. The CS141 polynucleotide
30 encodes an amino acid sequence having at least one CS141 epitope. Another composition of matter provided by the present invention comprises a polypeptide with at least one CS141 epitope of about 8-10 amino acids. The polypeptide comprises an amino acid sequence having at least 60% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 24,
35 SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27,

SEQUENCE ID NO 28, and fragments thereof. Also provided is a gene, or a fragment thereof, coding for a CS141 polypeptide which has at least 60% identity with SEQUENCE ID NO 24; and a gene, or a fragment thereof, comprising DNA having at least 50% identity with SEQUENCE ID NO 12 or SEQUENCE ID NO 13.

Brief Description of the Drawings

Figures 1A-1C show the nucleotide alignment of clones 775133 (SEQUENCE ID NO 1), 1338704 (SEQUENCE ID NO 2), 2645837 (SEQUENCE ID NO 3), 775762 (SEQUENCE ID NO 4), 3210629 (SEQUENCE ID NO 5), 1281865 (SEQUENCE ID NO 6), 1807758 (SEQUENCE ID NO 7), 1735382 (SEQUENCE ID NO 8), 2128334 (SEQUENCE ID NO 9), g2197992 (SEQUENCE ID NO 10), g2409650 (SEQUENCE ID NO 11), the full-length sequence of clone 1281865 (designated as clone 1281865IH (SEQUENCE ID NO 12)); and the consensus sequence (SEQUENCE ID NO 13) derived therefrom.

Figure 2 shows the contig map depicting the formation of the consensus nucleotide sequence (SEQUENCE ID NO 13) from the nucleotide alignment of overlapping clones 775133 (SEQUENCE ID NO 1), 1338704 (SEQUENCE ID NO 2), 2645837 (SEQUENCE ID NO 3), 775762 (SEQUENCE ID NO 4), 3210629 (SEQUENCE ID NO 5), 1281865 (SEQUENCE ID NO 6), 1807758 (SEQUENCE ID NO 7), 1735382 (SEQUENCE ID NO 8), 2128334 (SEQUENCE ID NO 9), g2197992 (SEQUENCE ID NO 10), g2409650 (SEQUENCE ID NO 11), and 1281865IH (SEQUENCE ID NO 12).

Figure 3A is a scan of an ethidium bromide stained agarose gel of RNA from various tissue extracts and the corresponding Northern blot of RNA using a CS141 radiolabeled probe.

Figure 3B is a scan of an ethidium bromide stained agarose gel of RNA from various colon tissue extracts and the corresponding Northern blot of RNA using a CS141 radiolabeled probe.

Figure 4A is a scan of a SYBR® Green stained agarose gel of CS141 RNA-specific RT-PCR amplification products from colon tissue RNAs.

Figure 4B is a scan of a SYBR® Green stained agarose gel of CS141 RNA-specific RT-PCR amplification products from RNAs of normal or cancerous placenta, colon, breast, prostate, and lung tissue.

Figure 5 shows the results of the Western blot performed on a panel of tissue protein extracts probed with antiserum against a CS141 synthetic peptide (SEQUENCE ID NO 26).

5 Detailed Description of the Invention

The present invention provides a gene, or a fragment thereof, which codes for a CS141 polypeptide having at least about 60% identity with SEQUENCE ID NO 24. The present invention further encompasses a CS141 gene, or a fragment thereof, comprising DNA which has at least about 50% identity with SEQUENCE
10 ID NO 12 or SEQUENCE ID NO 13.

The present invention also provides methods for assaying a test sample for products of a gastrointestinal tract (GI tract) tissue gene designated as CS141, which comprises making cDNA from mRNA in the test sample, and detecting the cDNA as an indication of the presence of GI tract tissue gene CS141. The method may
15 include an amplification step, wherein one or more portions of the mRNA from CS141 corresponding to the gene or fragments thereof, is amplified. Methods also are provided for assaying for the translation products of CS141. Test samples which may be assayed by the methods provided herein include tissues, cells, body fluids and secretions. The present invention also provides reagents such as
20 oligonucleotide primers and polypeptides which are useful in performing these methods.

Portions of the nucleic acid sequences disclosed herein are useful as primers for the reverse transcription of RNA or for the amplification of cDNA; or as probes to determine the presence of certain mRNA sequences in test samples. Also
25 disclosed are nucleic acid sequences which permit the production of encoded polypeptide sequences which are useful as standards or reagents in diagnostic immunoassays, as targets for pharmaceutical screening assays and/or as components or as target sites for various therapies. Monoclonal and polyclonal antibodies directed against at least one epitope contained within these polypeptide sequences are
30 useful as delivery agents for therapeutic agents as well as for diagnostic tests and for screening for diseases or conditions associated with CS141, especially GI tract cancer. Isolation of sequences of other portions of the gene of interest can be accomplished utilizing probes or PCR primers derived from these nucleic acid sequences. This allows additional probes of the mRNA or cDNA of interest to be
35 established, as well as corresponding encoded polypeptide sequences. These

additional molecules are useful in detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition to diseases and conditions of the GI tract, such as GI tract cancer, characterized by CS141, as disclosed herein.

- 5 Techniques for determining amino acid sequence “similarity” are well-known in the art. In general, “similarity” means the exact amino acid to amino acid comparison of two or more polypeptides at the appropriate place, where amino acids are identical or possess similar chemical and/or physical properties such as charge or hydrophobicity. A so-termed “percent similarity” then can be determined between
10 the compared polypeptide sequences. Techniques for determining nucleic acid and amino acid sequence identity also are well known in the art and include determining the nucleotide sequence of the mRNA for that gene (usually via a cDNA intermediate) and determining the amino acid sequence encoded thereby, and comparing this to a second amino acid sequence. In general, “identity” refers to an
15 exact nucleotide to nucleotide or amino acid to amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Two or more polynucleotide sequences can be compared by determining their “percent identity.” Two or more amino acid sequences likewise can be compared by determining their “percent identity.” The programs available in the Wisconsin Sequence Analysis
20 Package, Version 8 (available from Genetics Computer Group, Madison, WI), for example, the GAP program, are capable of calculating both the identity between two polynucleotides and the identity and similarity between two polypeptide sequences, respectively. Other programs for calculating identity or similarity between sequences are known in the art.
- 25 The compositions and methods described herein will enable the identification of certain markers as indicative of a GI tract tissue disease or condition; the information obtained therefrom will aid in the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining diseases or conditions associated with CS141, especially GI tract cancer. Test methods include,
30 for example, probe assays which utilize the sequence(s) provided herein and which also may utilize nucleic acid amplification methods such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), and hybridization. In addition, the nucleotide sequences provided herein contain open reading frames from which an immunogenic epitope may be found. This epitope is believed to be unique to the
35 disease state or condition associated with CS141. It also is thought that the

polynucleotides or polypeptides and protein encoded by the CS141 gene are useful as a marker. This marker is either elevated in disease such as GI tract cancer, altered in disease such as GI tract cancer, or present as a normal protein but appearing in an inappropriate body compartment. The uniqueness of the epitope may be determined by (i) its immunological reactivity and specificity with antibodies directed against proteins and polypeptides encoded by the CS141 gene, and (ii) its nonreactivity with any other tissue markers. Methods for determining immunological reactivity are well-known and include, but are not limited to, for example, radioimmunoassay (RIA), enzyme-linked immunoabsorbent assay (ELISA), hemagglutination (HA), fluorescence polarization immunoassay (FPIA), chemiluminescent immunoassay (CLIA) and others. Several examples of suitable methods are described herein.

Unless otherwise stated, the following terms shall have the following meanings:

A polynucleotide "derived from" or "specific for" a designated sequence refers to a polynucleotide sequence which comprises a contiguous sequence of approximately at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10-12 nucleotides, and even more preferably at least about 15-20 nucleotides corresponding, i.e., identical or complementary to, a region of the designated nucleotide sequence. The sequence may be complementary or identical to a sequence which is unique to a particular polynucleotide sequence as determined by techniques known in the art. Comparisons to sequences in databanks, for example, can be used as a method to determine the uniqueness of a designated sequence. Regions from which sequences may be derived, include but are not limited to, regions encoding specific epitopes, as well as non-translated and/or non-transcribed regions.

The derived polynucleotide will not necessarily be derived physically from the nucleotide sequence of interest under study, but may be generated in any manner, including, but not limited to, chemical synthesis, replication, reverse transcription or transcription, which is based on the information provided by the sequence of bases in the region(s) from which the polynucleotide is derived. As such, it may represent either a sense or an antisense orientation of the original polynucleotide. In addition, combinations of regions corresponding to that of the designated sequence may be modified in ways known in the art to be consistent with the intended use.

5 A "fragment" of a specified polynucleotide refers to a polynucleotide sequence which comprises a contiguous sequence of approximately at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10-12 nucleotides, and even more preferably at least about 15-20 nucleotides corresponding, i.e., identical or complementary to, a region of the specified nucleotide sequence.

10 The term "primer" denotes a specific oligonucleotide sequence which is complementary to a target nucleotide sequence and used to hybridize to the target nucleotide sequence. A primer serves as an initiation point for nucleotide polymerization catalyzed by either DNA polymerase, RNA polymerase or reverse transcriptase.

15 The term "probe" denotes a defined nucleic acid segment (or nucleotide analog segment, e.g., PNA as defined hereinbelow) which can be used to identify a specific polynucleotide present in samples bearing the complementary sequence.

20 "Encoded by" refers to a nucleic acid sequence which codes for a polypeptide sequence, wherein the polypeptide sequence or a portion thereof contains an amino acid sequence of at least 3 to 5 amino acids, more preferably at least 8 to 10 amino acids, and even more preferably at least 15 to 20 amino acids from a polypeptide encoded by the nucleic acid sequence. Also encompassed are polypeptide sequences which are immunologically identifiable with a polypeptide encoded by the sequence. Thus, a "polypeptide," "protein," or "amino acid" sequence has at least about 50% identity, preferably about 60% identity, more preferably about 75-85% identity, and most preferably about 90-95% or more identity to a CS141 amino acid sequence. Further, the CS141 "polypeptide,"
25 "protein," or "amino acid" sequence may have at least about 60% similarity, preferably at least about 75% similarity, more preferably about 85% similarity, and most preferably about 95% or more similarity to a polypeptide or amino acid sequence of CS141. This amino acid sequence can be selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof.

30 A "recombinant polypeptide," "recombinant protein," or "a polypeptide produced by recombinant techniques," which terms may be used interchangeably herein, describes a polypeptide which by virtue of its origin or manipulation is not associated with all or a portion of the polypeptide with which it is associated in nature and/or is linked to a polypeptide other than that to which it is linked in nature.

A recombinant or encoded polypeptide or protein is not necessarily translated from a designated nucleic acid sequence. It also may be generated in any manner, including chemical synthesis or expression of a recombinant expression system.

5 The term "synthetic peptide" as used herein means a polymeric form of amino acids of any length, which may be chemically synthesized by methods well-known to the routineer. These synthetic peptides are useful in various applications.

10 The term "polynucleotide" as used herein means a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, the term includes double- and single-stranded DNA, as well as double- and single-stranded RNA. It also includes modifications, such as methylation or capping and unmodified forms of the polynucleotide. The terms "polynucleotide," "oligomer," "oligonucleotide," and "oligo" are used interchangeably herein.

15 "A sequence corresponding to a cDNA" means that the sequence contains a polynucleotide sequence that is identical or complementary to a sequence in the designated DNA. The degree (or "percent") of identity or complementarity to the cDNA will be approximately 50% or greater, preferably at least about 70% or greater, and more preferably at least about 90% or greater. The sequence that corresponds to the identified cDNA will be at least about 50 nucleotides in length, 20 preferably at least about 60 nucleotides in length, and more preferably at least about 70 nucleotides in length. The correspondence between the gene or gene fragment of interest and the cDNA can be determined by methods known in the art and include, for example, a direct comparison of the sequenced material with the cDNAs described, or hybridization and digestion with single strand nucleases, followed by 25 size determination of the digested fragments.

30 "Purified polynucleotide" refers to a polynucleotide of interest or fragment thereof which is essentially free, e.g., contains less than about 50%, preferably less than about 70%, and more preferably less than about 90%, of the protein with which the polynucleotide is naturally associated. Techniques for purifying polynucleotides of interest are well-known in the art and include, for example, disruption of the cell containing the polynucleotide with a chaotropic agent and separation of the polynucleotide(s) and proteins by ion-exchange chromatography, affinity chromatography and sedimentation according to density.

35 "Purified polypeptide" or "purified protein" means a polypeptide of interest or fragment thereof which is essentially free of, e.g., contains less than about 50%,

preferably less than about 70%, and more preferably less than about 90%, cellular components with which the polypeptide of interest is naturally associated. Methods for purifying polypeptides of interest are known in the art.

5 The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, which is separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide could be part of a vector and/or such polynucleotide
10 or polypeptide could be part of a composition, and still be isolated in that the vector or composition is not part of its natural environment.

"Polypeptide" and "protein" are used interchangeably herein and indicate at least one molecular chain of amino acids linked through covalent and/or non-covalent bonds. The terms do not refer to a specific length of the product. Thus
15 peptides, oligopeptides and proteins are included within the definition of polypeptide. The terms include post-translational modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. In addition, protein fragments, analogs, mutated or variant proteins, fusion proteins and the like are included within the meaning of polypeptide.

20 A "fragment" of a specified polypeptide refers to an amino acid sequence which comprises at least about 3-5 amino acids, more preferably at least about 8-10 amino acids, and even more preferably at least about 15-20 amino acids derived from the specified polypeptide.

"Recombinant host cells," "host cells," "cells," "cell lines," "cell cultures,"
25 and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be, or have been, used as recipients for recombinant vector or other transferred DNA, and include the original progeny of the original cell which has been transfected.

As used herein "replicon" means any genetic element, such as a plasmid, a
30 chromosome or a virus, that behaves as an autonomous unit of polynucleotide replication within a cell.

A "vector" is a replicon in which another polynucleotide segment is attached, such as to bring about the replication and/or expression of the attached segment.

35 The term "control sequence" refers to a polynucleotide sequence which is necessary to effect the expression of a coding sequence to which it is ligated. The

nature of such control sequences differs depending upon the host organism. In prokaryotes, such control sequences generally include a promoter, a ribosomal binding site and terminators; in eukaryotes, such control sequences generally include promoters, terminators and, in some instances, enhancers. The term “control
5 sequence” thus is intended to include at a minimum all components whose presence is necessary for expression, and also may include additional components whose presence is advantageous, for example, leader sequences.

“Operably linked” refers to a situation wherein the components described are in a relationship permitting them to function in their intended manner. Thus, for
10 example, a control sequence “operably linked” to a coding sequence is ligated in such a manner that expression of the coding sequence is achieved under conditions compatible with the control sequence.

The term “open reading frame” or “ORF” refers to a region of a polynucleotide sequence which encodes a polypeptide. This region may represent a
15 portion of a coding sequence or a total coding sequence.

A “coding sequence” is a polynucleotide sequence which is transcribed into mRNA and translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5' -terminus and a translation stop
20 codon at the 3' -terminus. A coding sequence can include, but is not limited to, mRNA, cDNA and recombinant polynucleotide sequences.

The term “immunologically identifiable with/as” refers to the presence of epitope(s) and polypeptide(s) which also are present in and are unique to the designated polypeptide(s). Immunological identity may be determined by antibody
25 binding and/or competition in binding. These techniques are known to the routineer and also are described herein. The uniqueness of an epitope also can be determined by computer searches of known data banks, such as GenBank, for the polynucleotide sequence which encodes the epitope and by amino acid sequence comparisons with other known proteins.

30 As used herein, “epitope” means an antigenic determinant of a polypeptide or protein. Conceivably, an epitope can comprise three amino acids in a spatial conformation which is unique to the epitope. Generally, an epitope consists of at least five such amino acids and more usually, it consists of at least eight to ten amino acids. Methods of examining spatial conformation are known in the art and include,

for example, x-ray crystallography and two-dimensional nuclear magnetic resonance.

5 A “conformational epitope” is an epitope that is comprised of a specific juxtaposition of amino acids in an immunologically recognizable structure, such amino acids being present on the same polypeptide in a contiguous or non-contiguous order or present on different polypeptides.

10 A polypeptide is “immunologically reactive” with an antibody when it binds to an antibody due to antibody recognition of a specific epitope contained within the polypeptide. Immunological reactivity may be determined by antibody binding, more particularly, by the kinetics of antibody binding, and/or by competition in binding using as competitor(s) a known polypeptide(s) containing an epitope against which the antibody is directed. The methods for determining whether a polypeptide is immunologically reactive with an antibody are known in the art.

15 As used herein, the term “immunogenic polypeptide containing an epitope of interest” means naturally occurring polypeptides of interest or fragments thereof, as well as polypeptides prepared by other means, for example, by chemical synthesis or the expression of the polypeptide in a recombinant organism.

20 The term “transfection” refers to the introduction of an exogenous polynucleotide into a prokaryotic or eucaryotic host cell, irrespective of the method used for the introduction. The term “transfection” refers to both stable and transient introduction of the polynucleotide, and encompasses direct uptake of polynucleotides, transformation, transduction, and f-mating. Once introduced into the host cell, the exogenous polynucleotide may be maintained as a non-integrated replicon, for example, a plasmid, or alternatively, may be integrated into the host genome.

25 “Treatment” refers to prophylaxis and/or therapy.

30 The term “individual” as used herein refers to vertebrates, particularly members of the mammalian species and includes, but is not limited to, domestic animals, sports animals, primates and humans; more particularly, the term refers to humans.

The term “sense strand” or “plus strand” (or “+”) as used herein denotes a nucleic acid that contains the sequence that encodes the polypeptide. The term “antisense strand” or “minus strand” (or “-”) denotes a nucleic acid that contains a sequence that is complementary to that of the “plus” strand.

The term "test sample" refers to a component of an individual's body which is the source of the analyte (such as antibodies of interest or antigens of interest). These components are well known in the art. A test sample is typically anything suspected of containing a target sequence. Test samples can be prepared using methodologies well known in the art such as by obtaining a specimen from an individual and, if necessary, disrupting any cells contained thereby to release target nucleic acids. These test samples include biological samples which can be tested by the methods of the present invention described herein and include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, sputum, bronchial washing, bronchial aspirates, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells, myelomas and the like; biological fluids such as cell culture supernatants; tissue specimens which may be fixed; and cell specimens which may be fixed.

"Purified product" refers to a preparation of the product which has been isolated from the cellular constituents with which the product is normally associated and from other types of cells which may be present in the sample of interest.

"PNA" denotes a "peptide nucleic acid analog" which may be utilized in a procedure such as an assay described herein to determine the presence of a target.

"MA" denotes a "morpholino analog" which may be utilized in a procedure such as an assay described herein to determine the presence of a target. See, for example, U.S. Patent No. 5,378,841, which is incorporated herein by reference. PNAs are neutrally charged moieties which can be directed against RNA targets or DNA.

PNA probes used in assays in place of, for example, the DNA probes of the present invention, offer advantages not achievable when DNA probes are used. These advantages include manufacturability, large scale labeling, reproducibility, stability, insensitivity to changes in ionic strength and resistance to enzymatic degradation which is present in methods utilizing DNA or RNA. These PNAs can be labeled with ("attached to") such signal generating compounds as fluorescein, radionucleotides, chemiluminescent compounds and the like. PNAs or other nucleic acid analogs such as MAs thus can be used in assay methods in place of DNA or RNA. Although assays are described herein utilizing DNA probes, it is within the scope of the routine that PNAs or MAs can be substituted for RNA or DNA with appropriate changes if and as needed in assay reagents.

“Analyte,” as used herein, is the substance to be detected which may be present in the test sample. The analyte can be any substance for which there exists a naturally occurring specific binding member (such as an antibody), or for which a specific binding member can be prepared. Thus, an analyte is a substance that can bind to one or more specific binding members in an assay. “Analyte” also includes any antigenic substances, haptens, antibodies and combinations thereof. As a member of a specific binding pair, the analyte can be detected by means of naturally occurring specific binding partners (pairs) such as the use of intrinsic factor protein as a member of a specific binding pair for the determination of Vitamin B12, the use of folate-binding protein to determine folic acid, or the use of a lectin as a member of a specific binding pair for the determination of a carbohydrate. The analyte can include a protein, a polypeptide, an amino acid, a nucleotide target and the like.

The terms “diseases of the GI tract,” “GI tract disease,” and “condition of the GI tract” are used interchangeably herein to refer to any disease or condition of the esophagus, stomach, small and large intestines, rectum and pancreas including, but not limited to, Barret’s esophagus, gastric ulcer, gastritis, leiomyoma, polyps, Crohn’s disease, ulcerative colitis, pancreatitis and cancer.

“GI tract cancer,” as used herein, refers to any malignant disease of the gastrointestinal tract including, but not limited to, adenocarcinoma, mucinous adenocarcinoma, carcinoid tumor, squamous cell carcinoma, lymphoma, and sarcoma.

An “Expressed Sequence Tag” or “EST” refers to the partial sequence of a cDNA insert which has been made by reverse transcription of mRNA extracted from a tissue followed by insertion into a vector.

A “transcript image” refers to a table or list giving the quantitative distribution of ESTs in a library and represents the genes active in the tissue from which the library was made.

The present invention provides assays which utilize specific binding members. A “specific binding member,” as used herein, is a member of a specific binding pair. That is, two different molecules where one of the molecules, through chemical or physical means, specifically binds to the second molecule. Therefore, in addition to antigen and antibody specific binding pairs of common immunoassays, other specific binding pairs can include biotin and avidin, carbohydrates and lectins, complementary nucleotide sequences, effector and receptor molecules, cofactors and enzymes, enzyme inhibitors, and enzymes and the like. Furthermore, specific

binding pairs can include members that are analogs of the original specific binding members, for example, an analyte-analog. Immunoreactive specific binding members include antigens, antigen fragments, antibodies and antibody fragments, both monoclonal and polyclonal and complexes thereof, including those formed by
5 recombinant DNA molecules.

The term "haptten," as used herein, refers to a partial antigen or non-protein binding member which is capable of binding to an antibody, but which is not capable of eliciting antibody formation unless coupled to a carrier protein.

A "capture reagent," as used herein, refers to an unlabeled specific binding
10 member which is specific either for the analyte as in a sandwich assay, for the indicator reagent or analyte as in a competitive assay, or for an ancillary specific binding member, which itself is specific for the analyte, as in an indirect assay. The capture reagent can be directly or indirectly bound to a solid phase material before the performance of the assay or during the performance of the assay, thereby
15 enabling the separation of immobilized complexes from the test sample.

The "indicator reagent" comprises a "signal-generating compound" ("label") which is capable of generating and generates a measurable signal detectable by external means, conjugated ("attached") to a specific binding member. In addition to being an antibody member of a specific binding pair, the indicator reagent also can
20 be a member of any specific binding pair, including either hapten-anti-hapten systems such as biotin or anti-biotin, avidin or biotin, a carbohydrate or a lectin, a complementary nucleotide sequence, an effector or a receptor molecule, an enzyme cofactor and an enzyme, an enzyme inhibitor or an enzyme and the like. An immunoreactive specific binding member can be an antibody, an antigen, or an
25 antibody/antigen complex that is capable of binding either to the polypeptide of interest as in a sandwich assay, to the capture reagent as in a competitive assay, or to the ancillary specific binding member as in an indirect assay. When describing probes and probe assays, the term "reporter molecule" may be used. A reporter molecule comprises a signal generating compound as described hereinabove
30 conjugated to a specific binding member of a specific binding pair, such as carbazole or adamantane.

The various "signal-generating compounds" (labels) contemplated include chromagens, catalysts such as enzymes, luminescent compounds such as fluorescein and rhodamine, chemiluminescent compounds such as dioxetanes, acridiniums,
35 phenanthridiniums and luminol, radioactive elements and direct visual labels.

-22-

Examples of enzymes include alkaline phosphatase, horseradish peroxidase, beta-galactosidase and the like. The selection of a particular label is not critical, but it must be capable of producing a signal either by itself or in conjunction with one or more additional substances.

- 5 “Solid phases” (“solid supports”) are known to those in the art and include the walls of wells of a reaction tray, test tubes, polystyrene beads, magnetic or non-magnetic beads, nitrocellulose strips, membranes, microparticles such as latex particles, sheep (or other animal) red blood cells and Duracytes® (red blood cells “fixed” by pyruvic aldehyde and formaldehyde, available from Abbott Laboratories, 10 Abbott Park, IL) and others. The “solid phase” is not critical and can be selected by one skilled in the art. Thus, latex particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood cells and Duracytes® are all suitable examples. Suitable methods for immobilizing peptides on solid phases 15 include ionic, hydrophobic, covalent interactions and the like. A “solid phase,” as used herein, refers to any material which is insoluble, or can be made insoluble by a subsequent reaction. The solid phase can be chosen for its intrinsic ability to attract and immobilize the capture reagent. Alternatively, the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent. 20 The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid phase and which has the ability to immobilize the capture reagent through a specific binding reaction. 25 The receptor molecule enables the indirect binding of the capture reagent to a solid phase material before the performance of the assay or during the performance of the assay. The solid phase thus can be a plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, Duracytes® 30 and other configurations known to those of ordinary skill in the art.

It is contemplated and within the scope of the present invention that the solid phase also can comprise any suitable porous material with sufficient porosity to allow access by detection antibodies and a suitable surface affinity to bind antigens. Microporous structures generally are preferred, but materials with a gel structure in 35 the hydrated state may be used as well. Such useful solid supports include, but are

not limited to, nitrocellulose and nylon. It is contemplated that such porous solid supports described herein preferably are in the form of sheets of thickness from about 0.01 to 0.5 mm, preferably about 0.1 mm. The pore size may vary within wide limits and preferably is from about 0.025 to 15 microns, especially from about 0.15 to 15 microns. The surface of such supports may be activated by chemical processes which cause covalent linkage of the antigen or antibody to the support. The irreversible binding of the antigen or antibody is obtained, however, in general, by adsorption on the porous material by poorly understood hydrophobic forces. Other suitable solid supports are known in the art.

Reagents.

The present invention provides reagents such as polynucleotide sequences derived from a GI tract tissue of interest and designated as CS141, polypeptides encoded thereby and antibodies specific for these polypeptides. The present invention also provides reagents such as oligonucleotide fragments derived from the disclosed polynucleotides and nucleic acid sequences complementary to these polynucleotides. The polynucleotides, polypeptides, or antibodies of the present invention may be used to provide information leading to the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating of, or determining the predisposition to, diseases and conditions of the GI tract, such as GI tract cancer.

The sequences disclosed herein represent unique polynucleotides which can be used in assays or for producing a specific profile of gene transcription activity. Such assays are disclosed in European Patent Number 0373203B1 and International Publication No. WO 95/11995, which are hereby incorporated by reference.

Selected CS141-derived polynucleotides can be used in the methods described herein for the detection of normal or altered gene expression. Such methods may employ CS141 polynucleotides or oligonucleotides, fragments or derivatives thereof, or nucleic acid sequences complementary thereto.

The polynucleotides disclosed herein, their complementary sequences, or fragments of either, can be used in assays to detect, amplify or quantify genes, nucleic acids, cDNAs or mRNAs relating to GI tract tissue disease and conditions associated therewith. They also can be used to identify an entire or partial coding region of a CS141 polypeptide. They further can be provided in individual containers in the form of a kit for assays, or provided as individual compositions. If provided in a kit for assays, other suitable reagents such as buffers, conjugates and the like may be included.

1 The polynucleotide may be in the form of RNA or DNA. Polynucleotides in
the form of DNA, cDNA, genomic DNA, nucleic acid analogs and synthetic DNA
are within the scope of the present invention. The DNA may be double-stranded or
single-stranded, and if single stranded, may be the coding (sense) strand or non-
5 coding (anti-sense) strand. The coding sequence which encodes the polypeptide
may be identical to the coding sequence provided herein or may be a different coding
sequence which coding sequence, as a result of the redundancy or degeneracy of the
genetic code, encodes the same polypeptide as the DNA provided herein.

10 This polynucleotide may include only the coding sequence for the
polypeptide, or the coding sequence for the polypeptide and an additional coding
sequence such as a leader or secretory sequence or a proprotein sequence, or the
coding sequence for the polypeptide (and optionally an additional coding sequence)
and non-coding sequence, such as a non-coding sequence 5' and/or 3' of the coding
sequence for the polypeptide.

15 In addition, the invention includes variant polynucleotides containing
modifications such as polynucleotide deletions, substitutions or additions; and any
polypeptide modification resulting from the variant polynucleotide sequence. A
polynucleotide of the present invention also may have a coding sequence which is a
naturally occurring allelic variant of the coding sequence provided herein.

20 In addition, the coding sequence for the polypeptide may be fused in the
same reading frame to a polynucleotide sequence which aids in expression and
secretion of a polypeptide from a host cell, for example, a leader sequence which
functions as a secretory sequence for controlling transport of a polypeptide from the
cell. The polypeptide having a leader sequence is a preprotein and may have the
25 leader sequence cleaved by the host cell to form the polypeptide. The
polynucleotides may also encode for a proprotein which is the protein plus additional
5' amino acid residues. A protein having a prosequence is a proprotein and may, in
some cases, be an inactive form of the protein. Once the prosequence is cleaved, an
active protein remains. Thus, the polynucleotide of the present invention may
30 encode for a protein, or for a protein having a prosequence, or for a protein having
both a prosequence (leader sequence) and a prosequence.

35 The polynucleotides of the present invention may also have the coding
sequence fused in frame to a marker sequence which allows for purification of the
polypeptide of the present invention. The marker sequence may be a hexa-histidine
tag supplied by a pQE-9 vector to provide for purification of the polypeptide fused to

the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. a COS-7 cell line, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein. See, for example, I. Wilson et al., Cell 37:767 (1984).

5 It is contemplated that polynucleotides will be considered to hybridize to the sequences provided herein if there is at least 50%, preferably at least 70%, and more preferably at least 90% identity between the polynucleotide and the sequence.

10 The present invention also provides an antibody produced by using a purified CS141 polypeptide of which at least a portion of the polypeptide is encoded by a CS141 polynucleotide selected from the polynucleotides provided herein. These antibodies may be used in the methods provided herein for the detection of CS141 antigen in test samples. The presence of CS141 antigen in the test samples is indicative of the presence of a GI tract disease or condition. The antibody also may be used for therapeutic purposes, for example, in neutralizing the activity of CS141
15 polypeptide in conditions associated with altered or abnormal expression.

The present invention further relates to a CS141 polypeptide which has the deduced amino acid sequence as provided herein, as well as fragments, analogs and derivatives of such polypeptide. The polypeptide of the present invention may be a recombinant polypeptide, a natural purified polypeptide or a synthetic polypeptide.
20 The fragment, derivative or analog of the CS141 polypeptide may be one in which one or more of the amino acid residues is substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code; or it may be one in which one or more of the amino acid residues includes a
25 substituent group; or it may be one in which the polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol); or it may be one in which the additional amino acids are fused to the polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the polypeptide or a proprotein sequence.
30 Such fragments, derivatives and analogs are within the scope of the present invention. The polypeptides and polynucleotides of the present invention are provided preferably in an isolated form and preferably purified.

Thus, a polypeptide of the present invention may have an amino acid sequence that is identical to that of the naturally occurring polypeptide or that is
35 different by minor variations due to one or more amino acid substitutions. The

variation may be a "conservative change" typically in the range of about 1 to 5 amino acids, wherein the substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine or threonine with serine. In contrast, variations may include nonconservative changes, e.g., replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without changing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software (DNASTAR Inc., Madison WI).

Probes constructed according to the polynucleotide sequences of the present invention can be used in various assay methods to provide various types of analysis. For example, such probes can be used in fluorescent in situ hybridization (FISH) technology to perform chromosomal analysis, and used to identify cancer-specific structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR-generated and/or allele specific oligonucleotides probes, allele specific amplification or by direct sequencing. Probes also can be labeled with radioisotopes, directly- or indirectly-detectable haptens, or fluorescent molecules, and utilized for in situ hybridization studies to evaluate the mRNA expression of the gene comprising the polynucleotide in tissue specimens or cells.

This invention also provides teachings as to the production of the polynucleotides and polypeptides provided herein.

Probe Assays

The sequences provided herein may be used to produce probes which can be used in assays for the detection of nucleic acids in test samples. The probes may be designed from conserved nucleotide regions of the polynucleotides of interest or from non-conserved nucleotide regions of the polynucleotide of interest. The design of such probes for optimization in assays is within the skill of the routineer.

Generally, nucleic acid probes are developed from non-conserved or unique regions when maximum specificity is desired, and nucleic acid probes are developed from conserved regions when assaying for nucleotide regions that are closely related to, for example, different members of a multi-gene family or in related species like mouse and man.

The polymerase chain reaction (PCR) is a technique for amplifying a desired nucleic acid sequence (target) contained in a nucleic acid or mixture thereof. In PCR, a pair of primers are employed in excess to hybridize to the complementary strands of the target nucleic acid. The primers are each extended by a polymerase using the target nucleic acid as a template. The extension products become target sequences themselves, following dissociation from the original target strand. New primers then are hybridized and extended by a polymerase, and the cycle is repeated to geometrically increase the number of target sequence molecules. PCR is disclosed in U.S. Patents 4,683,195 and 4,683,202, which are incorporated herein by reference.

The Ligase Chain Reaction (LCR) is an alternate method for nucleic acid amplification. In LCR, probe pairs are used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are employed in molar excess to target. The first probe hybridizes to a first segment of the target strand, and the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5' phosphate-3' hydroxyl relationship, and so that a ligase can covalently fuse or ligate the two probes into a fused product. In addition, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar abutting fashion. Of course, if the target is initially double stranded, the secondary probes also will hybridize to the target complement in the first instance. Once the ligated strand of primary probes is separated from the target strand, it will hybridize with the third and fourth probes which can be ligated to form a complementary, secondary ligated product. It is important to realize that the ligated products are functionally equivalent to either the target or its complement. By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. This technique is described more completely in EP-A- 320 308 to K. Backman published June 16, 1989 and EP-A- 439 182 to K. Backman et al, published July 31, 1991, both of which are incorporated herein by reference.

For amplification of mRNAs, it is within the scope of the present invention to reverse transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps as described in U.S. Patent No. 5,322,770, which is incorporated herein by reference; or reverse transcribe mRNA into cDNA followed by asymmetric gap ligase chain reaction (RT-AGLCR) as

described by R.L. Marshall et al., PCR Methods and Applications 4: 80-84 (1994), which also is incorporated herein by reference.

Other known amplification methods which can be utilized herein include but are not limited to the so-called "NASBA" or "3SR" technique described by J.C.

- 5 Guatelli et al., PNAS USA 87:1874-1878 (1990) and also described by J. Compton, Nature 350 (No. 6313):91-92 (1991); Q-beta amplification as described in published European Patent Application (EPA) No. 4544610; strand displacement amplification (as described in G.T. Walker et al., Clin. Chem. 42:9-13 (1996) and European Patent Application No. 684315; and target mediated amplification, as
10 described in International Publication No. WO 93/22461.

- Detection of CS141 may be accomplished using any suitable detection method, including those detection methods which are currently well known in the art, as well as detection strategies which may evolve later. Examples of the foregoing presently known detection methods are hereby incorporated herein by
15 reference. See, for example, Caskey et al., U.S. Patent No. 5,582,989, Gelfand et al., U.S. Patent No. 5,210,015. Examples of such detection methods include target amplification methods as well as signal amplification technologies. An example of presently known detection methods would include the nucleic acid amplification technologies referred to as PCR, LCR, NASBA, SDA, RCR and TMA. See, for
20 example, Caskey et al., U.S. Patent No. 5,582,989, Gelfand et al., U.S. Patent No. 5,210,015. All of the foregoing are hereby incorporated by reference.

- Detection may also be accomplished using signal amplification such as that disclosed in Snitman et al., U.S. Patent No. 5,273,882. While the amplification of target or signal is preferred at present, it is contemplated and within the scope of the present
25 invention that ultrasensitive detection methods which do not require amplification can be utilized herein.

- Detection, both amplified and non-amplified, may be (combined) carried out using a variety of heterogeneous and homogeneous detection formats. Examples of heterogeneous detection formats are disclosed in Snitman et al., U.S. Patent No.
30 5,273,882, Albarella et al in EP-84114441.9, Urdea et al., U.S. Patent No. 5,124,246, Ullman et al. U.S. Patent No. 5,185,243 and Kourilsky et al., U.S. Patent No. 4,581,333. All of the foregoing are hereby incorporated by reference. Examples of homogeneous detection formats are disclosed in, Caskey et al., U.S. Patent No. 5,582,989, Gelfand et al., U.S. Patent No. 5,210,015, which are
35 incorporated herein by reference. Also contemplated and within the scope of the

present invention is the use of multiple probes in the hybridization assay, which use improves sensitivity and amplification of the CS141 signal. See, for example, Caskey et al., U.S. Patent No. 5,582,989, Gelfand et al., U.S. Patent No. 5,210,015, which are incorporated herein by reference.

5 In one embodiment, the present invention generally comprises the steps of contacting a test sample suspected of containing a target polynucleotide sequence with amplification reaction reagents comprising an amplification primer, and a detection probe that can hybridize with an internal region of the amplicon sequences. Probes and primers employed according to the method provided herein are labeled
10 with capture and detection labels, wherein probes are labeled with one type of label and primers are labeled with another type of label. Additionally, the primers and probes are selected such that the probe sequence has a lower melt temperature than the primer sequences. The amplification reagents, detection reagents and test sample are placed under amplification conditions whereby, in the presence of target
15 sequence, copies of the target sequence (an amplicon) are produced. In the usual case, the amplicon is double stranded because primers are provided to amplify a target sequence and its complementary strand. The double stranded amplicon then is thermally denatured to produce single stranded amplicon members. Upon formation of the single stranded amplicon members, the mixture is cooled to allow the
20 formation of complexes between the probes and single stranded amplicon members.

 As the single stranded amplicon sequences and probe sequences are cooled, the probe sequences preferentially bind the single stranded amplicon members. This finding is counterintuitive given that the probe sequences generally are selected to be shorter than the primer sequences and therefore have a lower melt temperature than
25 the primers. Accordingly, the melt temperature of the amplicon produced by the primers should also have a higher melt temperature than the probes. Thus, as the mixture cools, the re-formation of the double stranded amplicon would be expected. As previously stated, however, this is not the case. The probes are found to preferentially bind the single stranded amplicon members. Moreover, this
30 preference of probe/single stranded amplicon binding exists even when the primer sequences are added in excess of the probes.

 After the probe/single stranded amplicon member hybrids are formed, they are detected. Standard heterogeneous assay formats are suitable for detecting the hybrids using the detection labels and capture labels present on the primers and
35 probes. The hybrids can be bound to a solid phase reagent by virtue of the capture

-30-

label and detected by virtue of the detection label. In cases where the detection label is directly detectable, the presence of the hybrids on the solid phase can be detected by causing the label to produce a detectable signal, if necessary, and detecting the signal. In cases where the label is not directly detectable, the captured hybrids can
5 be contacted with a conjugate, which generally comprises a binding member attached to a directly detectable label. The conjugate becomes bound to the complexes and the conjugate's presence on the complexes can be detected with the directly detectable label. Thus, the presence of the hybrids on the solid phase reagent can be determined. Those skilled in the art will recognize that wash steps may be employed
10 to wash away unhybridized amplicon or probe as well as unbound conjugate.

Although the target sequence is described as single stranded, it also is contemplated to include the case where the target sequence is actually double stranded but is merely separated from its complement prior to hybridization with the amplification primer sequences. In the case where PCR is employed in this method,
15 the ends of the target sequences are usually known. In cases where LCR or a modification thereof is employed in the preferred method, the entire target sequence is usually known. Typically, the target sequence is a nucleic acid sequence such as, for example, RNA or DNA.

The method provided herein can be used in well-known amplification
20 reactions that include thermal cycle reaction mixtures, particularly in PCR and gap LCR (GLCR). Amplification reactions typically employ primers to repeatedly generate copies of a target nucleic acid sequence, which target sequence is usually a small region of a much larger nucleic acid sequence. Primers are themselves nucleic acid sequences that are complementary to regions of a target sequence. Under
25 amplification conditions, these primers hybridize or bind to the complementary regions of the target sequence. Copies of the target sequence typically are generated by the process of primer extension and/or ligation which utilizes enzymes with polymerase or ligase activity, separately or in combination, to add nucleotides to the hybridized primers and/or ligate adjacent probe pairs. The nucleotides that are added
30 to the primers or probes, as monomers or preformed oligomers, are also complementary to the target sequence. Once the primers or probes have been sufficiently extended and/or ligated, they are separated from the target sequence, for example, by heating the reaction mixture to a "melt temperature" which is one in which complementary nucleic acid strands dissociate. Thus, a sequence
35 complementary to the target sequence is formed.

A new amplification cycle then can take place to further amplify the number of target sequences by separating any double stranded sequences, allowing primers or probes to hybridize to their respective targets, extending and/or ligating the hybridized primers or probes and re-separating. The complementary sequences that are generated by amplification cycles can serve as templates for primer extension or filling the gap of two probes to further amplify the number of target sequences. Typically, a reaction mixture is cycled between 20 and 100 times, more typically, a reaction mixture is cycled between 25 and 50 times. The numbers of cycles can be determined by the routineer. In this manner, multiple copies of the target sequence and its complementary sequence are produced. Thus, primers initiate amplification of the target sequence when it is present under amplification conditions.

Generally, two primers which are complementary to a portion of a target strand and its complement are employed in PCR. For LCR, four probes, two of which are complementary to a target sequence and two of which are similarly complementary to the target's complement, are generally employed. In addition to the primer sets and enzymes previously mentioned, a nucleic acid amplification reaction mixture may also comprise other reagents which are well known and include but are not limited to: enzyme cofactors such as manganese; magnesium; salts; nicotinamide adenine dinucleotide (NAD); and deoxynucleotide triphosphates (dNTPs) such as, for example, deoxyadenine triphosphate, deoxyguanine triphosphate, deoxycytosine triphosphate and deoxythymine triphosphate.

While the amplification primers initiate amplification of the target sequence, the detection (or hybridization) probe is not involved in amplification. Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs such as, for example, peptide nucleic acids which are disclosed in International Publication No. WO 92/20702; morpholino analogs which are described in U.S. Patents Nos 5,185,444, 5,034,506 and 5,142,047; and the like. Depending upon the type of label carried by the probe, the probe is employed to capture or detect the amplicon generated by the amplification reaction. The probe is not involved in amplification of the target sequence and therefore may have to be rendered "non-extendible" in that additional dNTPs cannot be added to the probe. In and of themselves, analogs usually are non-extendible and nucleic acid probes can be rendered non-extendible by modifying the 3' end of the probe such that the hydroxyl group is no longer capable of participating in elongation. For example, the 3' end of the probe can be functionalized with the capture or detection label to thereby

consume or otherwise block the hydroxyl group. Alternatively, the 3' hydroxyl group simply can be cleaved, replaced or modified. U.S. Patent Application Serial No. 07/049,061 filed April 19, 1993 and incorporated herein by reference describes modifications which can be used to render a probe non-extendible.

5 The ratio of primers to probes is not important. Thus, either the probes or primers can be added to the reaction mixture in excess whereby the concentration of one would be greater than the concentration of the other. Alternatively, primers and probes can be employed in equivalent concentrations. Preferably, however, the primers are added to the reaction mixture in excess of the probes. Thus, primer to
10 probe ratios of, for example, 5:1 and 20:1, are preferred.

 While the length of the primers and probes can vary, the probe sequences are selected such that they have a lower melt temperature than the primer sequences. Hence, the primer sequences are generally longer than the probe sequences. Typically, the primer sequences are in the range of between 20 and 50 nucleotides
15 long, more typically in the range of between 20 and 30 nucleotides long. The typical probe is in the range of between 10 and 25 nucleotides long.

 Various methods for synthesizing primers and probes are well known in the art. Similarly, methods for attaching labels to primers or probes are also well known in the art. For example, it is a matter of routine to synthesize desired nucleic
20 acid primers or probes using conventional nucleotide phosphoramidite chemistry and instruments available from Applied Biosystems, Inc., (Foster City, CA), DuPont (Wilmington, DE), or Milligen (Bedford MA). Many methods have been described for labeling oligonucleotides such as the primers or probes of the present invention. Enzo Biochemical (New York, NY) and Clontech (Palo Alto, CA) both have
25 described and commercialized probe labeling techniques. For example, a primary amine can be attached to a 3' oligo terminus using 3'-Amine-ON CPG™ (Clontech, Palo Alto, CA). Similarly, a primary amine can be attached to a 5' oligo terminus using Aminomodifier II® (Clontech). The amines can be reacted to various haptens using conventional activation and linking chemistries. In addition, copending
30 applications U.S. Serial Nos. 625,566, filed December 11, 1990 and 630,908, filed December 20, 1990, which are each incorporated herein by reference, teach methods for labeling probes at their 5' and 3' termini, respectively. International Publication Nos WO 92/10505, published 25 June 1992, and WO 92/11388, published 9 July 1992, teach methods for labeling probes at their 5' and 3' ends, respectively.

35 According to one known method for labeling an oligonucleotide, a label-

-33-

phosphoramidite reagent is prepared and used to add the label to the oligonucleotide during its synthesis. See, for example, N.T. Thuong et al., Tet. Letters 29(46):5905-5908 (1988); or J.S. Cohen et al., published U.S. Patent Application 07/246,688 (NTIS ORDER No. PAT-APPL-7-246,688) (1989). Preferably,
5 probes are labeled at their 3' and 5' ends.

A capture label is attached to the primers or probes and can be a specific binding member which forms a binding pair with the solid phase reagent's specific binding member. It will be understood that the primer or probe itself may serve as the capture label. For example, in the case where a solid phase reagent's binding
10 member is a nucleic acid sequence, it may be selected such that it binds a complementary portion of the primer or probe to thereby immobilize the primer or probe to the solid phase. In cases where the probe itself serves as the binding member, those skilled in the art will recognize that the probe will contain a sequence or "tail" that is not complementary to the single stranded amplicon members. In the
15 case where the primer itself serves as the capture label, at least a portion of the primer will be free to hybridize with a nucleic acid on a solid phase because the probe is selected such that it is not fully complementary to the primer sequence.

Generally, probe/single stranded amplicon member complexes can be detected using techniques commonly employed to perform heterogeneous
20 immunoassays. Preferably, in this embodiment, detection is performed according to the protocols used by the commercially available Abbott LCx[®] instrumentation (Abbott Laboratories, Abbott Park, IL).

The primers and probes disclosed herein are useful in typical PCR assays, wherein the test sample is contacted with a pair of primers, amplification is
25 performed, the hybridization probe is added, and detection is performed.

Another method provided by the present invention comprises contacting a test sample with a plurality of polynucleotides, wherein at least one polynucleotide is a CS141 molecule as described herein, hybridizing the test sample with the plurality of polynucleotides and detecting hybridization complexes. Hybridization complexes
30 are identified and quantitated to compile a profile which is indicative of GI tract tissue disease, such as GI tract cancer. Expressed RNA sequences may further be detected by reverse transcription and amplification of the DNA product by procedures well-known in the art, including polymerase chain reaction (PCR).

Drug Screening and Gene Therapy.

The present invention also encompasses the use of gene therapy methods for the introduction of anti-sense CS141 derived molecules, such as polynucleotides or oligonucleotides of the present invention, into patients with conditions associated with abnormal expression of polynucleotides related to a GI tract tissue disease or condition especially GI tract cancer. These molecules, including antisense RNA and DNA fragments and ribozymes, are designed to inhibit the translation of CS141-mRNA, and may be used therapeutically in the treatment of conditions associated with altered or abnormal expression of CS141 polynucleotide.

Alternatively, the oligonucleotides described above can be delivered to cells by procedures known in the art such that the anti-sense RNA or DNA may be expressed in vivo to inhibit production of a CS141 polypeptide in the manner described above. Antisense constructs to a CS141 polynucleotide, therefore, reverse the action of CS141 transcripts and may be used for treating GI tract tissue disease conditions, such as GI tract cancer. These antisense constructs may also be used to treat tumor metastases.

The present invention also provides a method of screening a plurality of compounds for specific binding to CS141 polypeptide(s), or any fragment thereof, to identify at least one compound which specifically binds the CS141 polypeptide. Such a method comprises the steps of providing at least one compound; combining the CS141 polypeptide with each compound under suitable conditions for a time sufficient to allow binding; and detecting the CS141 polypeptide binding to each compound.

The polypeptide or peptide fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of screening utilizes eukaryotic or prokaryotic host cells which are stably transfected with recombinant nucleic acids which can express the polypeptide or peptide fragment. A drug, compound, or any other agent may be screened against such transfected cells in competitive binding assays. For example, the formation of complexes between a polypeptide and the agent being tested can be measured in either viable or fixed cells.

The present invention thus provides methods of screening for drugs, compounds, or any other agent which can be used to treat diseases associated with CS141. These methods comprise contacting the agent with a polypeptide or fragment thereof and assaying for either the presence of a complex between the agent

and the polypeptide, or for the presence of a complex between the polypeptide and the cell. In competitive binding assays, the polypeptide typically is labeled. After suitable incubation, free (or uncomplexed) polypeptide or fragment thereof is separated from that present in bound form, and the amount of free or uncomplexed label is used as a measure of the ability of the particular agent to bind to the polypeptide or to interfere with the polypeptide/cell complex.

The present invention also encompasses the use of competitive screening assays in which neutralizing antibodies capable of binding polypeptide specifically compete with a test agent for binding to the polypeptide or fragment thereof. In this manner, the antibodies can be used to detect the presence of any polypeptide in the test sample which shares one or more antigenic determinants with a CS141 polypeptide as provided herein.

Another technique for screening provides high throughput screening for compounds having suitable binding affinity to at least one polypeptide of CS141 disclosed herein. Briefly, large numbers of different small peptide test compounds are synthesized on a solid phase, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptide and washed. Polypeptide thus bound to the solid phase is detected by methods well-known in the art. Purified polypeptide can also be coated directly onto plates for use in the screening techniques described herein. In addition, non-neutralizing antibodies can be used to capture the polypeptide and immobilize it on the solid support. See, for example, EP 84/03564, published on September 13, 1984, which is incorporated herein by reference.

The goal of rational drug design is to produce structural analogs of biologically active polypeptides of interest or of the small molecules including agonists, antagonists, or inhibitors with which they interact. Such structural analogs can be used to design drugs which are more active or stable forms of the polypeptide or which enhance or interfere with the function of a polypeptide in vivo. J. Hodgson, Bio/Technology 9:19-21 (1991), incorporated herein by reference.

For example, in one approach, the three-dimensional structure of a polypeptide, or of a polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of a polypeptide may be gained by

modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design analogous polypeptide-like molecules or to identify efficient inhibitors

Useful examples of rational drug design may include molecules which have improved activity or stability as shown by S. Braxton et al., Biochemistry 31:7796-7801 (1992), or which act as inhibitors, agonists, or antagonists of native peptides as shown by S.B.P. Athauda et al., J Biochem. (Tokyo) 113 (6):742-746 (1993), incorporated herein by reference.

It also is possible to isolate a target-specific antibody selected by an assay as described hereinabove, and then to determine its crystal structure. In principle this approach yields a pharmacophore upon which subsequent drug design can be based. It further is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies ("anti-ids") to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-id is an analog of the original receptor. The anti-id then can be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides then can act as the pharmacophore (that is, a prototype pharmaceutical drug).

A sufficient amount of a recombinant polypeptide of the present invention may be made available to perform analytical studies such as X-ray crystallography. In addition, knowledge of the polypeptide amino acid sequence which is derivable from the nucleic acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of, or in addition to, x-ray crystallography.

Antibodies specific to a CS141 polypeptide (e.g., anti-CS141 antibodies) further may be used to inhibit the biological action of the polypeptide by binding to the polypeptide. In this manner, the antibodies may be used in therapy, for example, to treat GI tract tissue diseases including GI tract cancer and its metastases.

Further, such antibodies can detect the presence or absence of a CS141 polypeptide in a test sample and, therefore, are useful as diagnostic markers for the diagnosis of a GI tract tissue disease or condition especially GI tract cancer. Such antibodies may also function as a diagnostic marker for GI tract tissue disease conditions, such as GI tract cancer.

The present invention also is directed to antagonists and inhibitors of the polypeptides of the present invention. The antagonists and inhibitors are those which inhibit or eliminate the function of the polypeptide. Thus, for example, an

-37-

antagonist may bind to a polypeptide of the present invention and inhibit or eliminate its function. The antagonist, for example, could be an antibody against the polypeptide which eliminates the activity of a CS141 polypeptide by binding a CS141 polypeptide, or in some cases the antagonist may be an oligonucleotide.

5 Examples of small molecule inhibitors include, but are not limited to, small peptides or peptide-like molecules.

The antagonists and inhibitors may be employed as a composition with a pharmaceutically acceptable carrier including, but not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. Administration
10 of CS141 polypeptide inhibitors is preferably systemic. The present invention also provides an antibody which inhibits the action of such a polypeptide.

Antisense technology can be used to reduce gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes for the polypeptide of the present
15 invention, is used to design an antisense RNA oligonucleotide of from 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription, thereby preventing transcription and the production of the CS141 polypeptide. For triple helix, see, for example, Lee et al,
20 Nuc. Acids Res. 6:3073 (1979); Cooney et al, Science 241:456 (1988); and Dervan et al, Science 251:1360 (1991) The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of a mRNA molecule into the CS141 polypeptide. For antisense, see, for example, Okano, J. Neurochem. 56:560 (1991); and "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression,"
25 CRC Press, Boca Raton, Fla. (1988). Antisense oligonucleotides act with greater efficacy when modified to contain artificial internucleotide linkages which render the molecule resistant to nucleolytic cleavage. Such artificial internucleotide linkages include, but are not limited to, methylphosphonate, phosphorothiolate and phosphoroamidate internucleotide linkages.

30 Recombinant Technology.

The present invention provides host cells and expression vectors comprising CS141 polynucleotides of the present invention and methods for the production of the polypeptide(s) they encode. Such methods comprise culturing the host cells under conditions suitable for the expression of the CS141 polynucleotide and
35 recovering the CS141 polypeptide from the cell culture.

-38-

The present invention also provides vectors which include CS141 polynucleotides of the present invention, host cells which are genetically engineered with vectors of the present invention and the production of polypeptides of the present invention by recombinant techniques.

5 Host cells are genetically engineered (transfected, transduced or transformed) with the vectors of this invention which may be cloning vectors or expression vectors. The vector may be in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transfected cells, or amplifying
10 CS141 gene(s). The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

 The polynucleotides of the present invention may be employed for producing a polypeptide by recombinant techniques. Thus, the polynucleotide sequence may
15 be included in any one of a variety of expression vehicles, in particular, vectors or plasmids for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus
20 and pseudorabies. However, any other plasmid or vector may be used so long as it is replicable and viable in the host.

 The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into appropriate restriction endonuclease sites by procedures known in the art. Such procedures and others are
25 deemed to be within the scope of those skilled in the art. The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. Representative examples of such promoters include, but are not limited to, the LTR or the SV40 promoter, the E. coli lac or trp, the phage lambda P sub L promoter and other promoters known to control
30 expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. In addition, the expression vectors preferably contain a gene to provide a phenotypic trait for selection of transfected host cells such as

dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.

5 The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transfect an appropriate host to permit the host to express the protein. As
representative examples of appropriate hosts, there may be mentioned: bacterial
cells, such as E. coli, Salmonella typhimurium; Streptomyces sp.; fungal cells, such
as yeast; insect cells, such as Drosophila and Sf9; animal cells, such as CHO, COS
or Bowes melanoma; plant cells, etc. The selection of an appropriate host is deemed
10 to be within the scope of those skilled in the art from the teachings provided herein.

More particularly, the present invention also includes recombinant constructs
comprising one or more of the sequences as broadly described above. The
constructs comprise a vector, such as a plasmid or viral vector, into which a
sequence of the invention has been inserted, in a forward or reverse orientation. In a
15 preferred aspect of this embodiment, the construct further comprises regulatory
sequences including, for example, a promoter, operably linked to the sequence.
Large numbers of suitable vectors and promoters are known to those of skill in the
art and are commercially available. The following vectors are provided by way of
example. Bacterial: pINCY (Incyte Pharmaceuticals Inc., Palo Alto, CA),
20 pSPORT1 (Life Technologies, Gaithersburg, MD), pQE70, pQE60, pQE-9
(Qiagen) pBs, phagescript, psiX174, pBluescript SK, pBsKS, pNH8a, pNH16a,
pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5
(Pharmacia); Eukaryotic: pWLneo, pSV2cat, pOG44, pXT1, pSG (Stratagene)
pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector
25 may be used as long as it is replicable and viable in the host.

Plasmid pINCY is generally identical to the plasmid pSPORT1 (available
from Life Technologies, Gaithersburg, MD) with the exception that it has two
modifications in the polylinker (multiple cloning site). These modifications are (1) it
lacks a HindIII restriction site and (2) its EcoRI restriction site lies at a different
30 location. pINCY is created from pSPORT1 by cleaving pSPORT1 with both
HindIII and EcoRI and replacing the excised fragment of the polylinker with
synthetic DNA fragments (SEQUENCE ID NO 14 and SEQUENCE ID NO 15).
This replacement may be made in any manner known to those of ordinary skill in the
art. For example, the two nucleotide sequences, SEQUENCE ID NO 14 and
35 SEQUENCE ID NO 15, may be generated synthetically with 5' terminal

-40-

phosphates, mixed together, and then ligated under standard conditions for performing staggered end ligations into the pSPORT1 plasmid cut with HindIII and EcoRI. Suitable host cells (such as E. coli DH5 μ cells) then are transfected with the ligated DNA and recombinant clones are selected for ampicillin resistance. Plasmid
5 DNA then is prepared from individual clones and subjected to restriction enzyme analysis or DNA sequencing in order to confirm the presence of insert sequences in the proper orientation. Other cloning strategies known to the ordinary artisan also may be employed.

Promoter regions can be selected from any desired gene using CAT
10 (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, SP6, T7, gpt, lambda P sub R, P sub L and trp. Eukaryotic promoters include cytomegalovirus (CMV) immediate early, herpes simplex virus (HSV) thymidine kinase, early and late SV40, LTRs from retroviruses and mouse
15 metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

In a further embodiment, the present invention provides host cells containing the above-described construct. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can
20 be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (L. Davis et al., "Basic Methods in Molecular Biology," 2nd edition, Appleton and Lang, Paramount Publishing, East Norwalk, CT (1994)).

25 The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.

Recombinant proteins can be expressed in mammalian cells, yeast, bacteria,
30 or other cells, under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, (Cold Spring
35 Harbor, NY, 1989), which is hereby incorporated by reference.

Transcription of a DNA encoding the polypeptide(s) of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin (bp 100 to 270), a cytomegalovirus early promoter enhancer, a polyoma enhancer on the late side of the replication origin and adenovirus enhancers.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transfection of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), alpha factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transfection include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces and Staphylococcus, although others may also be employed as a routine matter of choice.

Useful expression vectors for bacterial use comprise a selectable marker and bacterial origin of replication derived from plasmids comprising genetic elements of the well-known cloning vector pBR322 (ATCC 37017). Other vectors include but are not limited to PKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, WI). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

-42-

Following transfection of a suitable host and growth of the host to an appropriate cell density, the selected promoter is derepressed by appropriate means (e.g., temperature shift or chemical induction), and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well-known to the ordinary artisan.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts described by Gluzman, Cell 23:175 (1981), and other cell lines capable of expressing a compatible vector, such as the C127, HEK-293, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer and also any necessary ribosome binding sites, polyadenylation sites, splice donor and acceptor sites, transcriptional termination sequences and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements. Representative, useful vectors include pRc/CMV and pcDNA3 (available from Invitrogen, San Diego, CA).

CS141 polypeptides are recovered and purified from recombinant cell cultures by known methods including affinity chromatography, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxyapatite chromatography or lectin chromatography. It is preferred to have low concentrations (approximately 0.1-5 mM) of calcium ion present during purification (Price, et al., J. Biol. Chem. 244:917 (1969)). Protein refolding steps can be used, as necessary, in completing configuration of the polypeptide. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

Thus, polypeptides of the present invention may be naturally purified products expressed from a high expressing cell line, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and

mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated with mammalian or other eukaryotic carbohydrates or may be non-glycosylated. The polypeptides of the invention may also include an initial methionine amino acid residue.

The starting plasmids can be constructed from available plasmids in accord with published, known procedures. In addition, equivalent plasmids to those described are known in the art and will be apparent to one of ordinary skill in the art.

The following is the general procedure for the isolation and analysis of cDNA clones. In a particular embodiment disclosed herein, mRNA was isolated from GI tract tissue and used to generate the cDNA library. GI tract tissue was obtained from patients by surgical resection and was classified as tumor or non-tumor tissue by a pathologist.

The cDNA inserts from random isolates of the GI tract tissue libraries were sequenced in part, analyzed in detail as set forth in the Examples, and are disclosed in the Sequence Listing as SEQUENCE ID NOS 1-11. Also analyzed in detail as set forth in the Examples, and disclosed in the Sequence Listing, is the full-length sequence of clone 1281865 (referred to as clone 1281865IH (SEQUENCE ID NO 12)). The consensus sequence of these inserts is presented as SEQUENCE ID NO 13. These polynucleotides may contain an entire open reading frame with or without associated regulatory sequences for a particular gene, or they may encode only a portion of the gene of interest. This is attributed to the fact that many genes are several hundred and sometimes several thousand bases in length and, with current technology, cannot be cloned in their entirety because of vector limitations, incomplete reverse transcription of the first strand, or incomplete replication of the second strand. Contiguous, secondary clones containing additional nucleotide sequences may be obtained using a variety of methods known to those of skill in the art.

Methods for DNA sequencing are well known in the art. Conventional enzymatic methods employ DNA polymerase, Klenow fragment, Sequenase (US Biochemical Corp, Cleveland, OH) or Taq polymerase to extend DNA chains from an oligonucleotide primer annealed to the DNA template of interest. Methods have been developed for the use of both single-stranded and double-stranded templates. The chain termination reaction products may be electrophoresed on urea/polyacrylamide gels and detected either by autoradiography (for radionucleotide

labeled precursors) or by fluorescence (for fluorescent-labeled precursors). Recent improvements in mechanized reaction preparation, sequencing and analysis using the fluorescent detection method have permitted expansion in the number of sequences that can be determined per day using machines such as the Applied Biosystems 377 DNA Sequencers (Applied Biosystems, Foster City, CA).

The reading frame of the nucleotide sequence can be ascertained by several types of analyses. First, reading frames contained within the coding sequence can be analyzed for the presence of start codon ATG and stop codons TGA, TAA or TAG. Typically, one reading frame will continue throughout the major portion of a cDNA sequence while other reading frames tend to contain numerous stop codons. In such cases, reading frame determination is straightforward. In other more difficult cases, further analysis is required.

Algorithms have been created to analyze the occurrence of individual nucleotide bases at each putative codon triplet. See, for example J.W. Fickett, Nuc. Acids Res. 10:5303 (1982). Coding DNA for particular organisms (bacteria, plants and animals) tends to contain certain nucleotides within certain triplet periodicities, such as a significant preference for pyrimidines in the third codon position. These preferences have been incorporated into widely available software which can be used to determine coding potential (and frame) of a given stretch of DNA. The algorithm-derived information combined with start/stop codon information can be used to determine proper frame with a high degree of certainty. This, in turn, readily permits cloning of the sequence in the correct reading frame into appropriate expression vectors.

The nucleic acid sequences disclosed herein may be joined to a variety of other polynucleotide sequences and vectors of interest by means of well-established recombinant DNA techniques. See J. Sambrook et al., supra. Vectors of interest include cloning vectors, such as plasmids, cosmids, phage derivatives, phagemids, as well as sequencing, replication and expression vectors, and the like. In general, such vectors contain an origin of replication functional in at least one organism, convenient restriction endonuclease digestion sites and selectable markers appropriate for particular host cells. The vectors can be transferred by a variety of means known to those of skill in the art into suitable host cells which then produce the desired DNA, RNA or polypeptides.

Occasionally, sequencing or random reverse transcription errors will mask the presence of the appropriate open reading frame or regulatory element. In such

-45-

cases, it is possible to determine the correct reading frame by attempting to express the polypeptide and determining the amino acid sequence by standard peptide mapping and sequencing techniques. See, F.M. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY (1989). Additionally, the
5 actual reading frame of a given nucleotide sequence may be determined by transfection of host cells with vectors containing all three potential reading frames. Only those cells with the nucleotide sequence in the correct reading frame will produce a peptide of the predicted length.

The nucleotide sequences provided herein have been prepared by current,
10 state-of-the-art, automated methods and, as such, may contain unidentified nucleotides. These will not present a problem to those skilled in the art who wish to practice the invention. Several methods employing standard recombinant techniques, described in J. Sambrook (supra) or periodic updates thereof, may be used to complete the missing sequence information. The same techniques used for
15 obtaining a full length sequence, as described herein, may be used to obtain nucleotide sequences.

Expression of a particular cDNA may be accomplished by subcloning the cDNA into an appropriate expression vector and transfecting this vector into an appropriate expression host. The cloning vector used for the generation of the GI tract tissue cDNA library can be used for transcribing mRNA of a particular cDNA and contains a promoter for beta-galactosidase, an amino-terminal met and the
20 subsequent seven amino acid residues of beta-galactosidase. Immediately following these eight residues is an engineered bacteriophage promoter useful for artificial priming and transcription, as well as a number of unique restriction sites, including
25 EcoRI, for cloning. The vector can be transfected into an appropriate host strain of E. coli.

Induction of the isolated bacterial strain with isopropylthiogalactoside (IPTG) using standard methods will produce a fusion protein which contains the first seven residues of beta-galactosidase, about 15 residues of linker and the peptide
30 encoded within the cDNA. Since cDNA clone inserts are generated by an essentially random process, there is one chance in three that the included cDNA will lie in the correct frame for proper translation. If the cDNA is not in the proper reading frame, the correct frame can be obtained by deletion or insertion of an appropriate number of bases by well known methods including in vitro mutagenesis, digestion with
35 exonuclease III or mung bean nuclease, or oligonucleotide linker inclusion.

-46-

1 The cDNA can be shuttled into other vectors known to be useful for
expression of protein in specific hosts. Oligonucleotide primers containing cloning
sites and segments of DNA sufficient to hybridize to stretches at both ends of the
target cDNA can be synthesized chemically by standard methods. These primers can
5 then be used to amplify the desired gene segments by PCR. The resulting new gene
segments can be digested with appropriate restriction enzymes under standard
conditions and isolated by gel electrophoresis. Alternately, similar gene segments
can be produced by digestion of the cDNA with appropriate restriction enzymes and
filling in the missing gene segments with chemically synthesized oligonucleotides.
10 Segments of the coding sequence from more than one gene can be ligated together
and cloned in appropriate vectors to optimize expression of recombinant sequence.

Suitable expression hosts for such chimeric molecules include, but are not
limited to, mammalian cells, such as Chinese Hamster Ovary (CHO) and human
embryonic kidney (HEK) 293 cells, insect cells, such as Sf9 cells, yeast cells, such
15 as Saccharomyces cerevisiae and bacteria, such as E. coli. For each of these cell
systems, a useful expression vector may also include an origin of replication to
allow propagation in bacteria and a selectable marker such as the beta-lactamase
antibiotic resistance gene to allow selection in bacteria. In addition, the vectors may
include a second selectable marker, such as the neomycin phosphotransferase gene,
20 to allow selection in transfected eukaryotic host cells. Vectors for use in eukaryotic
expression hosts may require the addition of 3' poly A tail if the sequence of interest
lacks poly A.

Additionally, the vector may contain promoters or enhancers which increase
gene expression. Such promoters are host specific and include, but are not limited
25 to, MMTV, SV40, or metallothionine promoters for CHO cells; trp, lac, tac or T7
promoters for bacterial hosts; or alpha factor, alcohol oxidase or PGH promoters for
yeast. Adenoviral vectors with or without transcription enhancers, such as the Rous
sarcoma virus (RSV) enhancer, may be used to drive protein expression in
mammalian cell lines. Once homogeneous cultures of recombinant cells are
30 obtained, large quantities of recombinantly produced protein can be recovered from
the conditioned medium and analyzed using chromatographic methods well known
in the art. An alternative method for the production of large amounts of secreted
protein involves the transfection of mammalian embryos and the recovery of the
recombinant protein from milk produced by transgenic cows, goats, sheep, etc.
35 Polypeptides and closely related molecules may be expressed recombinantly in such

-47-

1 a way as to facilitate protein purification. One approach involves expression of a
chimeric protein which includes one or more additional polypeptide domains not
naturally present on human polypeptides. Such purification-facilitating domains
include, but are not limited to, metal-chelating peptides such as histidine-tryptophan
5 domains that allow purification on immobilized metals, protein A domains that allow
purification on immobilized immunoglobulin and the domain utilized in the FLAGS
extension/affinity purification system (Immunex Corp, Seattle, WA). The inclusion
of a cleavable linker sequence such as Factor XA or enterokinase from Invitrogen
(San Diego, CA) between the polypeptide sequence and the purification domain may
10 be useful for recovering the polypeptide.

Immunoassays.

CS141 polypeptides, including fragments, derivatives, and analogs thereof,
or cells expressing such polypeptides, can be utilized in a variety of assays, many of
which are described herein, for the detection of antibodies to GI tract tissue. They
15 also can be used as immunogens to produce antibodies. These antibodies can be,
for example, polyclonal or monoclonal antibodies, chimeric, single chain and
humanized antibodies, as well as Fab fragments, or the product of an Fab
expression library. Various procedures known in the art may be used for the
production of such antibodies and fragments.

20 For example, antibodies generated against a polypeptide comprising a
sequence of the present invention can be obtained by direct injection of the
polypeptide into an animal or by administering the polypeptide to an animal such as a
mouse, rabbit, goat or human. A mouse, rabbit or goat is preferred. The
polypeptide is selected from the group consisting of SEQUENCE ID NO 24,
25 SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27,
SEQUENCE ID NO 28, and fragments thereof. The antibody so obtained then will
bind the polypeptide itself. In this manner, even a sequence encoding only a
fragment of the polypeptide can be used to generate antibodies that bind the native
polypeptide. Such antibodies then can be used to isolate the polypeptide from test
30 samples such as tissue suspected of containing that polypeptide. For preparation of
monoclonal antibodies, any technique which provides antibodies produced by
continuous cell line cultures can be used. Examples include the hybridoma
technique as described by Kohler and Milstein, Nature 256:495-497 (1975), the
trioma technique, the human B-cell hybridoma technique as described by Kozbor et
35 al, Immun. Today 4:72 (1983) and the EBV-hybridoma technique to produce human

monoclonal antibodies as described by Cole et al., in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc, New York, NY, pp. 77-96 (1985). Techniques described for the production of single chain antibodies can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention. See,
5 for example, U.S. Patent No. 4,946,778, which is incorporated herein by reference.

Various assay formats may utilize the antibodies of the present invention, including "sandwich" immunoassays and probe assays. For example, the antibodies of the present invention, or fragments thereof, can be employed in various assay systems to determine the presence, if any, of CS141 antigen in a test sample. For
10 example, in a first assay format, a polyclonal or monoclonal antibody or fragment thereof, or a combination of these antibodies, which has been coated on a solid phase, is contacted with a test sample, to form a first mixture. This first mixture is incubated for a time and under conditions sufficient to form antigen/antibody complexes. Then, an indicator reagent comprising a monoclonal or a polyclonal
15 antibody or a fragment thereof, or a combination of these antibodies, to which a signal generating compound has been attached, is contacted with the antigen/antibody complexes to form a second mixture. This second mixture then is incubated for a time and under conditions sufficient to form antibody/antigen/antibody complexes. The presence of CS141 antigen in the test
20 sample and captured on the solid phase, if any, is determined by detecting the measurable signal generated by the signal generating compound. The amount of CS141 antigen present in the test sample is proportional to the signal generated.

In an alternative assay format, a mixture is formed by contacting: (1) a polyclonal antibody, monoclonal antibody, or fragment thereof, which specifically
25 binds to CS141 antigen, or a combination of such antibodies bound to a solid support; (2) the test sample; and (3) an indicator reagent comprising a monoclonal antibody, polyclonal antibody, or fragment thereof, which specifically binds to a different CS141 antigen (or a combination of these antibodies) to which a signal generating compound is attached. This mixture is incubated for a time and under
30 conditions sufficient to form antibody/antigen/antibody complexes. The presence, if any, of CS141 antigen present in the test sample and captured on the solid phase is determined by detecting the measurable signal generated by the signal generating compound. The amount of CS141 antigen present in the test sample is proportional to the signal generated.

In another assay format, one or a combination of at least two monoclonal antibodies of the invention can be employed as a competitive probe for the detection of antibodies to CS141 antigen. For example, CS141 polypeptides such as the recombinant antigens disclosed herein, either alone or in combination, are coated on a solid phase. A test sample suspected of containing antibody to CS141 antigen then is incubated with an indicator reagent comprising a signal generating compound and at least one monoclonal antibody of the invention for a time and under conditions sufficient to form antigen/antibody complexes of either the test sample and indicator reagent bound to the solid phase or the indicator reagent bound to the solid phase. The reduction in binding of the monoclonal antibody to the solid phase can be quantitatively measured.

In yet another detection method, each of the monoclonal or polyclonal antibodies of the present invention can be employed in the detection of CS141 antigens in tissue sections, as well as in cells, by immunohistochemical analysis. Cytochemical analysis wherein these antibodies are labeled directly (with, for example, fluorescein, colloidal gold, horseradish peroxidase, alkaline phosphatase, etc.) or are labeled by using secondary labeled anti-species antibodies (with various labels as exemplified herein) to track the histopathology of disease also are within the scope of the present invention.

In addition, these monoclonal antibodies can be bound to matrices similar to CNBr-activated Sepharose and used for the affinity purification of specific CS141 polypeptides from cell cultures or biological tissues such as to purify recombinant and native CS141 proteins.

The monoclonal antibodies of the invention also can be used for the generation of chimeric antibodies for therapeutic use, or other similar applications.

The monoclonal antibodies or fragments thereof can be provided individually to detect CS141 antigens. Combinations of the monoclonal antibodies (and fragments thereof) provided herein also may be used together as components in a mixture or "cocktail" of at least one CS141 antibody of the invention, along with antibodies which specifically bind to other CS141 regions, each antibody having different binding specificities. Thus, this cocktail can include the monoclonal antibodies of the invention which are directed to CS141 polypeptides disclosed herein and other monoclonal antibodies specific to other antigenic determinants of CS141 antigens or other related proteins.

The polyclonal antibody or fragment thereof which can be used in the assay formats should specifically bind to a CS141 polypeptide or other CS141 polypeptides additionally used in the assay. The polyclonal antibody used preferably is of mammalian origin such as, human, goat, rabbit or sheep polyclonal antibody which binds CS141 polypeptide. Most preferably, the polyclonal antibody is of rabbit origin. The polyclonal antibodies used in the assays can be used either alone or as a cocktail of polyclonal antibodies. Since the cocktails used in the assay formats are comprised of either monoclonal antibodies or polyclonal antibodies having different binding specificity to CS141 polypeptides, they are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition to, diseases and conditions of the GI tract, such as GI tract cancer.

It is contemplated and within the scope of the present invention that CS141 antigen may be detectable in assays by use of a recombinant antigen as well as by use of a synthetic peptide or purified peptide, which peptide comprises an amino acid sequence of CS141. The amino acid sequence of such a polypeptide is selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof. It also is within the scope of the present invention that different synthetic, recombinant or purified peptides, identifying different epitopes of CS141, can be used in combination in an assay for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition to diseases and conditions of the GI tract, such as GI tract cancer. In this case, all of these peptides can be coated onto one solid phase; or each separate peptide may be coated onto separate solid phases, such as microparticles, and then combined to form a mixture of peptides which can be later used in assays. Furthermore, it is contemplated that multiple peptides which define epitopes from different antigens may be used for the detection, diagnosis, staging, monitoring, prognosis, prevention or treatment of, or determining the predisposition to, diseases and conditions of the GI tract, such as GI tract cancer. Peptides coated on solid phases or labeled with detectable labels are then allowed to compete with those present in a patient sample (if any) for a limited amount of antibody. A reduction in binding of the synthetic, recombinant, or purified peptides to the antibody (or antibodies) is an indication of the presence of CS141 antigen in the patient sample. The presence of CS141 antigen indicates the presence of GI tract tissue disease,

-51-

especially GI tract cancer, in the patient. Variations of assay formats are known to those of ordinary skill in the art and many are discussed herein below.

In another assay format, the presence of anti-CS141 antibody and/or CS141 antigen can be detected in a simultaneous assay, as follows. A test sample is
5 simultaneously contacted with a capture reagent of a first analyte, wherein said capture reagent comprises a first binding member specific for a first analyte attached to a solid phase and a capture reagent for a second analyte, wherein said capture reagent comprises a first binding member for a second analyte attached to a second solid phase, to thereby form a mixture. This mixture is incubated for a time and
10 under conditions sufficient to form capture reagent/first analyte and capture reagent/second analyte complexes. These so-formed complexes then are contacted with an indicator reagent comprising a member of a binding pair specific for the first analyte labeled with a signal generating compound and an indicator reagent comprising a member of a binding pair specific for the second analyte labeled with a
15 signal generating compound to form a second mixture. This second mixture is incubated for a time and under conditions sufficient to form capture reagent/first analyte/indicator reagent complexes and capture reagent/second analyte/indicator reagent complexes. The presence of one or more analytes is determined by detecting a signal generated in connection with the complexes formed on either or both solid
20 phases as an indication of the presence of one or more analytes in the test sample. In this assay format, recombinant antigens derived from the expression systems disclosed herein may be utilized, as well as monoclonal antibodies produced from the proteins derived from the expression systems as disclosed herein. For example, in this assay system, CS141 antigen can be the first analyte. Such assay systems are
25 described in greater detail in EP Publication No. 0473065.

In yet other assay formats, the polypeptides disclosed herein may be utilized to detect the presence of antibody against CS141 antigen in test samples. For example, a test sample is incubated with a solid phase to which at least one polypeptide such as a recombinant protein or synthetic peptide has been attached.
30 The polypeptide is selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof. These are reacted for a time and under conditions sufficient to form antigen/antibody complexes. Following incubation, the antigen/antibody complex is detected. Indicator reagents may be
35 used to facilitate detection, depending upon the assay system chosen. In another

-52-

assay format, a test sample is contacted with a solid phase to which a recombinant protein produced as described herein is attached, and also is contacted with a monoclonal or polyclonal antibody specific for the protein, which preferably has been labeled with an indicator reagent. After incubation for a time and under conditions sufficient for antibody/antigen complexes to form, the solid phase is separated from the free phase, and the label is detected in either the solid or free phase as an indication of the presence of antibody against CS141 antigen. Other assay formats utilizing the recombinant antigens disclosed herein are contemplated. These include contacting a test sample with a solid phase to which at least one antigen from a first source has been attached, incubating the solid phase and test sample for a time and under conditions sufficient to form antigen/antibody complexes, and then contacting the solid phase with a labeled antigen, which antigen is derived from a second source different from the first source. For example, a recombinant protein derived from a first source such as E. coli is used as a capture antigen on a solid phase, a test sample is added to the so-prepared solid phase, and following standard incubation and washing steps as deemed or required, a recombinant protein derived from a different source (i.e., non-E. coli) is utilized as a part of an indicator reagent which subsequently is detected. Likewise, combinations of a recombinant antigen on a solid phase and synthetic peptide in the indicator phase also are possible. Any assay format which utilizes an antigen specific for CS141 produced or derived from a first source as the capture antigen and an antigen specific for CS141 from a different second source is contemplated. Thus, various combinations of recombinant antigens, as well as the use of synthetic peptides, purified proteins and the like, are within the scope of this invention. Assays such as this and others are described in U.S. Patent No. 5,254,458, which enjoys common ownership and is incorporated herein by reference.

Other embodiments which utilize various other solid phases also are contemplated and are within the scope of this invention. For example, ion capture procedures for immobilizing an immobilizable reaction complex with a negatively charged polymer (described in EP publication 0326100 and EP publication No. 0406473), can be employed according to the present invention to effect a fast solution-phase immunochemical reaction. An immobilizable immune complex is separated from the rest of the reaction mixture by ionic interactions between the negatively charged poly-anion/immune complex and the previously treated, positively charged porous matrix and detected by using various signal generating

systems previously described, including those described in chemiluminescent signal measurements as described in EPO Publication No. 0 273,115.

Also, the methods of the present invention can be adapted for use in systems which utilize microparticle technology including automated and semi-automated
5 systems wherein the solid phase comprises a microparticle (magnetic or non-magnetic). Such systems include those described in, for example, published EPO applications Nos. EP 0 425 633 and EP 0 424 634, respectively.

The use of scanning probe microscopy (SPM) for immunoassays also is a technology to which the monoclonal antibodies of the present invention are easily
10 adaptable. In scanning probe microscopy, particularly in atomic force microscopy, the capture phase, for example, at least one of the monoclonal antibodies of the invention, is adhered to a solid phase and a scanning probe microscope is utilized to detect antigen/antibody complexes which may be present on the surface of the solid phase. The use of scanning tunneling microscopy eliminates the need for labels
15 which normally must be utilized in many immunoassay systems to detect antigen/antibody complexes. The use of SPM to monitor specific binding reactions can occur in many ways. In one embodiment, one member of a specific binding partner (analyte specific substance which is the monoclonal antibody of the invention) is attached to a surface suitable for scanning. The attachment of the
20 analyte specific substance may be by adsorption to a test piece which comprises a solid phase of a plastic or metal surface, following methods known to those of ordinary skill in the art. Or, covalent attachment of a specific binding partner (analyte specific substance) to a test piece which test piece comprises a solid phase of derivatized plastic, metal, silicon, or glass may be utilized. Covalent attachment
25 methods are known to those skilled in the art and include a variety of means to irreversibly link specific binding partners to the test piece. If the test piece is silicon or glass, the surface must be activated prior to attaching the specific binding partner. Also, polyelectrolyte interactions may be used to immobilize a specific binding partner on a surface of a test piece by using techniques and chemistries. The
30 preferred method of attachment is by covalent means. Following attachment of a specific binding member, the surface may be further treated with materials such as serum, proteins, or other blocking agents to minimize non-specific binding. The surface also may be scanned either at the site of manufacture or point of use to verify its suitability for assay purposes. The scanning process is not anticipated to alter the
35 specific binding properties of the test piece.

-54-

While the present invention discloses the preference for the use of solid phases, it is contemplated that the reagents such as antibodies, proteins and peptides of the present invention can be utilized in non-solid phase assay systems. These assay systems are known to those skilled in the art, and are considered to be within the scope of the present invention.

It is contemplated that the reagent employed for the assay can be provided in the form of a test kit with one or more containers such as vials or bottles, with each container containing a separate reagent such as a probe, primer, monoclonal antibody or a cocktail of monoclonal antibodies, or a polypeptide (e.g. recombinantly, synthetically produced or purified) employed in the assay. The polypeptide is selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof. Other components such as buffers, controls and the like, known to those of ordinary skill in art, may be included in such test kits. It also is contemplated to provide test kits which have means for collecting test samples comprising accessible body fluids, e.g., blood, urine, saliva and stool. Such tools useful for collection ("collection materials") include lancets and absorbent paper or cloth for collecting and stabilizing blood; swabs for collecting and stabilizing saliva; cups for collecting and stabilizing urine or stool samples. Collection materials, papers, cloths, swabs, cups and the like, may optionally be treated to avoid denaturation or irreversible adsorption of the sample. The collection materials also may be treated with or contain preservatives, stabilizers or antimicrobial agents to help maintain the integrity of the specimens. Test kits designed for the collection, stabilization and preservation of test specimens obtained by surgery or needle biopsy are also useful. It is contemplated that all kits may be configured in two components which can be provided separately; one component for collection and transport of the specimen and the other component for the analysis of the specimen. The collection component, for example, can be provided to the open market user while the components for analysis can be provided to others such as laboratory personnel for determination of the presence, absence or amount of analyte. Further, kits for the collection, stabilization and preservation of test specimens may be configured for use by untrained personnel and may be available in the open market for use at home with subsequent transportation to a laboratory for analysis of the test sample.

-55-

E. coli bacteria (clone 1281865) was deposited on June 12, 1997 with the American Type Culture Collection (A.T.C.C.), 12301 Parklawn Drive, Rockville, Maryland 20852. This deposit was under the terms of the Budapest Treaty and will be maintained for a period of thirty (30) years from the date of deposit, or for five
5 (5) years after the last request for the deposit, or for the enforceable period of the U.S. patent, whichever is longer. The deposit and any other deposited material described herein are provided for convenience only, and are not required to practice the present invention in view of the teachings provided herein. The cDNA sequence in all of the deposited material is incorporated herein by reference. Clone 1281865
10 was accorded A.T.C.C. Deposit No. 98255.

The present invention will now be described by way of examples, which are meant to illustrate, but not to limit, the scope of the present invention.

EXAMPLES

15 Example 1: Identification of Gastrointestinal Tract Tissue Library CS141 Gene-Specific Clones

A. Library Comparison of Expressed Sequence Tags (ESTs) or Transcript Images. Partial sequences of cDNA clone inserts, so-called "expressed sequence tags" (ESTs), were derived from cDNA libraries made from GI tract tumor tissues, GI tract non-tumor tissues and numerous other tissues, both tumor and non-tumor
20 and entered into a database (LIFESEQ™ database, available from Incyte Pharmaceuticals, Palo Alto, CA) as gene transcript images. See International Publication No. WO 95/20681. (A transcript image is a listing of the number of EST's for each of the represented genes in a given tissue library. ESTs sharing
25 regions of mutual sequence overlap are classified into clusters. A cluster is assigned a clone number from a representative 5' EST. Often, a cluster of interest can be extended by comparing its consensus sequence with sequences of other EST's which did not meet the criteria for automated clustering. The alignment of all available clusters and single ESTs represent a contig from which a consensus
30 sequence is derived.) The transcript images then were evaluated to identify EST sequences that were representative primarily of the GI tract tissue libraries. These target clones then were ranked according to their abundance (occurrence) in the target libraries and their absence from background libraries. Higher abundance clones with low background occurrence were given higher study priority. ESTs
35 corresponding to the consensus sequence of CS141 were found in 41.4% (24 of 58)

-56-

of GI tract tissue libraries. ESTs corresponding to the consensus sequence
SEQUENCE ID NO 13 (or fragments thereof) were found in 3.4% (17 of 506) of
the other, non-GI tract, libraries of the data base. Therefore, the consensus
sequence or fragment thereof was found more than 12 times more often in GI tract
5 than non-GI tract tissues. Overlapping clones 775133 (SEQUENCE ID NO 1),
1338704 (SEQUENCE ID NO 2), 2645837 (SEQUENCE ID NO 3), 775762
(SEQUENCE ID NO 4), 3210629 (SEQUENCE ID NO 5), 1281865 (SEQUENCE
ID NO 6), 1807758 (SEQUENCE ID NO 7), 1735382 (SEQUENCE ID NO 8),
2128334 (SEQUENCE ID NO 9), g2197992 (SEQUENCE ID NO 10), and
10 g2409650 (SEQUENCE ID NO 11) were identified for further study. These
represented the minimum number of clones that were needed to form the contig and
from which, along with the full-length sequence of clone 1281865IH (SEQUENCE
ID NO 12), the consensus sequence provided herein (SEQUENCE ID NO 13) was
derived.

15 B. Generation of a Consensus Sequence. The nucleotide sequences of
clones 775133 (SEQUENCE ID NO 1), 1338704 (SEQUENCE ID NO 2),
2645837 (SEQUENCE ID NO 3), 775762 (SEQUENCE ID NO 4), 3210629
(SEQUENCE ID NO 5), 1281865 (SEQUENCE ID NO 6), 1807758 (SEQUENCE
ID NO 7), 1735382 (SEQUENCE ID NO 8), 2128334 (SEQUENCE ID NO 9),
20 g2197992 (SEQUENCE ID NO 10), g2409650 (SEQUENCE ID NO 11), and
1281865IH (SEQUENCE ID NO 12) were entered in the Sequencher™ Program
(available from Gene Codes Corporation, Ann Arbor, MI) in order to generate a
nucleotide alignment (contig map) and then generate their consensus sequence
(SEQUENCE ID NO 13). Figures 1A-1C show the nucleotide sequence alignment
25 of these clones and their resultant nucleotide consensus sequence (SEQUENCE ID
NO 13). Figure 2 presents the contig map depicting the clones 775133
(SEQUENCE ID NO 1), 1338704 (SEQUENCE ID NO 2), 2645837 (SEQUENCE
ID NO 3), 775762 (SEQUENCE ID NO 4), 3210629 (SEQUENCE ID NO 5),
1281865 (SEQUENCE ID NO 6), 1807758 (SEQUENCE ID NO 7), 1735382
30 (SEQUENCE ID NO 8), 2128334 (SEQUENCE ID NO 9), g2197992
(SEQUENCE ID NO 10), g2409650 (SEQUENCE ID NO 11), and 1281865IH
(SEQUENCE ID NO 12) which form overlapping regions of the CS141 gene, and
the resultant consensus nucleotide sequence (SEQUENCE ID NO 13) of these
clones in a graphic display. Following this, a three-frame translation was performed
35 on the consensus sequence (SEQUENCE ID NO 13). The first forward frame was

-57-

found to have an open reading frame encoding a 223 residue amino acid sequence which is presented as SEQUENCE ID NO 24.

Analysis of the LIFESEQ™ database indicates a possible G/T polymorphism at position 634 in the consensus nucleotide sequence (SEQUENCE ID NO 13). The ratio of G's to T's at this position in the database is 13:3. A polymorphism at 634 results in an amino acid shift between alanine (GGC) and serine (TGC).

The polypeptide sequence of SEQUENCE ID NO 24 was also compared with published sequences using software and techniques known to those skilled in the art. The polypeptide sequence encoded by a region of the human X chromosome in region Xq28 was found to be partially homologous to the CS141 polypeptide of SEQUENCE ID NO 24. This particular transcript of the Xq28 region is described in the publication by S. Bione et al. [Proc. Natl. Acad. Sci. USA 90(23):10977-10981(1993)].

Example 2: Sequencing of CS141 EST-Specific Clones

The DNA sequence of clone 1281865IH of the CS141 gene contig was determined (SEQUENCE ID NO 12) using dideoxy termination sequencing with dye terminators following known methods (F. Sanger et al., PNAS U.S.A. 74:5463 (1977)).

Because the pINCY vector (available from Incyte Pharmaceuticals, Inc., Palo Alto, CA) contains universal priming sites just adjacent to the 3' and 5' ligation junctions of the inserts, approximately 300 bases of the insert were sequenced in both directions using universal primers, SEQUENCE ID NO 16 and SEQUENCE ID NO 17 (New England Biolabs, Beverly, MA and Applied Biosystems Inc, Foster City, CA, respectively). The sequencing reactions were run on a polyacrylamide denaturing gel, and the sequences were determined by an Applied Biosystems 377 Sequencer (available from Applied Biosystems, Foster City, CA). Additional sequencing primers, SEQUENCE ID NO 18, SEQUENCE ID NO 19, SEQUENCE ID NO 20, and SEQUENCE ID NO 21, were designed from sequence information of the consensus sequence (SEQUENCE ID NO 13). These primers then were used to determine the remaining DNA sequence of the cloned insert from each DNA strand, as previously described.

Example 3: Nucleic Acid

A. RNA Extraction from Tissue. Total RNA was isolated from GI tract tissues and from non-GI tract tissues. Various methods were utilized, including but not limited to the lithium chloride/urea technique, known in the art and described by Kato et al. (J. Virol. 61:2182-2191, 1987), and TRIzol™ (Gibco-BRL, Grand Island, NY).

Briefly, tissue was placed in a sterile conical tube on ice and 10-15 volumes of 3 M LiCl, 6 M urea, 5 mM EDTA, 0.1 M β-mercaptoethanol, 50 mM Tris-HCl (pH 7.5) were added. The tissue was homogenized with a Polytron® homogenizer (Brinkman Instruments, Inc., Westbury, NY) for 30-50 sec on ice. The solution was transferred to a 15 ml plastic centrifuge tube and placed overnight at -20°C. The tube was centrifuged for 90 min at 9,000 x g at 0-4°C and the supernatant was immediately decanted. Ten ml of 3 M LiCl were added and the tube was vortexed for 5 sec. The tube was centrifuged for 45 min at 11,000 x g at 0-4°C. The decanting, resuspension in LiCl, and centrifugation was repeated and the final pellet was air dried and suspended in 2 ml of 1 mM EDTA, 0.5% SDS, 10 mM Tris (pH 7.5). Twenty microliters (20 μl) of Proteinase K (20 mg/ml) were added, and the solution was incubated for 30 min at 37°C with occasional mixing. One-tenth volume (0.22-0.25 ml) of 3 M NaCl was added and the solution was vortexed before transfer into another tube containing 2 ml of phenol/chloroform/isoamyl alcohol (PCI). The tube was vortexed for 1-3 sec and centrifuged for 20 min at 3,000 x g at 10°C. The PCI extraction was repeated and followed by two similar extractions with chloroform/isoamyl alcohol (CI). The final aqueous solution was transferred to a prechilled 15 ml Corex glass tube containing 6 ml of absolute ethanol, the tube was covered with parafilm, and placed at -20°C overnight. The tube was centrifuged for 30 min at 10,000 x g at 0-4°C and the ethanol supernatant was decanted immediately. The RNA pellet was washed four times with 10 ml of 75% ice-cold ethanol and the final pellet was air dried for 15 min at room temperature. The RNA was suspended in 0.5 ml of 10 mM TE (pH 7.6, 1 mM EDTA) and its concentration was determined spectrophotometrically. RNA samples were aliquoted and stored at -70°C as ethanol precipitates.

The quality of the RNA was determined by agarose gel electrophoresis (see Example 5, Northern Blot Analysis) and staining with 0.5 μg/ml ethidium bromide for one hour. RNA samples that did not contain intact rRNAs were excluded from the study.

-59-

Alternatively, for RT-PCR analysis, 1 ml of Ultraspec RNA reagent was added to 120 mg of pulverized tissue in a 2.0 ml polypropylene microfuge tube, homogenized with a Polytron® homogenizer (Brinkman Instruments, Inc., Westbury, NY) for 50 sec and placed on ice for 5 min. Then, 0.2 ml of chloroform was added to each sample, followed by vortexing for 15 sec. The sample was placed on ice for another 5 min, followed by centrifugation at 12,000 x g for 15 min at 4°C. The upper layer was collected and transferred to another RNase-free 2.0 ml microfuge tube. An equal volume of isopropanol was added to each sample, and the solution was placed on ice for 10 min. The sample was centrifuged at 12,000 x g for 10 min at 4°C, and the supernatant was discarded. The remaining pellet was washed twice with cold 75% ethanol, resuspended by vortexing, and the resuspended material was then pelleted by centrifugation at 7500 x g for 5 min at 4°C. Finally, the RNA pellet was dried in a Speedvac (Savant, Farmingdale, NY) for 5 min and reconstituted in RNase-free water.

B. RNA Extraction from Blood Mononuclear Cells. Mononuclear cells are isolated from blood samples from patients by centrifugation using Ficoll-Hypaque as follows. A 10 ml volume of whole blood is mixed with an equal volume of RPMI Medium (Gibco-BRL, Grand Island, NY). This mixture is then underlayered with 10 ml of Ficoll-Hypaque (Pharmacia, Piscataway, NJ) and centrifuged for 30 minutes at 200 x g. The buffy coat containing the mononuclear cells is removed, diluted to 50 ml with Dulbecco's PBS (Gibco-BRL, Grand Island, NY) and the mixture centrifuged for 10 minutes at 200 x g. After two washes, the resulting pellet is resuspended in Dulbecco's PBS to a final volume of 1 ml.

RNA is prepared from the isolated mononuclear cells as described by N. Kato et al., J. Virology 61: 2182-2191 (1987). Briefly, the pelleted mononuclear cells are brought to a final volume of 1 ml and then are resuspended in 250 µL of PBS and mixed with 2.5 ml of 3 M LiCl, 6 M urea, 5 mM EDTA, 0.1 M 2-mercaptoethanol, 50 mM Tris-HCl (pH 7.5). The resulting mixture is homogenized and incubated at -20°C overnight. The homogenate is centrifuged at 8,000 RPM in a Beckman J2-21M rotor for 90 minutes at 0-4°C. The pellet is resuspended in 10 ml of 3 M LiCl by vortexing and then centrifuged at 10,000 RPM in a Beckman J2-21M rotor centrifuge for 45 minutes at 0-4°C. The resuspending and pelleting steps then are repeated. The pellet is resuspended in 2 ml of 1 mM EDTA, 0.5% SDS, 10 mM Tris (pH 7.5) and 400 µg Proteinase K with vortexing and then it is incubated at 37°C for 30 minutes with shaking. One tenth volume of 3 M NaCl then is added

-60-

and the mixture is vortexed. Proteins are removed by two cycles of extraction with phenol/ chloroform/ isoamyl alcohol (PCI) followed by one extraction with chloroform/ isoamyl alcohol (CI). RNA is precipitated by the addition of 6 ml of absolute ethanol followed by overnight incubation at -20°C. After the precipitated
5 RNA is collected by centrifugation, the pellet is washed 4 times in 75% ethanol. The pelleted RNA is then dissolved in solution containing 1 mM EDTA, 10 mM Tris-HCl (pH 7.5).

Non-GI tract tissues are used as negative controls. The mRNA can be further purified from total RNA by using commercially available kits such as oligo
10 dT cellulose spin columns (RediCol™ from Pharmacia, Uppsala, Sweden) for the isolation of poly-adenylated RNA. Total RNA or mRNA can be dissolved in lysis buffer (5 M guanidine thiocyanate, 0.1 M EDTA, pH 7.0) for analysis in the ribonuclease protection assay.

C. RNA Extraction from polysomes. Tissue is minced in saline at 4°C and
15 mixed with 2.5 volumes of 0.8 M sucrose in a TK₁₅₀M (150 mM KCl, 5 mM MgCl₂, 50 mM Tris-HCl, pH 7.4) solution containing 6 mM 2-mercaptoethanol. The tissue is homogenized in a Teflon-glass Potter homogenizer with five strokes at 100-200 rpm followed by six strokes in a Dounce homogenizer, as described by B. Mechler, Methods in Enzymology 152:241-248 (1987). The homogenate then is
20 centrifuged at 12,000 x g for 15 min at 4°C to sediment the nuclei. The polysomes are isolated by mixing 2 ml of the supernatant with 6 ml of 2.5 M sucrose in TK₁₅₀M and layering this mixture over 4 ml of 2.5 M sucrose in TK₁₅₀M in a 38 ml polyallomer tube. Two additional sucrose TK₁₅₀M solutions are successively layered onto the extract fraction; a first layer of 13 ml 2.05 M sucrose followed by a
25 second layer of 6 ml of 1.3 M sucrose. The polysomes are isolated by centrifuging the gradient at 90,000 x g for 5 hr at 4°C. The fraction then is taken from the 1.3 M sucrose/2.05 M sucrose interface with a siliconized pasteur pipette and diluted in an equal volume of TE (10 mM Tris-HCl, pH 7.4, 1 mM EDTA). An equal volume of 90°C SDS buffer (1% SDS, 200 mM NaCl, 20 mM Tris-HCl, pH 7.4) is added and
30 the solution is incubated in a boiling water bath for 2 min. Proteins next are digested with a Proteinase-K digestion (50 mg/ml) for 15 min at 37°C. The mRNA is purified with 3 equal volumes of phenol-chloroform extractions followed by precipitation with 0.1 volume of 2 M sodium acetate (pH 5.2) and 2 volumes of 100% ethanol at -20°C overnight. The precipitated RNA is recovered by
35 centrifugation at 12,000 x g for 10 min at 4°C. The RNA is dried and resuspended

-61-

in TE (pH 7.4) or distilled water. The resuspended RNA then can be used in a slot blot or dot blot hybridization assay to check for the presence of CS141 mRNA (see Example 6).

5 The quality of nucleic acid and proteins is dependent on the method of preparation used. Each sample may require a different preparation technique to maximize isolation efficiency of the target molecule. These preparation techniques are within the skill of the ordinary artisan.

Example 4: Ribonuclease Protection Assay

10 A. Synthesis of Labeled Complementary RNA (cRNA) Hybridization Probe and Unlabeled Sense Strand. Labeled antisense and unlabeled sense riboprobes are transcribed from the CS141 gene cDNA sequence which contains a 5' RNA polymerase promoter such as SP6 or T7. The sequence may be from a vector containing the appropriate CS141 cDNA insert, or from a PCR-generated product of
15 the insert using PCR primers which incorporate a 5' RNA polymerase promoter sequence. For example, the described plasmid, clone 1281865 or another comparable clone, containing the CS141 gene cDNA sequence, flanked by opposed SP6 and T7 polymerase promoters, is purified using Qiagen Plasmid Purification Kit (Qiagen, Chatsworth, CA). Then 10 µg of the plasmid are linearized by cutting
20 with 10 U DdeI restriction enzyme for 1 hr at 37°C. The linearized plasmid is purified using QIAprep kits (Qiagen, Chatsworth, CA) and used for the synthesis of antisense transcript from the appropriate SP6 or T7 promoter using the Riboprobe® in vitro Transcription System (Promega Corporation, Madison, WI), as described by the supplier's instructions, incorporating either 6.3 µM (alpha³²P) UTP
25 (Amersham Life Sciences, Inc. Arlington Heights, IL) or 100-500 µM biotinylated UTP as a label. To generate the sense strand, 10 µg of the purified plasmid are cut with restriction enzymes 10U XbaI and 10 U NotI, and transcribed as above from the appropriate SP6 or T7 promoter. Both sense and antisense strands are isolated by spin column chromatography. Unlabeled sense strand is quantitated by UV
30 absorption at 260 nm.

B. Hybridization of Labeled Probe to Target. Frozen tissue is pulverized to powder under liquid nitrogen and 100-500 mg are dissolved in 1 ml of lysis buffer, available as a component of the Direct Protect™ Lysate RNase Protection kit (Ambion, Inc., Austin, TX). Further dissolution can be achieved using a tissue
35 homogenizer. In addition, a dilution series of a known amount of sense strand in

-62-

mouse liver lysate is made for use as a positive control. Finally, 45 µl of solubilized tissue or diluted sense strand is mixed directly with either 1) 1×10^5 cpm of radioactively labeled probe or 2) 250 pg of non-isotopically labeled probe in 5 µl of lysis buffer. Hybridization is allowed to proceed overnight at 37°C. See, T.

5 Kaabache et al., Anal. Biochem. 232:225-230 (1995).

C. RNase Digestion. RNA that is not hybridized to probe is removed from the reaction as per the Direct Protect™ protocol using a solution of RNase A and RNase T1 for 30 min at 37°C, followed by removal of RNase by Proteinase-K digestion in the presence of sodium sarcosyl. Hybridized fragments protected from
10 digestion are then precipitated by the addition of an equal volume of isopropanol and placed at -70°C for 3 hr. The precipitates are collected by centrifugation at 12,000 x g for 20 min.

D. Fragment Analysis. The precipitates are dissolved in denaturing gel loading dye (80% formamide, 10 mM EDTA (pH 8.0), 1 mg/ml xylene cyanol, 1
15 mg/ml bromophenol blue), heat denatured, and electrophoresed in 6% polyacrylamide TBE, 8 M urea denaturing gels. The gels are imaged and analyzed using the STORM™ storage phosphor autoradiography system (Molecular Dynamics, Sunnyvale, CA). Quantitation of protected fragment bands, expressed in femtograms (fg), is achieved by comparing the peak areas obtained from the test
20 samples to those from the known dilutions of the positive control sense strand (see Section B, supra). The results are expressed in molecules of CS141 RNA/cell and as a image rating score. In cases where non-isotopic labels are used, hybrids are transferred from the gels to membranes (nylon or nitrocellulose) by blotting and then analyzed using detection systems that employ streptavidin alkaline phosphatase
25 conjugates and chemiluminescence or chemifluorescence reagents.

Detection of a product comprising a sequence selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof, is indicative of the presence of CS141 mRNA(s), suggesting a diagnosis of a GI tract tissue disease or condition, such as GI tract cancer.

30

Example 5: Northern Blotting

The Northern blot technique is used to identify a specific size RNA species in a complex population of RNA using agarose gel electrophoresis and nucleic acid hybridization. Briefly, 5-10 µg of total RNA (see Example 3, Nucleic Acid
35 Preparation) were incubated in 15 µl of a solution containing 40 mM

-63-

morpholinopropanesulfonic acid (MOPS) (pH 7.0), 10 mM sodium acetate, 1 mM EDTA, 2.2 M formaldehyde, 50% v/v formamide for 15 min at 65°C. The denatured RNA was mixed with 2 µl of loading buffer (50% glycerol, 1 mM EDTA, 0.4% bromophenol blue, 0.4% xylene cyanol) and loaded into a denaturing 1.0% agarose gel containing 40 mM MOPS (pH 7.0), 10 mM sodium acetate, 1 mM EDTA and 2.2 M formaldehyde. The gel was electrophoresed at 60 V for 1.5 hr, stained with 0.5 µg/ml ethidium bromide for one hour and rinsed in RNase free water for 30-45 min. RNA was transferred from the gel onto nylon membranes (Brightstar-Plus, Ambion, Inc., Austin, TX) for 1.5 hours using the downward alkaline capillary transfer method (Chomczynski, Anal. Biochem. 201:134-139, 1992). The filter was rinsed with 1X SSC and RNA was crosslinked to the filter using a Stratalinker (Stratagene, Inc., La Jolla, CA) on the autocrosslinking mode and dried for 15 min. The membrane was then placed into a hybridization tube containing 20 ml of preheated prehybridization solution (5X SSC, 50% formamide, 5X Denhardt's solution, 100 µg/ml denatured salmon sperm DNA) and incubated in a 42°C hybridization oven for at least 3 hr. While the blot was prehybridizing, a ³²P-labeled random-primed probe was generated using the CS141 insert according to the manufacturer's instructions (Gibco-BRL, Grand Island, NY). Half of the probe was boiled for 10 min, quick chilled on ice and added to the hybridization tube. Hybridization was carried out at 42°C for at least 12 hr. The hybridization solution was discarded and the filter was washed twice in 30 ml of 3X SSC, 0.1% SDS at 42°C for 15 min, followed by two washes in 30 ml of 0.3X SSC, 0.1% SDS at 60°C for 15 min. each. The filter was wrapped in Saran Wrap and exposed to Kodak XAR-Omat film for 8-120 hr and the film was developed for analysis.

Results of the analysis of CS141 hybridization to a Northern blot containing GI tract tissues and non-GI tract tissues are shown in Figures 3A and 3B which depict ethidium bromide (EtBr)-stained RNA gels and the CS141 Northern blots. The positions of RNA size standards (in Kb) are shown to the left of each panel. As shown in Figure 3A, the CS141 probe detected an approximately 1.4 Kb RNA in the colon sample (lane 4) but not in any of the other eleven non-colon RNA samples (lanes 1, 2, 3, and 5-12). In Figure 3B, the CS141 probe detected an approximately 1.4 Kb RNA in 1 of 6 normal colon specimens and in 4 of 6 colon cancer specimens.

Detection of a product comprising a sequence selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof, is

indicative of the presence of CS141 mRNA(s), suggesting a diagnosis of a GI tract tissue disease or condition, such as GI tract cancer.

Example 6: Dot Blot/Slot Blot

5 Dot and slot blot assays are quick methods to evaluate the presence of a specific nucleic acid sequence in a complex mix of nucleic acid. To perform such assays, up to 50 µg of RNA are mixed in 50 µl of 50% formamide, 7% formaldehyde, 1X SSC, incubated 15 min at 68°C, and then cooled on ice. Then, 100 µl of 20X SSC are added to the RNA mixture and loaded under vacuum onto a
10 manifold apparatus that has a prepared nitrocellulose or nylon membrane. The membrane is soaked in water, 20X SSC for 1 hour, placed on two sheets of 20X SSC prewet Whatman #3 filter paper, and loaded into a slot blot or dot blot vacuum manifold apparatus. The slot blot is analyzed with probes prepared and labeled as described in Example 4, supra. Detection of mRNA corresponding to a sequence
15 selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof, is indicative of the presence of CS141 mRNA(s), suggesting a diagnosis of a GI tract tissue disease or condition, such as GI tract cancer.

Other methods and buffers which can be utilized in the methods described in Examples 5 and 6, but not specifically detailed herein, are known in the art and are
20 described in J. Sambrook et al, supra which is incorporated herein by reference.

Example 7: In Situ Hybridization

This method is useful to directly detect specific target nucleic acid sequences in cells using detectable nucleic acid hybridization probes.

25 Tissues are prepared with cross-linking fixative agents such as paraformaldehyde or glutaraldehyde for maximum cellular RNA retention. See, L. Angerer et al., Methods in Cell Biol. 35:37-71 (1991). Briefly, the tissue is placed in greater than 5 volumes of 1% glutaraldehyde in 50 mM sodium phosphate, pH 7.5 at 4°C for 30 min. The solution is changed with fresh glutaraldehyde solution
30 (1% glutaraldehyde in 50 mM sodium phosphate, pH 7.5) for a further 30 min fixing. The fixing solution should have an osmolality of approximately 0.375% NaCl. The tissue is washed once in isotonic NaCl to remove the phosphate.

The fixed tissues then are embedded in paraffin as follows. The tissue is dehydrated through a series of increasing ethanol concentrations for 15 min each:
35 50% (twice), 70% (twice), 85%, 90% and then 100% (twice). Next, the tissue is

-65-

soaked in two changes of xylene for 20 min each at room temperature. The tissue is then soaked in two changes of a 1:1 mixture of xylene and paraffin for 20 min each at 60°C; and then in three final changes of paraffin for 15 min each.

Next, the tissue is cut in 5 µm sections using a standard microtome and
5 placed on a slide previously treated with a tissue adhesive such as 3-aminopropyltriethoxysilane.

Paraffin is removed from the tissue by two 10 min xylene soaks and rehydrated in a series of decreasing ethanol concentrations: 99% (twice), 95%, 85%, 70%, 50%, 30%, and then distilled water (twice). The sections are pre-treated with
10 0.2 M HCl for 10 min and permeabilized with 2 µg/ml Proteinase-K at 37°C for 15 min.

Labeled Riboprobes transcribed from the CS141 gene plasmid (see Example 4) are hybridized to the prepared tissue sections and incubated overnight at 56°C in 3X standard saline extract and 50% formamide. Excess probe is removed by
15 washing in 2X standard saline citrate and 50% formamide followed by digestion with 100 µg/ml RNase A at 37°C for 30 min. Fluorescence probe is visualized by illumination with ultraviolet (UV) light under a microscope. Fluorescence in the cytoplasm is indicative of CS141 mRNA. Alternatively, the sections can be visualized by autoradiography.

20 Detection of a product comprising a sequence selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof, is indicative of the presence of CS141 mRNA(s), suggesting a diagnosis of a GI tract tissue disease or condition, such as GI tract cancer.

25 Example 8: Reverse Transcription PCR

A. One Step RT-PCR Assay. Target-specific primers are designed to detect the above-described target sequences by reverse transcription PCR using methods known in the art. One step RT-PCR is a sequential procedure that performs both RT and PCR in a single reaction mixture. The procedure is performed in a 200 µl
30 reaction mixture containing 50 mM (N,N-bis[2-Hydroxyethyl]glycine), pH 8.15, 81.7 mM KOAc, 33.33 mM KOH, 0.01 mg/ml bovine serum albumin, 0.1 mM ethylene diaminetetraacetic acid, 0.02 mg/ml NaN₃, 8% w/v glycerol, 150 µM each of dNTP, 0.25 µM each primer, 5U rTth polymerase, 3.25 mM Mn(OAc)₂ and 5 µl of target RNA (see Example 3). Since RNA and the rTth polymerase enzyme are
35 unstable in the presence of Mn(OAc)₂, the Mn(OAc)₂ should be added just before

target addition. Optimal conditions for cDNA synthesis and thermal cycling readily can be determined by those skilled in the art. The reaction is incubated in a Perkin-Elmer Thermal Cycler 480. Optimal conditions for cDNA synthesis and thermal cycling can readily be determined by those skilled in the art. Conditions which may
5 be found useful include cDNA synthesis at 60°-70°C for 15-45 min and 30-45 amplification cycles at 94°C, 1 min; 55°-70°C, 1 min; 72°C, 2 min. One step RT-PCR also may be performed by using a dual enzyme procedure with Taq polymerase and a reverse transcriptase enzyme, such as MMLV or AMV RT enzymes.

B. Traditional RT-PCR. A traditional two-step RT-PCR reaction was
10 performed, as described by K.Q. Hu et al., Virology 181:721-726 (1991). Briefly, 1.0 µg of extracted mRNA (see Example 3) was reverse transcribed in a 20 µl reaction mixture containing 1X PCR II buffer (Perkin-Elmer), 5 mM MgCl₂, 1 mM dNTP, 20 U RNasin, 2.5 µM random hexamers, and 50 U MMLV (Moloney murine leukemia virus) reverse transcriptase (RT). Reverse transcription was
15 performed at room temperature for 10 min, 42°C for 30 min in a PE-480 thermal cycler, followed by further incubation at 95°C for 5 min to inactivate the RT. PCR was performed using 2 µl of the cDNA reaction in a final PCR reaction volume of 50 µl containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 200 µM dNTP, 0.4 µM of each sense and antisense primer, SEQUENCE ID NO 22 and
20 SEQUENCE ID NO 23, respectively, and 2.5 U of Taq polymerase. The reaction was incubated in an MJ Research Model PTC-200 as follows: Denaturation at 94°C for 2 min. followed by 35 cycles of amplification (94°C, 45 sec; 55 °C, 45 sec; 72°C, 2 min); a final extension (72°C, 5 min); and a soak at 4°C.

C. PCR Fragment Analysis. The correct products were verified by size
25 determination using gel electrophoresis with a SYBR® Green nucleic acid gel stain (Molecular Probes, Eugene, OR). Gels were stained with SYBR® Green I at a 1:10,000 dilution in 1X TBE for 30 min. Gels were then destained in 1X TBE for 30 min. and imaged using a STORM imaging system (see Figures 4A and 4B). Figure 4A shows a 422 bp CS141-specific PCR amplification product in lanes 3, 4,
30 5, and 6. The 422 bp CS141-specific PCR amplification product is present in 1 of 2 normal colon tissue samples, and in 3 of 3 colon cancer tissue samples. Lanes 2 and 5 contain DNA derived from RNA of normal colon tissue. Lanes 3, 4, and 6 contain DNA derived from RNA of colon cancer tissue. Amplification of human placental DNA with the same primers in lane 7 did not result in the 422 bp product.
35 This suggests that the amplification products in lanes 3, 4, 5, and 6 are the result of

-67-

amplification of mRNA and not DNA. As shown in Figure 4B, the 422 bp product is detected in colon cancer tissue (lane 4) and in one of two BPH prostate tissues (lane 8). It was not detected using human placental DNA (lane 2) nor in RNA isolated from tissues of normal colon (lane 3), breast (lanes 5-7), lung (lanes 11-13), or prostate cancer (lane 9).

Detection of a product comprising a sequence selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof, is indicative of the presence of CS141 mRNA(s), suggesting a diagnosis of a GI tract tissue disease or condition, such as GI tract cancer.

Example 9: OH-PCR

A. Probe selection and Labeling. Target-specific primers and probes are designed to detect the above-described target sequences by oligonucleotide hybridization PCR. International Publication Nos WO 92/10505, published 25 June 1992, and WO 92/11388, published 9 July 1992, teach methods for labeling oligonucleotides at their 5' and 3' ends, respectively. According to one known method for labeling an oligonucleotide, a label-phosphoramidite reagent is prepared and used to add the label to the oligonucleotide during its synthesis. For example, see N. T. Thuong et al., Tet. Letters 29(46):5905-5908 (1988); or J. S. Cohen et al., published U.S. Patent Application 07/246,688 (NTIS ORDER No. PAT-APPL-7-246,688) (1989). Preferably, probes are labeled at their 3' end to prevent participation in PCR and the formation of undesired extension products. For one step OH-PCR, the probe should have a T_M at least 15°C below the T_M of the primers. The primers and probes are utilized as specific binding members, with or without detectable labels, using standard phosphoramidite chemistry and/or post-synthetic labeling methods which are well-known to one skilled in the art.

B. One Step Oligo Hybridization PCR. OH-PCR is performed on a 200 µl reaction containing 50 mM (N,N,-bis[2-Hydroxyethyl]glycine), pH 8.15, 81.7 mM KOAc, 33.33 mM KOH, 0.01 mg/ml bovine serum albumin, 0.1 mM ethylene diaminetetraacetic acid, 0.02 mg/ml NaN₃, 8% w/v glycerol, 150 µM each of dNTP, 0.25 µM each primer, 3.75 nM probe, 5U rTth polymerase, 3.25 mM Mn(OAc)₂ and 5 µl blood equivalents of target (see Example 3). Since RNA and the rTth polymerase enzyme are unstable in the presence of Mn(OAc)₂, the Mn(OAc)₂ should be added just before target addition. The reaction is incubated in a Perkin-Elmer Thermal Cycler 480. Optimal conditions for cDNA synthesis and thermal cycling

-68-

can be readily determined by those skilled in the art. Conditions which may be found useful include cDNA synthesis (60°C, 30 min), 30-45 amplification cycles (94°C, 40 sec; 55-70°C, 60 sec), oligo-hybridization (97°C, 5 min; 15°C, 5 min; 15°C soak). The correct reaction product contains at least one of the strands of the PCR product and an internally hybridized probe.

C. OH-PCR Product Analysis. Amplified reaction products are detected on an LCx[®] analyzer system (available from Abbott Laboratories, Abbott Park, IL). Briefly, the correct reaction product is captured by an antibody labeled microparticle at a capturable site on either the PCR product strand or the hybridization probe, and the complex is detected by binding of a detectable antibody conjugate to either a detectable site on the probe or the PCR strand. Only a complex containing a PCR strand hybridized with the internal probe is detectable. The detection of this complex then is indicative of the presence of CS141 mRNA, suggesting a diagnosis of a GI tract disease or condition, such as GI tract cancer.

Many other detection formats exist which can be used and/or modified by those skilled in the art to detect the presence of amplified or non-amplified CS141-derived nucleic acid sequences including, but not limited to, ligase chain reaction (LCR, Abbott Laboratories, Abbott Park, IL); Q-beta replicase (Gene-Trak[™], Naperville, Illinois), branched chain reaction (Chiron, Emeryville, CA) and strand displacement assays (Becton Dickinson, Research Triangle Park, NC).

Detection of a product comprising a sequence selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof, is indicative of the presence of CS141 mRNA(s), suggesting a diagnosis of a GI tract tissue disease or condition, such as GI tract cancer.

Example 10: Synthetic Peptide Production

Synthetic peptides were modeled and then prepared based upon the predicted amino acid sequence of the CS141 polypeptide consensus sequence (see Example 1). In particular, a number of CS141 peptides derived from SEQUENCE ID NO 24 were prepared, including the peptides of SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, and SEQUENCE ID NO 28. All peptides were synthesized on a Symphony Peptide Synthesizer (available from Rainin Instrument Co, Emeryville, CA) using Fmoc chemistry, standard cycles and in-situ HBTU activation. Cleavage and deprotection conditions were as follows: a volume of 2.5 ml of cleavage reagent (77.5% v/v trifluoroacetic acid, 15% v/v ethanedithiol, 2.5%

v/v water, 5% v/v thioanisole, 1-2% w/v phenol) were added to the resin, and agitated at room temperature for 2-4 hours. Then the filtrate was removed and the peptide was precipitated from the cleavage reagent with cold diethyl ether. Each peptide was filtered, purified via reverse-phase preparative HPLC using a
5 water/acetonitrile/0.1% TFA gradient, and lyophilized. The product was confirmed by mass spectrometry (see Example 12).

The purified peptides were used to immunize animals (see Example 14).

Example 11a: Expression of Protein in a Cell Line Using Plasmid 577

10 A. Construction of a CS141 Expression Plasmid. Plasmid 577, described in U.S. patent application Serial No. 08/478,073, filed June 7, 1995 and incorporated herein by reference, has been constructed for the expression of secreted antigens in a permanent cell line. This plasmid contains the following DNA
15 segments: (a) a 2.3 Kb fragment of pBR322 containing bacterial beta-lactamase and origin of DNA replication; (b) a 1.8 Kb cassette directing expression of a neomycin resistance gene under control of HSV-1 thymidine kinase promoter and poly-A addition signals; (c) a 1.9 Kb cassette directing expression of a dihydrofolate reductase gene under the control of an SV-40 promoter and poly-A addition signals;
20 (d) a 3.5 Kb cassette directing expression of a rabbit immunoglobulin heavy chain signal sequence fused to a modified hepatitis C virus (HCV) E2 protein under the control of the Simian Virus 40 T-Ag promoter and transcription enhancer, the hepatitis B virus surface antigen (HBsAg) enhancer I followed by a fragment of Herpes Simplex Virus-1 (HSV-1) genome providing poly-A addition signals; and
25 (e) a residual 0.7 Kb fragment of Simian Virus 40 genome late region of no function in this plasmid. All of the segments of the vector were assembled by standard methods known to those skilled in the art of molecular biology.

Plasmids for the expression of secretable CS141 proteins are constructed by replacing the hepatitis C virus E2 protein coding sequence in plasmid 577 with that of a CS141 polynucleotide sequence selected from the group consisting of
30 SEQUENCE ID NOS 1-13, and fragments or complements thereof, as follows. Digestion of plasmid 577 with XbaI releases the hepatitis C virus E2 gene fragment. The resulting plasmid backbone allows insertion of the CS141 cDNA insert downstream of the rabbit immunoglobulin heavy chain signal sequence which directs the expressed proteins into the secretory pathway of the cell. The CS141
35 cDNA fragment is generated by PCR using standard procedures. Encoded in the

-70-

5 sense PCR primer sequence is an XbaI site, immediately followed by a 12
nucleotide sequence that encodes the amino acid sequence Ser-Asn-Glu-Leu
("SNEL") to promote signal protease processing, efficient secretion and final
product stability in culture fluids. Immediately following this 12 nucleotide
10 sequence the primer contains nucleotides complementary to template sequences
encoding amino acids of the CS141 gene. The antisense primer incorporates a
sequence encoding the following eight amino acids just before the stop codons: Asp-
Tyr-Lys-Asp-Asp-Asp-Asp-Lys (SEQUENCE ID NO 29). Within this sequence is
incorporated a recognition site to aid in analysis and purification of the CS141
15 protein product. A recognition site (termed "FLAG") that is recognized by a
commercially available monoclonal antibody designated anti-FLAG M2 (Eastman
Kodak, Co., New Haven, CT) can be utilized, as well as other comparable
sequences and their corresponding antibodies. For example, PCR is performed
using GeneAmp® reagents obtained from Perkin-Elmer-Cetus, as directed by the
supplier's instructions. PCR primers are used at a final concentration of 0.5 µM.
20 PCR is performed on the CS141 plasmid template in a 100 µl reaction for 35 cycles
(94°C, 30 seconds; 55°C, 30 seconds; 72°C, 90 seconds) followed by an extension
cycle of 72°C for 10 min.

B. Transfection of Dihydrofolate Reductase Deficient Chinese Hamster

25 Ovary Cells. The plasmid described supra is transfected into CHO/dhfr- cells
(DXB-111, Uriacio et al., PNAS 77:4451-4466 (1980)). These cells are available
from the A.T.C.C., 12301 Parklawn Drive, Rockville, MD 20852, under Accession
No. CRL 9096. Transfection is carried out using the cationic liposome-mediated
procedure described by P. L. Felgner et al., PNAS 84:7413-7417 (1987).
25 Particularly, CHO/dhfr- cells are cultured in Ham's F-12 media supplemented with
10% fetal calf serum, L-glutamine (1 mM) and freshly seeded into a flask at a
density of 5-8 x 10⁵ cells per flask. The cells are grown to a confluency of between
60 and 80% for transfection. Twenty micrograms (20µg) of plasmid DNA is added
to 1.5 ml of Opti-MEM I medium and 100 µl of Lipofectin Reagent (Gibco-BRL;
30 Grand Island, NY) are added to a second 1.5 ml portion of Opti-MEM I media. The
two solutions are mixed and incubated at room temperature for 20 min. After the
culture medium is removed from the cells, the cells are rinsed 3 times with 5 ml of
Opti-MEM I medium. The Opti-MEM I-Lipofection-plasmid DNA solution then is
overlaid onto the cells. The cells are incubated for 3 h at 37°C, after which time the

-71-

Opti-MEM I-Lipofectin-DNA solution is replaced with culture medium for an additional 24 h prior to selection.

5 C. Selection and Amplification. One day after transfection, cells are
passaged 1:3 and incubated with dhfr/G418 selection medium (hereafter, "F-12
minus medium G"). Selection medium is Ham's F-12 with L-glutamine and without
hypoxanthine, thymidine and glycine (JRH Biosciences, Lenexa, Kansas) and 300
µg per ml G418 (Gibco-BRL; Grand Island, NY). Media volume-to-surface area
ratios of 5 ml per 25 cm² are maintained. After approximately two weeks,
DHFR/G418 cells are expanded to allow passage and continuous maintenance in F-
10 12 minus medium G.

Amplification of each of the transfected CS141 cDNA sequences is achieved
by stepwise selection of DHFR⁺, G418⁺ cells with methotrexate [reviewed by R.
Schimke, Cell 37:705-713 (1984)]. Cells are incubated with F-12 minus medium G
containing 150 nM methotrexate (MTX) (Sigma, St. Louis, MO) for approximately
15 two weeks until resistant colonies appear. Further gene amplification is achieved by
selection of 150 nM adapted cells with 5 µM MTX.

20 D. Antigen Production. F-12 minus medium G supplemented with 5 µM
MTX is overlaid onto just confluent monolayers for 12 to 24 h at 37°C in 5% CO₂.
The growth medium is removed and the cells are rinsed 3 times with Dulbecco's
phosphate buffered saline (PBS) with calcium and magnesium (Gibco-BRL; Grand
Island, NY) to remove the remaining media/serum which may be present. Cells then
are incubated with VAS custom medium (VAS custom formulation with L-glutamine
with HEPES without phenol red, available from JRH Bioscience; Lenexa, KS,
product number 52-08678P), for 1 h at 37°C in 5% CO₂. Cells then are overlaid
25 with VAS for production at 5 ml per T flask. Medium is removed after seven days
of incubation, retained, and then frozen to await purification with harvests 2, 3 and
4. The monolayers are overlaid with VAS for 3 more seven day harvests.

30 E. Analysis of GI tract Tissue Gene CS141 Antigen Expression. Aliquots
of VAS supernatants from the cells expressing the CS141 protein construct are
analyzed, either by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using
standard methods and reagents known in the art (Laemmli discontinuous gels), or by
mass spectrometry.

35 F. Purification. Purification of the CS141 protein containing the FLAG
sequence is performed by immunoaffinity chromatography using an affinity matrix
comprising anti-FLAG M2 monoclonal antibody covalently attached to agarose by

-72-

hydrazide linkage (Eastman Kodak Co., New Haven, CT). Prior to affinity purification, protein in pooled VAS medium harvests from roller bottles is exchanged into 50 mM Tris-HCl (pH 7.5), 150 mM NaCl buffer using a Sephadex G-25 (Pharmacia Biotech Inc., Uppsala, Sweden) column. Protein in this buffer is applied to the anti-FLAG M2 antibody affinity column. Non-binding protein is eluted by washing the column with 50 mM Tris-HCl (pH 7.5), 150 mM NaCl buffer. Bound protein is eluted using an excess of FLAG peptide in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl. The excess FLAG peptide can be removed from the purified CS141 protein by gel electrophoresis or HPLC.

Although plasmid 577 is utilized in this example, it is known to those skilled in the art that other comparable expression systems, such as CMV, can be utilized herein with appropriate modifications in reagent and/or techniques and are within the skill of the ordinary artisan.

The largest cloned insert containing the coding region of the CS141 gene is then sub-cloned into either (i) a eukaryotic expression vector which may contain, for example, a cytomegalovirus (CMV) promoter and/or protein fusible sequences which aid in protein expression and detection, or (ii) a bacterial expression vector containing a superoxide-dismutase (SOD) and CMP-KDO synthetase (CKS) or other protein fusion gene for expression of the protein sequence. Methods and vectors which are useful for the production of polypeptides which contain fusion sequences of SOD are described in EPO 0196056, published October 1, 1986, which is incorporated herein by reference and those containing fusion sequences of CKS are described in EPO Publication No. 0331961, published September 13, 1989, which publication is also incorporated herein by reference. This so-purified protein can be used in a variety of techniques, including, but not limited to animal immunization studies, solid phase immunoassays, etc.

Example 11b: Expression of Protein in a Cell Line Using pcDNA3.1/Myc-His

A. Construction of a CS141 Expression Plasmid. Plasmid pcDNA3.1/Myc-

His (Cat. # V855-20, Invitrogen, Carlsbad, CA) has been constructed, in the past, for the expression of secreted antigens by most mammalian cell lines. Expressed protein inserts are fused to a myc-his peptide tag. The myc-his tag is a 21 residue amino acid sequence having the following sequence: Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-Asn-Met-His-Thr-Glu-His-His-His-His-His (SEQUENCE ID NO 30) and comprises a myc epitope and a polyhistidine sequence which are useful

-73-

for the purification of an expressed fusion protein using either anti-myc or anti-his affinity columns, or metalloprotein binding columns.

Plasmids for the expression of secretable CS141 proteins are constructed by inserting an CS141 polynucleotide sequence selected from the group consisting of
5 SEQUENCE ID NOS 1-13, and fragments or complements thereof. Prior to construction of an CS141 expression plasmid, the CS141 cDNA sequence is first cloned into a pCR®-Blunt vector as follows.

The CS141 cDNA fragment is generated by PCR using standard procedures. For example, PCR is performed using Stratagene® reagents obtained from
10 Stratagene, La Jolla, CA, as directed by the supplier's instructions. PCR primers are used at a final concentration of 0.5 µM. PCR using 5 U of pfu polymerase (Stratagene) is performed on the CS141 plasmid template (see Example 2) in a 50 µl reaction for 30 cycles (94°C, 1 min; 65°C, 1.5 min; 72°C, 3 min) followed by an extension cycle at 72°C for 8 min. The sense PCR primer sequence comprises
15 nucleotides which are either complementary to the pINCY vector directly upstream of the CS141 gene insert or which incorporate a 5' EcoRI restriction site, an adjacent downstream protein translation consensus initiator, and a 3' nucleic acid sequence which is the same sense as the 5'-most end of the CS141 cDNA insert. The antisense primer incorporates a 5' NotI restriction sequence and a sequence
20 complementary to the 3' end of the CS141 cDNA insert just upstream of the 3'-most, in-frame stop codon. Five microliters (5 µl) of the resulting blunt-ended PCR product are ligated into 25 ng of linearized pCR®-Blunt vector (Invitrogen, Carlsbad, CA) interrupting the lethal ccdB gene of the vector. The resulting ligated vector is transfected into TOP10 *E. coli* (Invitrogen, Carlsbad, CA) using a One Shot™
25 transformation kit (Invitrogen, Carlsbad, CA) following the supplier's directions. The transfected cells are grown on LB-Kan (50 µg/ml kanamycin) selection plates at 37°C. Only cells containing a plasmid with an interrupted ccdB gene will grow after transfection (Grant, S.G.N., PNAS USA 87:4645-4649 (1990)). Transfected colonies are picked and grown up in 3 ml of LB-Kan broth at 37°C. Plasmid DNA
30 is isolated using a QIAprep® (Qiagen Inc., Santa Clarita, CA) procedure, as directed by the supplier's instructions. The DNA is cut with EcoRI or SnaBI, and NotI restriction enzymes to release the CS141 insert fragment. The fragment is run on 1% Seakem® LE agarose/0.5 µg/ml ethidium bromide/TE gel, visualized by UV irradiation, excised and purified using QIAquick™ (Qiagen Inc., Santa Clarita, CA)
35 procedures, as directed by the supplier's instructions.

-74-

5 The pcDNA3.1/Myc-His plasmid DNA is linearized by digestion with EcoRI or SnaBI, and NotI in the polylinker region of the plasmid DNA. The resulting plasmid DNA backbone allows insertion of the CS141 purified cDNA fragment, supra, downstream of a CMV promoter which directs expression of the proteins in mammalian cells. The ligated plasmid is transfected into DH5 alpha™ cells (GibcoBRL, Gaithersburg, MD) as directed by the supplier's instructions. Briefly, 10 ng of pcDNA3.1/Myc-His containing an CS141 insert is added to 50 µl of competent DH5 alpha cells, and the contents are mixed gently. The mixture is incubated on ice for 30 min, heat shocked for 20 sec at 37°C, and placed on ice for an additional 2 min. Upon addition of 0.95 ml of LB medium, the mixture is incubated for 1 h at 37°C while shaking at 225 rpm. The transfected cells are then plated onto 100 mm LB/Amp (50 µg/ml ampicillin) plates and grown at 37°C. Colonies are picked and grown in 3 ml of LB/Amp broth. Plasmid DNA is purified using a QIAprep® kit. Presence of the insert is confirmed using techniques known to those skilled in the art including, but not limited to, restriction digestion and gel analysis. See, e.g., J. Sambrook et al., supra.

10 B. Transfection of Human Embryonic Kidney 293 Cells. The CS141 expression plasmid described supra is purified from the DH5 alpha cells using a QIAfilter™ Maxi kit (Qiagen, Chatsworth, CA), and then transfected into HEK293 cells (F.L. Graham et al., J. Gen. Vir. 36:59-72 (1977)). These cells are available from the A.T.C.C., 12301 Parklawn Drive, Rockville, MD 20852, under Accession No. CRL 1573. Transfection is carried out using the cationic lipofectamine-mediated procedure described by P. Hawley-Nelson et al., Focus 15:73 (1993). Particularly, HEK293 cells are cultured in 10 ml DMEM media supplemented with 10% fetal bovine serum (FBS), L-glutamine (2 mM) and freshly seeded into 100 mm culture plates at a density of 9×10^6 cells per plate. The cells are grown at 37°C to a confluency of between 70% and 80% for transfection. Eight micrograms (8 µg) of plasmid DNA is added to 800 µl of Opti-MEM I® medium (Gibco-BRL, Grand Island, NY), and 48-96 µl of Lipofectamine™ Reagent (Gibco-BRL, Grand Island, NY) is added to a second 800 µl portion of Opti-MEM I® media. The two solutions are mixed and incubated at room temperature for 15-30 min. After the culture medium is removed from the cells, the cells are washed once with 10 ml of serum-free DMEM. The Opti-MEM I®-Lipofectamine-plasmid DNA solution is diluted in 6.4 ml of serum-free DMEM and then overlaid onto the cells. The cells are incubated for 5 h at 37°C, after which time, an additional 8 ml of DMEM with 20%

-75-

FBS is added. After 18-24 h, the old medium is aspirated, and the cells are overlaid with 5 ml of fresh DMEM with 10% FBS. Supernatants and cell extracts are analyzed for CS141 gene activity 72 h after transfection.

5 C. Analysis of GI Tract Tissue Gene CS141 Antigen Expression. The culture supernatant , supra, is transferred to cryotubes and stored on ice. HEK293 cells are harvested by washing twice with 10 ml cold Dulbecco's PBS and lysing by addition of 1.5 ml of CAT lysis buffer (Boehringer Mannheim, Indianapolis, IN), followed by incubation for 30 min at room temperature. Lysate is transferred to 1.7 ml polypropylene microfuge tubes and centrifuged at 1000 x g for 10 min. The
10 supernatant is transferred to new cryotubes and stored on ice. Aliquots of cell supernatants and the lysate of the cells expressing the CS141 protein construct are analyzed for the presence of CS141 recombinant protein. The aliquots can be analyzed using SDS-polyacrylamide gel electrophoresis (SDS-PAGE), using standard methods and reagents known in the art. See, e.g., J. Sambrook et al.,
15 supra. The gels can then be blotted onto a solid medium such as nitrocellulose, nytran, or the like, and the CS141 protein band can be visualized using western blotting techniques with anti-myc epitope or anti-histidine monoclonal antibodies (Invitrogen, Carlsbad, CA) or CS141 polyclonal serum (see Example 14). Alternatively, the expressed CS141 recombinant protein can be analyzed by mass
20 spectrometry (see Example 12).

D. Purification. Purification of the CS141 recombinant protein containing the myc-his sequence is performed using the Xpress® affinity chromatography system (Invitrogen, Carlsbad, CA) containing a nickel-charged agarose resin which specifically binds polyhistidine residues. Supernatants from 10 x 100 mm plates,
25 prepared as described supra, are pooled and passed over the nickel-charged column. Non-binding protein is eluted by washing the column with 50 mM Tris-HCl (pH 7.5)/150 mM NaCl buffer, leaving only the myc-his fusion proteins. Bound CS141 recombinant protein then is eluted from the column using either an excess of imidazole or histidine, or a low pH buffer. Alternatively, the recombinant protein
30 can also be purified by binding at the myc-his sequence to an affinity column consisting of either anti-myc or anti-histidine monoclonal antibodies conjugated through a hydrazide or other linkage to an agarose resin and eluting with an excess of myc peptide or histidine, respectively.

 The purified recombinant protein can then be covalently cross-linked to a
35 solid phase, such as N-hydroxysuccinimide-activated sepharose columns

(Pharmacia Biotech, Piscataway, NJ), as directed by supplier's instructions. These columns containing covalently linked CS141 recombinant protein, can then be used to purify anti-CS141 antibodies from rabbit or mouse sera (see Examples 13 and 14).

5 E. Coating Microtiter Plates with CS141 Expressed Proteins. Supernatant from a 100 mm plate, as described supra, is diluted in an appropriate volume of PBS. 100 µl of the resulting mixture is placed into each well of a Reacti-Bind™ metal chelate microtiter plate (Pierce, Rockford, IL), incubated at room temperature while shaking, and followed by three washes with 200 µl each of PBS with 0.05% 10 Tween® 20. The prepared microtiter plate can then be used to screen polyclonal antisera for the presence of CS141 antibodies (see Example 17).

Although pcDNA3.1/Myc-His is utilized in this example, it is known to those skilled in the art that other comparable expression systems can be utilized herein with appropriate modifications in reagent and/or techniques and are within the 15 skill of one of ordinary skill in the art. The largest cloned insert containing the coding region of the CS141 gene is sub-cloned into either (i) a eukaryotic expression vector which may contain, for example, a cytomegalovirus (CMV) promoter and/or protein fusible sequences which aid in protein expression and detection, or (ii) a bacterial expression vector containing a superoxide-dismutase (SOD) and CMP- 20 KDO synthetase (CKS) or other protein fusion gene for expression of the protein sequence. Methods and vectors which are useful for the production of polypeptides which contain fusion sequences of SOD are described in European patent application No. EP 0 196 056, published October 1, 1986, which is incorporated herein by reference, and vectors containing fusion sequences of CKS are described in 25 European patent application No. EP 0 331 961, published September 13, 1989, which publication is also incorporated herein by reference. The purified protein can be used in a variety of techniques, including but not limited to, animal immunization studies, solid phase immunoassays, etc.

30 Example 12: Chemical Analysis of GI tract Tissue Proteins

A. Analysis of Tryptic Peptide Fragments Using MS. Sera from patients with GI tract disease, such as GI tract cancer, sera from patients with no GI tract disease, extracts of GI tract tissues or cells from patients with GI tract disease, such as GI tract cancer, extracts of GI tract tissues or cells from patients with no GI tract 35 disease, and extracts of tissues or cells from other non-diseased or diseased organs

-77-

of patients, are run on a polyacrylamide gel using standard procedures and stained with Coomassie Blue. Sections of the gel suspected of containing the unknown polypeptide are excised and subjected to an in-gel reduction, acetamidation and tryptic digestion. P. Jenö et al, Anal. Bio. 224:451-455 (1995) and J. Rosenfeld et al, Anal. Bio. 203:173-179 (1992). The gel sections are washed with 100 mM NH_4HCO_3 and acetonitrile. The shrunken gel pieces are swollen in digestion buffer (50 mM NH_4HCO_3 , 5 mM CaCl_2 and 12.5 $\mu\text{g/ml}$ trypsin) at 4°C for 45 min. The supernatant is aspirated and replaced with 5 to 10 μl of digestion buffer without trypsin and allowed to incubate overnight at 37°C. Peptides are extracted with 3 changes of 5% formic acid and acetonitrile and evaporated to dryness. The peptides are adsorbed to approximately 0.1 μl of POROS R2 sorbent (Perseptive Biosystems, Framingham, Massachusetts) trapped in the tip of a drawn gas chromatography capillary tube by dissolving them in 10 μl of 5% formic acid and passing it through the capillary. The adsorbed peptides are washed with water and eluted with 5% formic acid in 60% methanol. The eluant is passed directly into the spraying capillary of an API III mass spectrometer (Perkin-Elmer Sciex, Thornhill, Ontario, Canada) for analysis by nano-electrospray mass spectrometry. M. Wilm et al., Int. J. Mass Spectrom. Ion Process 136:167-180 (1994) and M. Wilm et al., Anal. Chem. 66:1-8 (1994). The masses of the tryptic peptides are determined from the mass spectrum obtained off the first quadrupole. Masses corresponding to predicted peptides can be further analyzed in MS/MS mode to give the amino acid sequence of the peptide.

B. Peptide Fragment Analysis Using LC/MS. The presence of polypeptides predicted from mRNA sequences found in hyperplastic disease tissues also can be confirmed using liquid chromatography/tandem mass spectrometry (LC/MS/MS). D. Hess et al., METHODS, A Companion to Methods in Enzymology 6:227-238 (1994). The serum specimen or tumor extract from the patient is denatured with SDS and reduced with dithiothreitol (1.5 mg/ml) for 30 min at 90°C followed by alkylation with iodoacetamide (4 mg/ml) for 15 min at 25°C. Following acrylamide electrophoresis, the polypeptides are electroblotted to a cationic membrane and stained with Coomassie Blue. Following staining, the membranes are washed and sections thought to contain the unknown polypeptides are cut out and dissected into small pieces. The membranes are placed in 500 μl microcentrifuge tubes and immersed in 10 to 20 μl of proteolytic digestion buffer (100 mM Tris-HCl, pH 8.2, containing 0.1 M NaCl, 10% acetonitrile, 2 mM CaCl_2 and 5 $\mu\text{g/ml}$ trypsin) (Sigma,

St. Louis, MO). After 15 h at 37°C, 3 µl of saturated urea and 1 µl of 100 µg/ml trypsin are added and incubated for an additional 5 h at 37°C. The digestion mixture is acidified with 3 µl of 10% trifluoroacetic acid and centrifuged to separate supernatant from membrane. The supernatant is injected directly onto a microbore,
5 reverse phase HPLC column and eluted with a linear gradient of acetonitrile in 0.05% trifluoroacetic acid. The eluate is fed directly into an electrospray mass spectrometer, after passing through a stream splitter if necessary to adjust the volume of material. The data is analyzed following the procedures set forth in Example 12, Section A.

10 Example 13: Gene Immunization Protocol

A. In Vivo Antigen Expression. Gene immunization circumvents protein purification steps by directly expressing an antigen in vivo after inoculation of the appropriate expression vector. Also, production of antigen by this method may
15 allow correct protein folding and glycosylation since the protein is produced in mammalian tissue. The method utilizes insertion of the gene sequence into a plasmid which contains a CMV promoter, expansion and purification of the plasmid and injection of the plasmid DNA into the muscle tissue of an animal. Preferred animals include mice and rabbits. See, for example, H. Davis et al., Human Molecular
20 Genetics 2:1847-1851 (1993). After one or two booster immunizations, the animal can then be bled, ascites fluid collected, or the animal's spleen can be harvested for production of hybridomas.

B. Plasmid Preparation and Purification. CS141 cDNA sequences are generated from the CS141 cDNA-containing vector using appropriate PCR primers
25 containing suitable 5' restriction sites following the procedures described in Example 11. The PCR product is cut with appropriate restriction enzymes and inserted into a vector which contains the CMV promoter (for example, pRc/CMV or pcDNA3 vectors from Invitrogen, San Diego, CA). This plasmid then is expanded in the appropriate bacterial strain and purified from the cell lysate using a CsCl gradient or
30 a Qiagen plasmid DNA purification column. All these techniques are familiar to one of ordinary skill in the art of molecular biology.

C. Immunization Protocol. Anesthetized animals are immunized intramuscularly with 0.1-100 µg of the purified plasmid diluted in PBS or other DNA uptake enhancers (Cardiotoxin, 25% sucrose). See, for example, H. Davis et

al, Human Gene Therapy 4:733-740 (1993); and P. W. Wolff et al, Biotechniques 11:474-485 (1991). One to two booster injections are given at monthly intervals.

D. Testing and Use of Antiserum. Animals are bled and the resultant sera tested for antibody using peptides synthesized from the known gene sequence (see
5 Example 16) using techniques known in the art, such as western blotting or EIA techniques. Antisera produced by this method can then be used to detect the presence of the antigen in a patient's tissue or cell extract, or in a patient's serum, by ELISA or Western blotting techniques, such as those described in Examples 15 through 18.

10 Example 14: Production of Antibodies Against CS141

A. Production of Polyclonal Antisera. Antiserum against CS141 was prepared by injecting rabbits with peptides whose sequences were derived from that of the predicted amino acid sequence of the CS141 consensus sequence
15 (SEQUENCE ID NO 13). The synthesis of these peptides is described in Example 10. Unconjugated CS141 peptides (SEQUENCE ID NO 25, SEQUENCE ID NO 26, and SEQUENCE ID NO 28) were used as immunogens [i.e., peptides were not conjugated to a carrier such as keyhole limpet hemocyanine (KLH)].

Animal Immunization. Female white New Zealand rabbits weighing 2 kg or
20 more were used for raising polyclonal antiserum. One animal was immunized per unconjugated peptide (SEQUENCE ID NO 25, SEQUENCE ID NO 26, and SEQUENCE ID NO 28). One week prior to the first immunization, blood samples (5 to 10 ml) were obtained from the animals to serve as a non-immune prebleed sample.

25 Unconjugated peptides, SEQUENCE ID NO 25, SEQUENCE ID NO 26, and SEQUENCE ID NO 28, were used to prepare the primary immunogen by emulsifying 0.5 ml of the peptide at a concentration of 2 mg/ml in PBS (pH 7.2) which contained 0.5 ml of complete Freund's adjuvant (CFA) (Difco, Detroit, MI). The immunogen was injected into several sites of the animal via subcutaneous,
30 intraperitoneal, and intramuscular routes of administration. Four weeks following the primary immunization, a booster immunization was administered. The immunogen used for the booster immunization dose was prepared by emulsifying 0.5 ml of the same unconjugated peptide used for the primary immunogen, except that the peptide now was diluted to 1 mg/ml with 0.5 ml of incomplete Freund's
35 adjuvant (IFA) (Difco, Detroit, MI). Again, the booster dose was administered into

-80-

several sites via subcutaneous, intraperitoneal and intramuscular types of injections. The animals were bled (5 ml) two weeks after the booster immunizations and each serum was tested for immunoreactivity to the peptide as described below. The booster and bleed schedule was repeated at 4 week intervals until an adequate titer was obtained. The titer or concentration of antiserum was determined by using unconjugated peptides in a microtiter EIA as described in Example 17, below. An antibody titer of 1:500 or greater was considered an adequate titer for further use and study (see Table 1).

Table 1: Titer of rabbit anti-CS141 peptide antisera (13 week bleed)

Peptide Immunogen	Titer
SEQUENCE ID NO 25	23,000
SEQUENCE ID NO 26	58,000
SEQUENCE ID NO 28	48,000

B. Production of Monoclonal Antibody.

1. Immunization Protocol. Mice are immunized using peptides which can either be conjugated to a carrier such as KLH, prepared as described hereinbelow, or unconjugated (i.e., not conjugated to a carrier such as KLH), except that the amount of the unconjugated or conjugated peptide for monoclonal antibody production in mice is one-tenth the amount used to produce polyclonal antisera in rabbits. Thus, the primary immunogen consists of 100 µg of unconjugated or conjugated peptide in 0.1 ml of CFA emulsion; while the immunogen used for booster immunizations consists of 50 µg of unconjugated or conjugated peptide in 0.1 ml of IFA. Hybridomas for the generation of monoclonal antibodies are prepared and screened using standard techniques. The methods used for monoclonal antibody development follow procedures known in the art such as those detailed in Kohler and Milstein, Nature 256:494 (1975) and reviewed in J.G.R. Hurrell, ed., Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press, Inc., Boca Raton, FL (1982). Another method of monoclonal antibody development which is based on the Kohler and Milstein method is that of L.T. Mimms et al., Virology 176:604-619 (1990), which is incorporated herein by reference.

-81-

5 The immunization regimen (per mouse) consists of a primary immunization with additional booster immunizations. The primary immunogen used for the primary immunization consists of 100 µg of unconjugated or conjugated peptide in 50 µl of PBS (pH 7.2) previously emulsified in 50 µl of CFA. Booster immunizations performed at approximately two weeks and four weeks post primary immunization consist of 50 µg of unconjugated or conjugated peptide in 50 µl of PBS (pH 7.2) emulsified with 50 µl IFA. A total of 100 µl of this immunogen is inoculated intraperitoneally and subcutaneously into each mouse. Individual mice are screened for immune response by microtiter plate enzyme immunoassay (EIA) as described in Example 17 approximately four weeks after the third immunization. Mice are inoculated either intravenously, intrasplenically or intraperitoneally with 50 µg of unconjugated or conjugated peptide in PBS (pH 7.2) approximately fifteen weeks after the third immunization..

10 Three days after this intravenous boost, splenocytes are fused with, for example, Sp2/0-Ag14 myeloma cells (Milstein Laboratories, England) using the polyethylene glycol (PEG) method. The fusions are cultured in Iscove's Modified Dulbecco's Medium (IMDM) containing 10% fetal calf serum (FCS), plus 1% hypoxanthine, aminopterin and thymidine (HAT). Bulk cultures are screened by microtiter plate EIA following the protocol in Example 17. Clones reactive with the peptide used an immunogen and non-reactive with other peptides (i.e., peptides of CS141 not used as the immunogen) are selected for final expansion. Clones thus selected are expanded, aliquoted and frozen in IMDM containing 10% FCS and 10% dimethyl-sulfoxide.

2. Peptide Conjugation. Peptide is conjugated to maleimide activated keyhole limpet hemocyanine (KLH, commercially available as Imject®, available from Pierce Chemical Company, Rockford, IL). Imject® contains about 250 moles of reactive maleimide groups per mole of hemocyanine. The activated KLH is dissolved in phosphate buffered saline (PBS, pH 8.4) at a concentration of about 7.7 mg/ml. The peptide is conjugated through cysteines occurring in the peptide sequence, or to a cysteine previously added to the synthesized peptide in order to provide a point of attachment. The peptide is dissolved in dimethyl sulfoxide (DMSO, Sigma Chemical Company, St. Louis, MO) and reacted with the activated KLH at a mole ratio of about 1.5 moles of peptide per mole of reactive maleimide attached to the KLH. A procedure for the conjugation of a suitable CS141 peptide is provided hereinbelow. It is known to the ordinary artisan that the

-82-

amounts, times and conditions of such a procedure can be varied to optimize peptide conjugation.

The conjugation reaction described hereinbelow is based on obtaining 3 mg of KLH peptide conjugate ("conjugated peptide"), which contains about 0.77
5 μmoles of reactive maleimide groups. This quantity of peptide conjugate usually is adequate for one primary injection and four booster injections for production of polyclonal antisera in a rabbit. Briefly, a CS141 peptide is dissolved in DMSO at a concentration of 1.16 μmoles/100 μl of DMSO. One hundred microliters (100 μl)
10 of the DMSO solution is added to 380 μl of the activated KLH solution prepared as described hereinabove, and 20 μl of PBS (pH 8.4) is added to bring the volume to 500 μl. The reaction is incubated overnight at room temperature with stirring. The extent of reaction is determined by measuring the amount of unreacted thiol in the reaction mixture. The difference between the starting concentration of thiol and the final concentration is assumed to be the concentration of peptide which has coupled
15 to the activated KLH. The amount of remaining thiol is measured using Ellman's reagent (5,5'-dithiobis(2-nitrobenzoic acid), Pierce Chemical Company, Rockford, IL). Cysteine standards are made at a concentration of 0, 0.1, 0.5, 2, 5 and 20 mM by dissolving 35 mg of cysteine HCl (Pierce Chemical Company, Rockford, IL) in 10 ml of PBS (pH 7.2) and diluting the stock solution to the desired
20 concentration(s). The photometric determination of the concentration of thiol is accomplished by placing 200 μl of PBS (pH 8.4) in each well of an Immulon 2® microwell plate (Dynex Technologies, Chantilly, VA). Next, 10 μl of standard or reaction mixture is added to each well. Finally, 20 μl of Ellman's reagent at a concentration of 1 mg/ml in PBS (pH 8.4) is added to each well. The wells are
25 incubated for 10 minutes at room temperature, and the absorbance of all wells is read at 415 nm with a microplate reader (such as the BioRad Model 3550, BioRad, Richmond, CA). The absorbance of the standards is used to construct a standard curve and the thiol concentration of the reaction mixture is determined from the standard curve. A decrease in the concentration of free thiol is indicative of a
30 successful conjugation reaction. Unreacted peptide is removed by dialysis against PBS (pH 7.2) at room temperature for 6 hours. The conjugate is stored at 2-8°C if it is to be used immediately; otherwise, it is stored at -20°C or colder.

3. Production of Ascites Fluid Containing Monoclonal Antibodies.
Frozen hybridoma cells prepared as described hereinabove are thawed and placed
35 into expansion culture. Viable hybridoma cells are inoculated intraperitoneally into

-83-

Pristane treated mice. Ascitic fluid is removed from the mice, pooled, filtered through a 0.2 μ filter and subjected to an immunoglobulin class G (IgG) analysis to determine the volume of the Protein A column required for the purification.

4. Purification of Monoclonal Antibodies From Ascites Fluid.

5 Briefly, filtered and thawed ascites fluid is mixed with an equal volume of Protein A sepharose binding buffer (1.5 M glycine, 3.0 M NaCl, pH 8.9) and refiltered through a 0.2 μ filter. The volume of the Protein A column is determined by the quantity of IgG present in the ascites fluid. The eluate then is dialyzed against PBS (pH 7.2) overnight at 2-8°C. The dialyzed monoclonal antibody is sterile filtered
10 and dispensed in aliquots. The immunoreactivity of the purified monoclonal antibody is confirmed by determining its ability to specifically bind to the peptide used as the immunogen by use of the EIA microtiter plate assay procedure of Example 17. The specificity of the purified monoclonal antibody is confirmed by determining its lack of binding to irrelevant peptides such as peptides of CS141 not
15 used as the immunogen. The purified anti-CS141 monoclonal thus prepared and characterized is placed at either 2-8°C for short term storage or at -80°C for long term storage.

5. Further Characterization of Monoclonal Antibody. The isotype and subtype of the monoclonal antibody produced as described hereinabove can be
20 determined using commercially available kits (available from Amersham, Inc., Arlington Heights, IL). Stability testing also can be performed on the monoclonal antibody by placing an aliquot of the monoclonal antibody in continuous storage at 2-8°C and assaying optical density (OD) readings throughout the course of a given period of time.

25 C. Use of Recombinant Proteins as Immunogens. It is within the scope of the present invention that recombinant proteins made as described herein can be utilized as immunogens in the production of polyclonal and monoclonal antibodies, with corresponding changes in reagents and techniques known to those skilled in the art.

30

Example 15: Purification of Serum Antibodies Which Specifically
Bind to CS141 Peptides

Immune sera, obtained as described hereinabove in Examples 13 and/or 14, is affinity purified using immobilized synthetic peptides prepared as described in
35 Example 10, or recombinant proteins prepared as described in Example 11. An IgG

-84-

fraction of the antiserum is obtained by passing the diluted, crude antiserum over a Protein A column (Affi-Gel protein A, Bio-Rad, Hercules, CA). Elution with a buffer (Binding Buffer, supplied by the manufacturer) removes substantially all proteins that are not immunoglobulins. Elution with 0.1 M buffered glycine (pH 3) gives an immunoglobulin preparation that is substantially free of albumin and other serum proteins.

Immunoaffinity chromatography is performed to obtain a preparation with a higher fraction of specific antigen-binding antibody. The peptide used to raise the antiserum is immobilized on a chromatography resin, and the specific antibodies directed against its epitopes are adsorbed to the resin. After washing away non-binding components, the specific antibodies are eluted with 0.1 M glycine buffer, pH 2.3. Antibody fractions are immediately neutralized with 1.0 M Tris buffer (pH 8.0) to preserve immunoreactivity. The chromatography resin chosen depends on the reactive groups present in the peptide. If the peptide has an amino group, a resin such as Affi-Gel 10 or Affi-Gel 15 is used (Bio-Rad, Hercules, CA). If coupling through a carboxy group on the peptide is desired, Affi-Gel 102 can be used (Bio-Rad, Hercules, CA). If the peptide has a free sulfhydryl group, an organomercurial resin such as Affi-Gel 501 can be used (Bio-Rad, Hercules, CA).

Alternatively, spleens can be harvested and used in the production of hybridomas to produce monoclonal antibodies following routine methods known in the art as described hereinabove.

Example 16: Western Blotting of Tissue Samples

Protein extracts were prepared by homogenizing tissue samples in 0.1M Tris-HCl (pH 7.5), 15% (w/v) glycerol, 0.2 mM EDTA, 1.0 mM 1,4-dithiothreitol, 10 µg/ml leupeptin and 1.0 mM phenylmethylsulfonylfluoride (S. R. Kain et al., Biotechniques 17:982 (1994)). Following homogenization, the homogenates were centrifuged at 4°C for 5 minutes to separate supernatant from debris. For protein quantitation, 3-10 µl of supernatant were added to 1.5 ml of bicinchoninic acid reagent (Sigma, St. Louis, MO), and the resulting absorbance at 562 nm were measured.

For SDS-PAGE, samples were adjusted to desired protein concentration with Tricine Buffer (Novex, San Diego, CA), mixed with an equal volume of 2X Tricine sample buffer (Novex, San Diego, CA), and heated for 5 minutes at 100°C in a thermal cycler. Samples were then applied to a Novex 10-20% Precast Tricine

-85-

Gel for electrophoresis. Following electrophoresis samples were transferred from the gels to nitrocellulose membranes in Novex Tris-Glycine Transfer buffer. Membranes were then probed with specific anti-peptide antibodies using the reagents and procedures provided in the Western Lights Plus or Western Lights (Tropix, Bedford, MA) chemiluminescence detection kits. Chemiluminescent bands were visualized by exposing the developed membranes to Hyperfilm ECL (Amersham, Arlington Heights, IL).

Figure 5 shows the results of the western blot performed on a panel of tissue extracts using CS141 antiserum (see Example 14). Each lane of Figure 5 represents a different tissue protein extract: (1) kidney; (2) bladder; (3) prostate; (4) breast; (5) lung; (6, 7, 8 and 9) colon; (10, 11, 12 and 13) colon cancer; and (14) markers. A single band of approximately 21 kD (arrow), as determined by protein size markers (lane 14), was detected in all four normal colon tissue extracts but in only one (lane 11) of the colon cancer tissue extracts. The 21 kD band was also noted in normal kidney (lane 1) and normal prostate (lane 3).

Competition experiments were carried out in an analogous manner as above with the following exception: the primary antibodies (anti-peptide polyclonal antisera) were pre-incubated overnight at 4°C with varying concentrations of peptide immunogen prior to exposure to the nitrocellulose filter. Development of the Western were continued as above. Antibody binding to the band at 21 kD was inhibited at a concentration of 2.54 μ M of CS141 synthetic peptide (SEQUENCE ID NO 26).

After visualization of the bands on film, the bands were also visualized directly on the membranes by the addition and development of chromogenic substrate 5-bromo-4-chloro-3-indolyl phosphate (BCIP). This chromogenic solution contains 0.016% BCIP in a solution containing 100 mM NaCl, 5 mM $MgCl_2$ and 100 mM Tris-HCl, pH 9.5. The filter was incubated in the solution at room temperature until the bands developed to the desired intensity. Molecular mass determination was made based upon the mobility of pre-stained molecular weight standards (Novex, San Diego, CA) and biotinylated molecular weight standards (Tropix, Bedford, MA).

Example 17: EIA Microtiter Plate Assay

The immunoreactivity of antiserum obtained from rabbits as described in Example 14 was determined by means of a microtiter plate EIA, as follows. Briefly,

-86-

synthetic peptides, SEQUENCE ID NO 25, SEQUENCE ID NO 26, and SEQUENCE ID NO 28, prepared as described in Example 10, were dissolved in carbonate buffer (50 mM, pH 9.6) to a final concentration of 2 µg/ml. Next, 100 µl of the peptide solution were placed in each well of an Immulon 2[®] microtiter plate (Dynex Technologies, Chantilly, VA). The plate was incubated overnight at room temperature and then washed four times with deionized water. The wells were blocked by adding 125 µl of a suitable protein blocking agent, such as Superblock[®] (Pierce Chemical Company, Rockford, IL), to each well and then immediately discarding the solution. This blocking procedure was performed three times.

Antiserum obtained from immunized rabbits or mice, prepared as previously described, was diluted in a protein blocking agent (e.g., a 3% Superblock[®] solution) in PBS containing 0.05% Tween-20[®] (monolaurate polyoxyethylene ether) (Sigma Chemical Company, St. Louis, MO) and 0.05% sodium azide at dilutions of 1:100, 1:500, 1:2500, 1:12,500, and 1:62,500 and placed in each well of the coated microtiter plate. The wells then were incubated for three hours at room temperature. Each well was washed four times with deionized water. One hundred microliters of alkaline phosphatase-conjugated goat anti-rabbit IgG antiserum (Southern Biotech, Birmingham, AB) diluted 1:2000 in 3% Superblock[®] solution in phosphate buffered saline containing 0.05% Tween 20[®] and 0.05% sodium azide, were added to each well. The wells were incubated for two hours at room temperature. Next, each well was washed four times with deionized water. One hundred microliters of paranitrophenyl phosphate substrate (Kirkegaard and Perry Laboratories, Gaithersburg, MD) then were added to each well. The wells were incubated for thirty minutes at room temperature. The absorbance at 405 nm was read in each well. Positive reactions were identified by an increase in absorbance at 405 nm in the test well above that absorbance given by a non-immune serum (negative control). A positive reaction was indicative of the presence of detectable anti-CS141 antibodies. Titers of the anti-peptide antisera were calculated from the previously described dilutions of antisera and defined as the calculated dilution, where $A_{405nm}=0.5$ OD.

Example 18: Coating of Solid Phase Particles

A. Coating of Microparticles with Antibodies Which Specifically Bind to CS141 Antigen. Affinity purified antibodies which specifically bind to CS141 protein (see Example 15) are coated onto microparticles of polystyrene, carboxylated

-87-

polystyrene, polymethylacrylate or similar particles having a radius in the range of about 0.1 to 20 μm . Microparticles may be either passively or actively coated. One coating method comprises coating EDAC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (Aldrich Chemical Co., Milwaukee, WI) activated carboxylated latex microparticles with antibodies which specifically bind to CS141 protein, as follows. Briefly, a final 0.375% solid suspension of resin washed carboxylated latex microparticles (available from Bangs Laboratories, Carmel, IN or Serodyn, Indianapolis, IN) are mixed in a solution containing 50 mM MES buffer, pH 4.0 and 150 mg/l of affinity purified anti-CS141 antibody (see Example 14) for 15 min in an appropriate container. EDAC coupling agent is added to a final concentration of 5.5 $\mu\text{g/ml}$ to the mixture and mixed for 2.5 h at room temperature.

The microparticles then are washed with 8 volumes of a Tween 20[®]/sodium phosphate wash buffer (pH 7.2) by tangential flow filtration using a 0.2 μm Microgon Filtration module. Washed microparticles are stored in an appropriate buffer which usually contains a dilute surfactant and irrelevant protein as a blocking agent, until needed.

B. Coating of 1/4 Inch Beads. Antibodies which specifically bind to CS141-antigen also may be coated on the surface of 1/4 inch polystyrene beads by routine methods known in the art (Snitman et al, US Patent 5,273,882, incorporated herein by reference) and used in competitive binding or EIA sandwich assays.

Polystyrene beads first are cleaned by ultrasonically cleaning them for about 15 seconds in 10 mM NaHCO_3 buffer at pH 8.0. The beads then are washed in deionized water until all fines are removed. Beads then are immersed in an antibody solution in 10 mM carbonate buffer, pH 8 to 9.5. The antibody solution can be as dilute as 1 $\mu\text{g/ml}$ in the case of high affinity monoclonal antibodies or as concentrated as about 500 $\mu\text{g/ml}$ for polyclonal antibodies which have not been affinity purified. Beads are coated for at least 12 hours at room temperature, and then they are washed with deionized water. Beads may be air dried or stored wet (in PBS, pH 7.4). They also may be overcoated with protein stabilizers (such as sucrose) or protein blocking agents used as non-specific binding blockers (such as irrelevant proteins, Carnation skim milk, Superblock[®], or the like).

Example 19: Microparticle Enzyme Immunoassay (MEIA)

CS141 antigens are detected in patient test samples by performing a standard antigen competition EIA or antibody sandwich EIA and utilizing a solid phase such

-88-

as microparticles (MEIA). The assay can be performed on an automated analyzer such as the IMx[®] Analyzer (Abbott Laboratories, Abbott Park, IL).

5 A. Antibody Sandwich EIA. Briefly, samples suspected of containing CS141 antigen are incubated in the presence of anti-CS141 antibody-coated microparticles (prepared as described in Example 17) in order to form antigen/antibody complexes. The microparticles then are washed and an indicator reagent comprising an antibody conjugated to a signal generating compound (i.e., enzymes such as alkaline phosphatase or horseradish peroxide) is added to the antigen/antibody complexes or the microparticles and incubated. The microparticles
10 are washed and the bound antibody/antigen/antibody complexes are detected by adding a substrate (e.g., 4-methyl umbelliferyl phosphate (MUP), or OPD/peroxide, respectively), that reacts with the signal generating compound to generate a measurable signal. An elevated signal in the test sample, compared to the signal generated by a negative control, detects the presence of CS141 antigen. The
15 presence of CS141 antigen in the test sample is indicative of a diagnosis of a GI tract disease or condition, such as GI tract cancer.

B. Competitive Binding Assay. The competitive binding assay uses a peptide or protein that generates a measurable signal when the labeled peptide is contacted with an anti-peptide antibody coated microparticle. This assay can be
20 performed on the IMx[®] Analyzer (available from Abbott Laboratories, Abbott Park, IL). The labeled peptide is added to the CS141 antibody-coated microparticles (prepared as described in Example 17) in the presence of a test sample suspected of containing CS141 antigen, and incubated for a time and under conditions sufficient to form labeled CS141 peptide (or labeled protein) / bound antibody complexes
25 and/or patient CS141 antigen / bound antibody complexes. The CS141 antigen in the test sample competes with the labeled CS141 peptide (or CS141 protein) for binding sites on the microparticle. CS141 antigen in the test sample results in a lowered binding of labeled peptide and antibody coated microparticles in the assay since antigen in the test sample and the CS141 peptide or CS141 protein compete for
30 antibody binding sites. A lowered signal (compared to a control) indicates the presence of CS141 antigen in the test sample. The presence of CS141 antigen suggests the diagnosis of a GI tract disease or condition, such as GI tract cancer.

 The CS141 polynucleotides and the proteins encoded thereby which are provided and discussed hereinabove are useful as markers of GI tract tissue disease,
35 especially GI tract cancer. Tests based upon the appearance of this marker in a test

-89-

sample such as blood, plasma or serum can provide low cost, non-invasive, diagnostic information to aid the physician to make a diagnosis of cancer, to help select a therapy protocol, or to monitor the success of a chosen therapy. This marker may appear in readily accessible body fluids such as blood, urine or stool as
5 antigens derived from the diseased tissue which are detectable by immunological methods. This marker may be elevated in a disease state, altered in a disease state, or be a normal protein of the GI tract which appears in an inappropriate body compartment.

11/11/2011 11:11:11 AM

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: BILLING-MEDEL, PATRICIA
COHEN, MAURICE
COLPITTS, TRACEY L.
FRIEDMAN, PAULA N.
GORDON, JULIAN
GRANADOS, EDWARD N.
HAYDEN, MARK
HODGES, STEVEN C.
KLASS, MICHAEL R.
KRATOCHVIL, JON D.
ROBERTS-RAPP, LISA
RUSSELL, JOHN C.
STROUPE, STEPHEN D.
- (ii) TITLE OF THE INVENTION: REAGENTS AND METHODS USEFUL
FOR DETECTING DISEASES OF THE GASTROINTESTINAL
TRACT
- (iii) NUMBER OF SEQUENCES: 30
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Abbott Laboratories
(B) STREET: 100 Abbott Park Road
(C) CITY: Abbott Park
(D) STATE: IL
(E) COUNTRY: USA
(F) ZIP: 60064-3500
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/828,489
(B) FILING DATE: 31-MAR-1997
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Becker, Cheryl L.
(B) REGISTRATION NUMBER: 35,441
(C) REFERENCE/DOCKET NUMBER: 6064.US.P1
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 847/935-1729
(B) TELEFAX: 847/938-2623
(C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 273 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 55
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 62
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 190
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 201
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 204
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 206
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGNCAGAGCC	TGCGCAGGGC	AGGAGCAGCT	GGCCCACTGG	CGGCCCGCAA	CACTNCGTCT	60
TNACCCTCTG	GGCCCACTGC	ATCTAGAGGA	GGGCCGTCTG	TGAGGCCACT	ACCCCTCCAG	120
CAACTGGGAG	GTGGGACTGT	CAGAAGCTGG	CCCAGGGTGG	TGGTCAGCTG	GGTCAGGGAC	180
CTACGGCANC	TGCTGGACCA	NCTNGNCTTT	TCCATCGAAG	CAGGGAAGTG	GGAGCCTTGA	240
CCCCTTGGGT	GGAAGCTTGA	CCCCAAGCCA	CTT			273

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 250 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ix) FEATURE:
 (A) NAME/KEY: base_polymorphism
 (B) LOCATION: 69
 (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"
- (ix) FEATURE:
 (A) NAME/KEY: base_polymorphism
 (B) LOCATION: 97
 (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"
- (ix) FEATURE:
 (A) NAME/KEY: base_polymorphism
 (B) LOCATION: 140
 (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"
- (ix) FEATURE:
 (A) NAME/KEY: base_polymorphism
 (B) LOCATION: 223
 (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AGAGCCTGCG	CAGGGCAGGA	GCAGCTGGCC	CACTGGCGGC	CCGCAACACT	CCGTCTCACC	60
CTCTGGGCNC	ACTGCATCTA	GAGGAGGGCC	GTCTGTNAGG	CCACTACCCC	TCCAGCAACT	120
GGGAGGTGGG	ACTGTCAGAN	GCTGGCCCAG	GGTGGTGGTC	AGCTGGGTCA	GGGACCTACG	180
GCACCTGCTG	GACCACCTCG	CCTTCTCCAT	CGAAGCAGGG	AANTGGGAGC	CTCGAGCCCT	240
CGGGTGGAAG						250

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 250 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ix) FEATURE:
 (A) NAME/KEY: base_polymorphism
 (B) LOCATION: 68
 (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"
- (ix) FEATURE:
 (A) NAME/KEY: base_polymorphism
 (B) LOCATION: 232
 (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"
- (ix) FEATURE:
 (A) NAME/KEY: base_polymorphism
 (B) LOCATION: 233
 (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TGGCGGCCCCG	CAACACTCCG	TCTCACCCTC	TGGGCCCCACT	GCATCTAGAG	GAGGGCCGTC	60
TGTGAGGNCA	CTACCCCTCC	AGCAACTGGG	AGGTGGGACT	GTCAGAATCT	GGCCCAGGGT	120
GGTGGTCAGC	TGGGTCAGGG	ACCTACGGCA	CCTGCTGGAC	CACCTCGCCT	TCTCCATCGA	180
AGCAGGGAAG	TGGGAGCCTC	GAGCCCTCGG	GTGGAAGCTG	ACCCCAAGCC	ANNCTTCACC	240

TGGACAGGAT

250

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 233 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CCCTCTGGGC	CCACTGCATC	TAGAGGAGGG	CCGTCTGTGA	GGCCACTACC	CCTCCAGCAA	60
CTGGGAGGTG	GGACTGTCAG	AAGCTGGCCC	AGGGTGGTGG	TCAGCTGGGT	CAGGGACCTA	120
CGGCACCTGC	TGGACCACCT	CGCCTTCTCC	ATCGAAGCAG	GGAAGTGGGA	GCCTCGAGCC	180
CTCGGGTGGA	AGCTGACCCC	AAGCCACCCT	TCACCTGGAC	AGGATGAGAG	TGT	233

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 287 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 17
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 60
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 193
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CACGAGGGCC	GTCTGTNAGG	CCACTACCCC	TCCAGCAACT	GGGAGGTGGG	ACTGTCAGAN	60
GCTGGCCCAG	GGTGGTGGTC	AGCTGGGTCA	GGGACCTACG	GCACCTGCTG	GACCACCTCG	120
CCTTCTCCAT	CGAAGCAGGG	AAGTGGGAGC	CTCGAGCCCT	CGGGTGGAAG	CTGACCCCAA	180
GCCACCCTTC	ACNTGGACAG	GATGAGAGTG	TCAGGTGTGC	TTCGCCTCCT	GGCCCTCATC	240
TTTGCCATAG	TCACGACATG	GATGTTTATT	CGAAGCTACA	TGAGCTT		287

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 263 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GATGTTTATT	CGAAGCTACA	TGAGCTTCAG	CATGAAAACC	ATCCGTCTGC	CACGCTGGCT	60
GGCCTCGCCC	ACCAAGGAGA	TCCAGGTAA	AAAGTACAAG	TGTGGCCTCA	TCAAGCCCTG	120
CCCAGCCAAC	TACTTTGCGT	TTAAATCTG	CAGTGGGGCC	GCCAACGTCG	TGGGCCCTAC	180

TATGTGCTTT GAAGACCGCA TGATCATGAG TCCTGTGAAA AACAATGTGG GCAGAGGCCT 240
AAACATCGCC CTGGTGAATG GAA 263

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 228 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GTGAAAAACA ATGTGGGCAG AGGCCTAAAC ATCGCCCTGG TGAATGGAAC CACGGGAGCT 60
GTGCTGGGAC AGAAGGCATT TGACATGTAC TCTGGAGATG TTATGCACCT AGTGAAATTC 120
CTTAAAGAAA TTCCGGGGGG TGCATGGTG CTGGTGGCCT CCTACGACGA TCCAGGGACC 180
AAAATGAACG ATGAAAGCAG GAAACTCTTC TCTGACTTGG GGAGTTCC 228

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 251 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GGGGGGTGCA CTGGTGCTGG TGGCCTCCTA CGACGATCCA GGGACCAAAA TGAACGATGA 60
AAGCAGGAAA CTCTTCTCTG ACTTGGGGAG TTCCTACGCA AAACAACCTGG GCTTCCGGGA 120
CAGCTGGGTC TTCATAGGAG CCAAAGACCT CAGGGGTAAA AGCCCCTTTG AGCAGTTCTT 180
AAAGAACAGC CCAGACACAA ACAAATACGA GGGATGGCCA GAGCTGCTGG AGATGGAGGG 240
CTGCATGCCC C 251

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 187 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 148
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 185
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 186
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GGGATGGCCA GAGCTGCTGG AGATGGAGGG CTGCATGCCC CCGAAGCCAT TTTAGGGTGG 60
CTGTGGCTCT TCCTCAGCCA GGGGCCTGAA GAAGCTCCTG CCTGACTTAG GAGTCAGAGC 120

CCGGCAGGGG CTGAGGAGGA GGAGCAGNGG GTGCTGCGTG GAAGGTGCTG CAAGTCCTTG 180
AAAGNNG 187

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 301 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TTTTTTTTTT	TCAAAACCAG	CAAAAATAAA	ATTTAATTGG	GCTCAAGTCT	GGGCAGTTTG	60
TCCTTCCTCA	GGACCAGCCG	TCAGCAGTCC	CTGACGAAAG	CACCCCATTC	TCTCCACAGA	120
CAGCTGGTTC	CAGAAGGACC	CTCTGAGGCT	GGTCTTCCGG	GTAGGATGTG	CTGTGGGAGG	180
GTTCTGTTTC	CGAGGAGGAG	AGGCGCGACA	CAGCGTGCAA	GGACCTGCAG	CACCTTCCAC	240
GCAGCACCCC	CTGCTCCTCC	TCCTCAGCCC	CTGCCGGGCT	CTGACTCCTA	AGTCAGGCAG	300
G						301

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 123 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TTTTTCAAAA	CCAGCAAAAA	TAAATTTTAA	TTGGGCTCAA	GTCTGGGCAG	TTTGTCTTTC	60
CTCAGGACCA	GCCGTCAGCA	GTCCCTGACG	AAAGCACCCC	ATTCTCTCCA	CAGACAGCTG	120
GTT						123

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 955 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GATGTTTATT	CGAAGCTACA	TGAGCTTCAG	CATGAAAACC	ATCCGTCTGC	CACGCTGGCT	60
GGCCTCGCCC	ACCAAGGAGA	TCCAGGTTAA	AAAGTACAAG	TGTGGCCTCA	TCAAGCCCTG	120
CCCAGCCAAC	TACTTTGCGT	TTAAAATCTG	CAGTGGGGCC	GCCAACGTCG	TGGGCCCCTAC	180
TATGTGCTTT	GAAGACCGCA	TGATCATGAG	TCCTGTGAAA	AACAATGTGG	GCAGAGGCCT	240
AAACATCGCC	CTGGTGAATG	GAACCACGGG	AGCTGTGCTG	GGACAGAAGG	CATTTGACAT	300
GTAATCTGGA	GATGTTATGC	ACCTAGTGAA	ATTCTTTAAA	GAAATTCCGG	GGGGTGCAC	360
GGTGCTGGTG	GCCTCCTACG	ACGATCCAGG	GACCAAAATG	AACGATGAAA	GCAGGAAACT	420
CTTCTCTGAC	TTGGGGAGTT	CCTACGCAAA	ACAACCTGGG	TTCCGGGACA	GCTGGGTCTT	480
CATAGGAGCC	AAAGACCTCA	GGGGTAAAAG	CCCCTTTGAG	CAGTTCTTAA	AGAACAGCCC	540
AGACACAAAC	AAATACGAGG	GATGGCCAGA	GCTGCTGGAG	ATGGAGGGCT	GCATGCCCCC	600
GAAGCCATTT	TAGGGTGGCT	GTGGCTCTTC	CTCAGCCAGG	GGCCTGAAGA	AGCTCCTGCC	660
TGACTTAGGA	GTCAGAGCCC	GGCAGGGGCT	GAGGAGGAGG	AGCAGGGGGT	GCTGCGTGGA	720
AGGTGCTGCA	GGTCCTTGCA	CGCTGTGTCG	CGCCTCTCCT	CCTCGGAAAC	AGAACCCTCC	780
CACAGCACAT	CCTACCCGGA	AGACCAGCCT	CAGAGGGTCC	TTCTGGAACC	AGCTGTCTGT	840
GGAGAGAATG	GGGTGCTTTC	GTCAGGGACT	GCTGACGGCT	GGTCTGAGG	AAGGACAAAC	900
TGCCCAGACT	TGAGCCCAAT	TAAATTTTAT	TTTTGCTGGT	AAAAAMAAAW	AAMMA	955

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1299 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: base_polymorphism
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "'N' represents an A or G or T or C polymorphism at this position"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GGNCAGAGCC	TGCGCAGGGC	AGGAGCAGCT	GGCCCACTGG	CGGCCCGCAA	CACTCCGTCT	60
CACCCCTCTGG	GCCCACTGCA	TCTAGAGGAG	GGCCGTCTGT	GAGGCCACTA	CCCCCTCCAGC	120
AACTGGGAGG	TGGGACTGTC	AGAAGCTGGC	CCAGGGTGGT	GGTCAGCTGG	GGTCAGGGACC	180
TACGGCACCT	GCTGGACCAC	CTCGCCTTCT	CCATCGAAGC	AGGGAAGTGG	GAGCCTCGAG	240
CCCTCGGGTG	GAAGCTGACC	CCAAGCCACC	CTTCACCTGG	ACAGGATGAG	AGTGTGAGGT	300
GTGCTTCGCC	TCCTGGCCCT	CATCTTTGCC	ATAGTCACGA	CATGGATGTT	TATTCGAAGC	360
TACATGAGCT	TCAGCATGAA	AACCATCCGT	CTGCCACGCT	GGCTGGCCCTC	GCCCACCAAG	420
GAGATCCAGG	TTAAAAAGTA	CAAGTGTGGC	CTCATCAAGC	CCTGCCCAGC	CAACTACTTT	480
GCGTTTAAAA	TCTGCAGTGG	GGCCGCCAAC	GTCGTGGGCC	CTACTATGTG	CTTTGAAGAC	540
CGCATGATCA	TGAGTCCTGT	GAAAAACAAT	GTGGGCAGAG	GCCTAAACAT	CGCCCTGGTG	600
AATGGAACCA	CGGGAGCTGT	GCTGGGACAG	AAGGCATTTG	ACATGTACTC	TGGAGATGTT	660
ATGCACCTAG	TGAAATTCCT	TAAAGAAATT	CCGGGGGGTG	CACTGGTGCT	GGTGGCCTCC	720
TACGACGATC	CAGGGACCAA	AATGAACGAT	GAAAGCAGGA	AACTCTTCTC	TGACTTGGGG	780
AGTTCCTACG	CAAAACAAC	GGGCTTCCGG	GACAGCTGGG	TCTTCATAGG	AGCCAAAGAC	840
CTCAGGGGTA	AAAGCCCCTT	TGAGCAGTTC	TTAAAGAACA	GCCCAGACAC	AAACAAATAC	900
GAGGGATGGC	CAGAGCTGCT	GGAGATGGAG	GGCTGCATGC	CCCCGAAGCC	ATTTTAGGGT	960
GGCTGTGGCT	CTTCCTCAGC	CAGGGGCCCTG	AAGAAGCTCC	TGCCTGACTT	AGGAGTCAGA	1020
GCCCGGCAGG	GGCTGAGGAG	GAGGAGCAGG	GGGTGCTGCG	TGGAAGGTGC	TGCAGGTCCT	1080
TGCACGCTGT	GTCGCGCCTC	TCCTCCTCGG	AAACAGAACC	CTCCCACAGC	ACATCCTACC	1140
CGGAAGACCA	GCCTCAGAGG	GTCCTTCTGG	AACCAGCTGT	CTGTGGAGAG	AATGGGGTGC	1200
TTTCGTCAGG	GACTGCTGAC	GGCTGGTCCT	GAGGAAGGAC	AAACTGCCCCA	GACTTGAGCC	1260
CAATTAAATT	TTATTTTTGC	TGTTTTTGAA	AAAAAAAAAA			1299

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 68 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGCTCGGAAT	TCCGAGCTTG	GATCCTCTAG	AGCGGCCGCC	GACTAGTGAG	CTCGTCGACC	60
CGGGAATT						68

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 68 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

AATTAATTCC	CGGGTCGACG	AGCTCACTAG	TCGGCGGCCG	CTCTAGAGGA	TCCAAGCTCG	60
GAATTCGG						68

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

AGCGGATAAC AATTCACAC AGGA

24

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TGTAAAACGA CGGCCAGT

18

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GGGACAGAAG GCATTGGA

18

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GAACAGCCCCA GACACAAAC

19

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CCCAAGTCAG AGAAGAGTTT CC

22

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ACTTGCAGCA CCTTCCAC

18

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CAGCATGAAA ACCATCCGTC TGC

23

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

TTGCGTAGGA ACTCCCAAG TCAG

24

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 223 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Met	Arg	Val	Ser	Gly	Val	Leu	Arg	Leu	Leu	Ala	Leu	Ile	Phe	Ala	Ile
1				5				10					15		
Val	Thr	Thr	Trp	Met	Phe	Ile	Arg	Ser	Tyr	Met	Ser	Phe	Ser	Met	Lys
			20					25				30			
Thr	Ile	Arg	Leu	Pro	Arg	Trp	Leu	Ala	Ser	Pro	Thr	Lys	Glu	Ile	Gln
			35				40					45			
Val	Lys	Lys	Tyr	Lys	Cys	Gly	Leu	Ile	Lys	Pro	Cys	Pro	Ala	Asn	Tyr
			50			55					60				
Phe	Ala	Phe	Lys	Ile	Cys	Ser	Gly	Ala	Ala	Asn	Val	Val	Gly	Pro	Thr
65				70						75				80	
Met	Cys	Phe	Glu	Asp	Arg	Met	Ile	Met	Ser	Pro	Val	Lys	Asn	Asn	Val
				85						90				95	
Gly	Arg	Gly	Leu	Asn	Ile	Ala	Leu	Val	Asn	Gly	Thr	Thr	Gly	Ala	Val
			100					105					110		
Leu	Gly	Gln	Lys	Ala	Phe	Asp	Met	Tyr	Ser	Gly	Asp	Val	Met	His	Leu
			115				120					125			

Val Lys Phe Leu Lys Glu Ile Pro Gly Gly Ala Leu Val Leu Val Ala
 130 135 140
 Ser Tyr Asp Asp Pro Gly Thr Lys Met Asn Asp Glu Ser Arg Lys Leu
 145 150 155 160
 Phe Ser Asp Leu Gly Ser Ser Tyr Ala Lys Gln Leu Gly Phe Arg Asp
 165 170 175
 Ser Trp Val Phe Ile Gly Ala Lys Asp Leu Arg Gly Lys Ser Pro Phe
 180 185 190
 Glu Gln Phe Leu Lys Asn Ser Pro Asp Thr Asn Lys Tyr Glu Gly Trp
 195 200 205
 Pro Glu Leu Leu Glu Met Glu Gly Cys Met Pro Pro Lys Pro Phe
 210 215 220

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Arg Trp Leu Ala Ser Pro Thr Lys Glu Ile Gln Val Lys Lys Tyr Lys
 1 5 10 15
 Cys Gly Leu Ile Lys Pro Cys Pro Ala Asn Tyr Phe Ala Phe Lys Ile
 20 25 30
 Cys Ser Gly Ala Ala Asn
 35

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Gly Pro Thr Met Cys Phe Glu Asp Arg Met Ile Met Ser Pro Val Lys
 1 5 10 15
 Asn Asn Val Gly Arg Gly Leu Asn Ile Ala Leu Val Asn Gly Thr Thr
 20 25 30
 Gly Ala Val Leu Gly Gln Lys
 35

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Lys Glu Ile Pro Gly Gly Ala Leu Val Leu Val Ala Ser Tyr Asp Asp
 1 5 10 15

Pro Gly Thr Lys Met Asn Asp Glu Ser Arg Lys Leu Phe Ser Asp Leu
20 25 30
Gly Ser Ser Tyr Ala
35

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Trp Val Phe Ile Gly Ala Lys Asp Leu Arg Gly Lys Ser Pro Phe Glu
1 5 10 15
Gln Phe Leu Lys Asn Ser Pro Asp Thr Asn Lys Tyr Glu Gly Trp Pro
20 25 30
Glu Leu Leu Glu Met Glu Gly Cys
35 40

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Asp Tyr Lys Asp Asp Asp Asp Lys
1 5

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Met His Thr Glu His
1 5 10 15
His His His His His
20

-101-

We Claim:

1. A method of detecting the presence of a target CS141 polynucleotide in a test sample, comprising:
 - 5 (a) contacting said test sample with at least one CS141-specific polynucleotide or complement thereof; and
 - (b) detecting the presence of said target CS141 polynucleotide in the test sample, wherein said CS141-specific polynucleotide has at least 50% identity with a polynucleotide selected from the group consisting of SEQUENCE ID NOS 1-13,
10 and fragments or complements thereof.
2. The method of claim 1, wherein said target CS141 polynucleotide is attached to a solid phase prior to performing step (a).
- 15 3. A method for detecting mRNA of CS141 in a test sample, comprising:
 - (a) performing reverse transcription with at least one primer in order to produce cDNA;
 - (b) amplifying the cDNA obtained from step (a) using CS141
20 oligonucleotides as sense and antisense primers to obtain CS141 amplicon; and
 - (c) detecting the presence of said CS141 amplicon in the test sample, wherein the CS141 oligonucleotides utilized in steps (a) and (b) have at least 50% identity with a polynucleotide selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof.
25
4. The method of claim 3, wherein said test sample is reacted with a solid phase prior to performing one of steps (a), (b), or (c).
5. The method of claim 3, wherein said detection step comprises
30 utilizing a detectable label capable of generating a measurable signal.
6. A method of detecting a target CS141 polynucleotide in a test sample suspected of containing said target, comprising:

-102-

(a) contacting said test sample with at least one CS141 oligonucleotide as a sense primer and with at least one CS141 oligonucleotide as an anti-sense primer and amplifying to obtain a first stage reaction product;

(b) contacting said first stage reaction product with at least one other
5 CS141 oligonucleotide to obtain a second stage reaction product, with the proviso that the other CS141 oligonucleotide is located 3' to the CS141 oligonucleotides utilized in step (a) and is complementary to said first stage reaction product; and

(c) detecting said second stage reaction product as an indication of the presence of the target CS141 polynucleotide, wherein the CS141 oligonucleotides
10 utilized in steps (a) and (b) have at least 50% identity with a polynucleotide selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof.

7. The method of claim 6, wherein said test sample is reacted with a
15 solid phase prior to performing one of steps (a), (b), or (c).

8. The method of claim 6, wherein said detection step comprises utilizing a detectable label capable of generating a measurable signal.

9. The method of claim 8, wherein said detectable label is reacted to a
20 solid phase.

10. A test kit useful for detecting CS141 polynucleotide in a test sample, comprising a container containing at least one CS141 polynucleotide having at least
25 50% identity to a sequence selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof.

11. A purified polynucleotide or fragment thereof derived from a CS141 gene, wherein said polynucleotide is capable of selectively hybridizing to the nucleic
30 acid of said CS141 gene and has at least 50% identity with a sequence selected from the group consisting of (a) SEQUENCE ID NOS 1-9, SEQUENCE ID NO 12, SEQUENCE ID NO 13, and complements thereof, and (b) fragments of SEQUENCE ID NOS 1-9.

-103-

12. The purified polynucleotide of claim 11, wherein said polynucleotide is produced by recombinant techniques.

13. The purified polynucleotide of claim 11, wherein said polynucleotide
5 is produced by synthetic techniques.

14. The purified polynucleotide of claim 11, wherein said polynucleotide comprises a sequence encoding at least one CS141 epitope.

10 15. A recombinant expression system comprising a nucleic acid sequence that includes an open reading frame derived from CS141 operably linked to a control sequence compatible with a desired host, wherein said nucleic acid sequence has at least 50% identity with a polynucleotide selected from the group consisting of
SEQUENCE ID NOS 1-13, and fragments or complements thereof.

15 16. A cell transfected with the recombinant expression system of claim
15.

17. A CS141 polypeptide having at least 60% identity with an amino acid
20 sequence selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof.

18. The polypeptide of claim 17, wherein said polypeptide is produced
25 by recombinant techniques.

19. The polypeptide of claim 17, wherein said polypeptide is produced by synthetic techniques.

20. An antibody which specifically binds to at least one CS141 epitope,
30 wherein said CS141 epitope is derived from an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof.

35

-104-

21. An assay kit for determining the presence of CS141 antigen or anti-CS141 antibody in a test sample, comprising a container containing a CS141 polypeptide having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25,
5 SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof.

22. The assay kit of claim 21, wherein said polypeptide is attached to a solid phase.
10

23. An assay kit for determining the presence of CS141 antigen in a test sample, comprising a container containing an antibody which specifically binds to a CS141 antigen which comprises at least one CS141 epitope.

24. The kit of claim 23, wherein said antibody is attached to a solid phase.
15

25. A method for producing a polypeptide comprising at least one CS141 epitope, said method comprising incubating host cells that have been transfected with an expression vector containing a polynucleotide sequence encoding a polypeptide, wherein said polypeptide comprises an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26,
20 SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof.

26. A method for detecting CS141 antigen in a test sample suspected of containing said CS141 antigen, comprising:
25

(a) contacting the test sample with an antibody or fragment thereof which specifically binds to at least one epitope of a CS141 antigen selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof,
30 wherein said contacting is carried out for a time and under conditions sufficient for the formation of antibody/antigen complexes; and

(b) detecting said complexes.
35

-105-

27. The method of claim 26, wherein said antibody is attached to a solid phase.

28. A method for detecting the presence of antibodies specific for a
5 CS141 antigen in a test sample suspected of containing such antibodies, said method comprising:

(a) contacting the test sample with a CS141 polypeptide, wherein said CS141 polypeptide contains at least one CS141 epitope derived from an amino acid sequence or fragment thereof having at least 50% identity with an amino acid
10 sequence selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof, and further wherein said contacting is carried out for a time and under conditions sufficient to allow antigen/antibody complexes to form; and
15 (b) detecting said complexes.

29. The method of claim 28, wherein said CS141 polypeptide is attached to a solid phase.

30. A cell transfected with a nucleic acid sequence encoding at least one CS141 epitope, wherein said nucleic acid sequence is selected from the group consisting of SEQUENCE ID NOS 1-13, and fragments or complements thereof.

31. A method for producing antibodies which specifically bind to CS141
25 antigen, comprising administering to an individual an isolated immunogenic polypeptide or fragment thereof in an amount sufficient to elicit an immune response, wherein said immunogenic polypeptide comprises at least one CS141 epitope and has at least 50% identity to a sequence selected from the group consisting of SEQUENCE ID NO 24, SEQUENCE ID NO 25, SEQUENCE ID NO
30 26, SEQUENCE ID NO 27, SEQUENCE ID NO 28, and fragments thereof.

32. A method for producing antibodies which specifically bind to CS141 antigen, comprising administering to an individual a plasmid comprising a sequence which encodes at least one CS141 epitope derived from a polypeptide having an
35 amino acid sequence selected from the group consisting of SEQUENCE ID NO 24,

-106-

SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27,
SEQUENCE ID NO 28, and fragments thereof.

5 33. A composition of matter comprising a CS141 polynucleotide or
fragment thereof, wherein said polynucleotide has at least 50% identity with a
sequence selected from the group consisting of (a) SEQUENCE ID NOS 1-9,
SEQUENCE ID NO 12, SEQUENCE ID NO 13, and complements thereof, and (b)
fragments of SEQUENCE ID NOS 1-9.

10 34. A composition of matter comprising a polypeptide containing at least
one CS141 epitope, wherein said polypeptide has at least 60% identity with a
sequence selected from the group consisting of SEQUENCE ID NO 24,
SEQUENCE ID NO 25, SEQUENCE ID NO 26, SEQUENCE ID NO 27,
SEQUENCE ID NO 28, and fragments thereof.

15 35. The test kit of claim 10 further comprising a container with tools
useful for collection of said sample, wherein the tools are selected from the group
consisting of lancets, absorbent paper, cloth, swabs and cups.

20 36. The assay kit of claim 21 further comprising a container with tools
useful for collection of said sample, wherein the tools are selected from the group
consisting of lancets, absorbent paper, cloth, swabs and cups.

25 37. The test kit of claim 23 further comprising a container with tools
useful for collection of said sample, wherein the tools are selected from the group
consisting of lancets, absorbent paper, cloth, swabs and cups.

30 38. A gene, or a fragment thereof, which codes for a CS141 protein
which comprises an amino acid sequence having at least 60% identity with
SEQUENCE ID NO 24.

39. A gene, or a fragment thereof, comprising DNA having at least 50%
identity with SEQUENCE ID NO 12 or SEQUENCE ID NO 13.

REAGENTS AND METHODS USEFUL FOR DETECTING
DISEASES OF THE GASTROINTESTINAL TRACT

5

10

Abstract of the Disclosure

15

20

A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS141 and transcribed from GI tract tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS141-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS141 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.

Figure 1A

>775133	GGNCAGAGCC	TGCGCAGGGC	AGGAGCAGCT	GGCCCACTGG	CGGCCCCGCAA
>1338704	AGAGCC	TGCGCAGGGC	AGGAGCAGCT	GGCCCACTGG	CGGCCCCGCAA
>2645837				TGG	CGGCCCCGCAA
Consensus	GGNCAGAGCC	TGCGCAGGGC	AGGAGCAGCT	GGCCCACTGG	CGGCCCCGCAA
>775133	CACTNCGTCT	TNACCCTCTG	GGCCCACTGC	ATCTAGAGGA	GGGCCGTCTG
>1338704	CACTCCGTCT	:CACCCTCTG	GGCNCACCTGC	ATCTAGAGGA	GGGCCGTCTG
>2645837	CACTCCGTCT	:CACCCTCTG	GGCCCACTGC	ATCTAGAGGA	GGGCCGTCTG
>775762		CCCTCTG	GGCCCACTGC	ATCTAGAGGA	GGGCCGTCTG
>3210629				CACGA	GGGCCGTCTG
Consensus	CACTCCGTCT	:CACCCTCTG	GGCCCACTGC	ATCTAGAGGA	GGGCCGTCTG
>775133	TGAGGCCACT	ACCCCTCCAG	CAACTGGGAG	GTGGGACTGT	CAGAAGCTGG
>1338704	TNAGGCCACT	ACCCCTCCAG	CAACTGGGAG	GTGGGACTGT	CAGANGCTGG
>2645837	TGAGGNCACT	ACCCCTCCAG	CAACTGGGAG	GTGGGACTGT	CAGAATCTGG
>775762	TGAGGCCACT	ACCCCTCCAG	CAACTGGGAG	GTGGGACTGT	CAGAAGCTGG
>3210629	TNAGGCCACT	ACCCCTCCAG	CAACTGGGAG	GTGGGACTGT	CAGANGCTGG
Consensus	TGAGGCCACT	ACCCCTCCAG	CAACTGGGAG	GTGGGACTGT	CAGAAGCTGG
>775133	CCCAGGGTGG	TGGTCAGCTG	GGTCAGGGAC	CTACGGCANC	TGCTGGACCA
>1338704	CCCAGGGTGG	TGGTCAGCTG	GGTCAGGGAC	CTACGGCACC	TGCTGGACCA
>2645837	CCCAGGGTGG	TGGTCAGCTG	GGTCAGGGAC	CTACGGCACC	TGCTGGACCA
>775762	CCCAGGGTGG	TGGTCAGCTG	GGTCAGGGAC	CTACGGCACC	TGCTGGACCA
>3210629	CCCAGGGTGG	TGGTCAGCTG	GGTCAGGGAC	CTACGGCACC	TGCTGGACCA
Consensus	CCCAGGGTGG	TGGTCAGCTG	GGTCAGGGAC	CTACGGCACC	TGCTGGACCA
>775133	NCTNGNCTTT	TCCATCGAAG	CAGGGAAGTG	GGAGCCTTGA	GCCCTTGCGGT
>1338704	CCTCGCCTTC	TCCATCGAAG	CAGGGAANTG	GGAGCCTCGA	GCCCTCGCGGT
>2645837	CCTCGCCTTC	TCCATCGAAG	CAGGGAAGTG	GGAGCCTCGA	GCCCTCGCGGT
>775762	CCTCGCCTTC	TCCATCGAAG	CAGGGAAGTG	GGAGCCTCGA	GCCCTCGCGGT
>3210629	CCTCGCCTTC	TCCATCGAAG	CAGGGAAGTG	GGAGCCTCGA	GCCCTCGCGGT
Consensus	CCTCGCCTTC	TCCATCGAAG	CAGGGAAGTG	GGAGCCTCGA	GCCCTCGCGGT
>775133	GGAAGCTTGA	CCCCAAGCCA	CTT		
>1338704	GGAAG				
>2645837	GGAAGCT:GA	CCCCAAGCCA	NNCTTCACCT	GGACAGGAT	
>775762	GGAAGCT:GA	CCCCAAGCCA	CCCTTCACCT	GGACAGGATG	AGAGTGT
>3210629	GGAAGCT:GA	CCCCAAGCCA	CCCTTCACNT	GGACAGGATG	AGAGTGTGTCAG
Consensus	GGAAGCT:GA	CCCCAAGCCA	CCCTTCACCT	GGACAGGATG	AGAGTGTGTCAG
>3210629	GTGTGCTTCG	CCTCCTGGCC	CTCATCTTTG	CCATAGTCAC	GACATGGATG
>1281865					GATG
>1281865					GATG
Consensus	GTGTGCTTCG	CCTCCTGGCC	CTCATCTTTG	CCATAGTCAC	GACATGGATG
>3210629	TTTATTTCGAA	GCTACATGAG	CTT		
>1281865	TTTATTTCGAA	GCTACATGAG	CTTCAGCATG	AAAACCATCC	GTCTGCCACG
>1281865	TTTATTTCGAA	GCTACATGAG	CTTCAGCATG	AAAACCATCC	GTCTGCCACG
Consensus	TTTATTTCGAA	GCTACATGAG	CTTCAGCATG	AAAACCATCC	GTCTGCCACG

Figure 1B


>1281865	CTGGCTGGCC	TCGCCCACCA	AGGAGATCCA	GGTTAAAAAG	TACAAGTGTG
>1281865	CTGGCTGGCC	TCGCCCACCA	AGGAGATCCA	GGTTAAAAAG	TACAAGTGTG
Consensus	CTGGCTGGCC	TCGCCCACCA	AGGAGATCCA	GGTTAAAAAG	TACAAGTGTG
>1281865	GCCTCATCAA	GCCCTGCCCC	GCCAACTACT	TTGCGTTTAA	AATCTGCAGT
>1281865	GCCTCATCAA	GCCCTGCCCC	GCCAACTACT	TTGCGTTTAA	AATCTGCAGT
Consensus	GCCTCATCAA	GCCCTGCCCC	GCCAACTACT	TTGCGTTTAA	AATCTGCAGT
>1281865	GGGGCCGCCA	ACGTCGTGGG	CCCTACTATG	TGCTTTGAAG	ACCGCATGAT
>1281865	GGGGCCGCCA	ACGTCGTGGG	CCCTACTATG	TGCTTTGAAG	ACCGCATGAT
Consensus	GGGGCCGCCA	ACGTCGTGGG	CCCTACTATG	TGCTTTGAAG	ACCGCATGAT
>1281865	CATGAGTCCT	GTGAAAAACA	ATGTGGGCAG	AGGCCTAAAC	ATCGCCCTGG
>1281865	CATGAGTCCT	GTGAAAAACA	ATGTGGGCAG	AGGCCTAAAC	ATCGCCCTGG
>1807758		GTGAAAAACA	ATGTGGGCAG	AGGCCTAAAC	ATCGCCCTGG
Consensus	CATGAGTCCT	GTGAAAAACA	ATGTGGGCAG	AGGCCTAAAC	ATCGCCCTGG
>1281865	TGAATGGAA				
>1281865	TGAATGGAAC	CACGGGAGCT	GTGCTGGGAC	AGAAGGCATT	TGACATGTAC
>1807758	TGAATGGAAC	CACGGGAGCT	GTGCTGGGAC	AGAAGGCATT	TGACATGTAC
Consensus	TGAATGGAAC	CACGGGAGCT	GTGCTGGGAC	AGAAGGCATT	TGACATGTAC
>1281865	TCTGGAGATG	TTATGCACCT	AGTGAAATTC	CTTAAAGAAA	TTCCGGGGGG
>1807758	TCTGGAGATG	TTATGCACCT	AGTGAAATTC	CTTAAAGAAA	TTCCGGGGGG
>1735382					GGGGGG
Consensus	TCTGGAGATG	TTATGCACCT	AGTGAAATTC	CTTAAAGAAA	TTCCGGGGGG
>1281865	TGCACTGGTG	CTGGTGGCCT	CCTACGACGA	TCCAGGGACC	AAAATGAACG
>1807758	TGCACTGGTG	CTGGTGGCCT	CCTACGACGA	TCCAGGGACC	AAAATGAACG
>1735382	TGCACTGGTG	CTGGTGGCCT	CCTACGACGA	TCCAGGGACC	AAAATGAACG
Consensus	TGCACTGGTG	CTGGTGGCCT	CCTACGACGA	TCCAGGGACC	AAAATGAACG
>1281865	ATGAAAGCAG	GAAACTCTTC	TCTGACTTGG	GGAGTTCCTA	CGAAAAACAA
>1807758	ATGAAAGCAG	GAAACTCTTC	TCTGACTTGG	GGAGTTCCTA	CGAAAAACAA
>1735382	ATGAAAGCAG	GAAACTCTTC	TCTGACTTGG	GGAGTTCCTA	CGAAAAACAA
Consensus	ATGAAAGCAG	GAAACTCTTC	TCTGACTTGG	GGAGTTCCTA	CGAAAAACAA
>1281865	CTGGGCTTCC	GGGACAGCTG	GGTCTTCATA	GGAGCCAAAG	ACCTCAGGGG
>1735382	CTGGGCTTCC	GGGACAGCTG	GGTCTTCATA	GGAGCCAAAG	ACCTCAGGGG
Consensus	CTGGGCTTCC	GGGACAGCTG	GGTCTTCATA	GGAGCCAAAG	ACCTCAGGGG
>1281865	TAAAAGCCCC	TTTGAGCAGT	TCTTAAAGAA	CAGCCCAGAC	ACAAACAAAT
>1735382	TAAAAGCCCC	TTTGAGCAGT	TCTTAAAGAA	CAGCCCAGAC	ACAAACAAAT
Consensus	TAAAAGCCCC	TTTGAGCAGT	TCTTAAAGAA	CAGCCCAGAC	ACAAACAAAT
>1281865	ACGAGGGATG	GCCAGAGCTG	CTGGAGATGG	AGGGCTGCAT	GCCCCCGAAG
>1735382	ACGAGGGATG	GCCAGAGCTG	CTGGAGATGG	AGGGCTGCAT	GCCCC
>2128334		GGGATG	GCCAGAGCTG	CTGGAGATGG	AGGGCTGCAT
Consensus	ACGAGGGATG	GCCAGAGCTG	CTGGAGATGG	AGGGCTGCAT	GCCCCCGAAG

Figure 1C

>1281865	CCATTTTAGG	GTGGCTGTGG	CTCTTCCTCA	GCCAGGGGCC	TGAAGAAGCT
>2128334	CCATTTTAGG	GTGGCTGTGG	CTCTTCCTCA	GCCAGGGGCC	TGAAGAAGCT
Consensus	CCATTTTAGG	GTGGCTGTGG	CTCTTCCTCA	GCCAGGGGCC	TGAAGAAGCT
>1281865	CCTGCCTGAC	TTAGGAGTCA	GAGCCCCGCA	GGGGCTGAGG	AGGAGGAGCA
>2128334	CCTGCCTGAC	TTAGGAGTCA	GAGCCCCGCA	GGGGCTGAGG	AGGAGGAGCA
Consensus	CCTGCCTGAC	TTAGGAGTCA	GAGCCCCGCA	GGGGCTGAGG	AGGAGGAGCA
>1281865	GGGGGTGCTG	CGTGGAAAGGT	GCTGCAGGTC	CTTGCACGCT	GTGTCGCGCC
>2128334	GNGGGTGCTG	CGTGGAAAGGT	GCTGCAAGTC	CTTGAAAGNN	G
<g2197992		GTGGAAAGGT	GCTGCAGGTC	CTTGCACGCT	GTGTCGCGCC
Consensus	GGGGGTGCTG	CGTGGAAAGGT	GCTGCAGGTC	CTTGCACGCT	GTGTCGCGCC
>1281865	TCTCCTCCTC	GGAAACAGAA	CCCTCCCACA	GCACATCCTA	CCCGGAAGAC
<g2197992	TCTCCTCCTC	GGAAACAGAA	CCCTCCCACA	GCACATCCTA	CCCGGAAGAC
Consensus	TCTCCTCCTC	GGAAACAGAA	CCCTCCCACA	GCACATCCTA	CCCGGAAGAC
>1281865	CAGCCTCAGA	GGGTCCTTCT	GGAACCAGCT	GTCTGTGGAG	AGAATGGGGT
<g2197992	CAGCCTCAGA	GGGTCCTTCT	GGAACCAGCT	GTCTGTGGAG	AGAATGGGGT
<g2409650			AACCAGCT	GTCTGTGGAG	AGAATGGGGT
Consensus	CAGCCTCAGA	GGGTCCTTCT	GGAACCAGCT	GTCTGTGGAG	AGAATGGGGT
>1281865	GCTTTCGTCA	GGGACTGCTG	ACGGCTGGTC	CTGAGGAAGG	ACAAACTGCC
<g2197992	GCTTTCGTCA	GGGACTGCTG	ACGGCTGGTC	CTGAGGAAGG	ACAAACTGCC
<g2409650	GCTTTCGTCA	GGGACTGCTG	ACGGCTGGTC	CTGAGGAAGG	ACAAACTGCC
Consensus	GCTTTCGTCA	GGGACTGCTG	ACGGCTGGTC	CTGAGGAAGG	ACAAACTGCC
>1281865	CAGACTTGAG	CCCAATTAAA	TTTTATTTTT	GCTGGTAAAA	AMAAAWAAMM
<g2197992	CAGACTTGAG	CCCAATTAAA	TTTTATTTTT	GCTGGTTTTG	AAAAAAAAAA
<g2409650	CAGACTTGAG	CCCAATTAAA	TTTTATTTTT	GCTGGTTTTG	AAAAA
Consensus	CAGACTTGAG	CCCAATTAAA	TTTTATTTTT	GCTGGTTTTG	AAAAAAAAAA
>1281865	A				
<g2197992	A				
Consensus	A				

CCATTTTAGG GTGGCTGTGG CTCTTCCTCA GCCAGGGGCC TGAAGAAGCT


Figure 3A



Lane	Tissue
1	Bladder
2	Brain
3	Breast
4	Colon
5	Kidney
6	Lung

Lane	Tissue
7	Muscle
8	Ovary
9	Placenta
10	Prostate
11	Spleen
12	Testis


Figure 3B



Lane	Tissue
1	Normal Colon
2	Normal Colon
3	Normal Colon
4	Normal Colon
5	Normal Colon
6	Normal Colon


Lane	Tissue
7	Cancer Colon
8	Cancer Colon
9	Cancer Colon
10	Cancer Colon
11	Cancer Colon
12	Cancer Colon

Figure 4A




Lane	Tissue
1	DNA Molecular Weight Marker
2	Normal Colon
3	Cancer Colon
4	Cancer Colon
5	Normal Colon
6	Cancer Colon
7	Placental DNA Control

Figure 4B



Lane	Tissue
1	DNA Molecular Weight Marker
2	Placental DNA Control
3	Normal Colon
4	Cancer Colon
5	Normal Breast
6	Cancer Breast
7	Cancer Breast
8	BPH Prostate
9	Cancer Prostate
10	BPH Prostate
11	Normal Lung
12	Normal Lung
13	Cancer Lung

Figure 5



Lane	Tissue	Lane	Tissue
1	Kidney	8	Normal Colon
2	Bladder	9	Normal Colon
3	Prostate	10	Cancer Colon
4	Breast	11	Cancer Colon
5	Lung	12	Cancer Colon
6	Normal Colon	13	Cancer Colon
7	Normal Colon	14	Markers

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Patricia A. BILLING-
MEDEL, Maurice COHEN, Tracey L.
COLPITTS, Paula N. FRIEDMAN, Julian
GORDON, Edward N. GRANADOS, Mark
HAYDEN, Steven C. HODGES, Michael
R. KLASS, Jon D. KRATOCHVIL, Lisa
ROBERTS-RAPP, John C. RUSSELL and
Stephen D. STROUPE

Serial No.: unassigned

Filed: on even date herewith

Title: REAGENTS AND METHODS
USEFUL FOR DETECTING DISEASES OF
THE GASTROINTESTINAL TRACT

Case No.: 6064.US.P1

Certificate of Mailing Under 37 C.F.R. §1.10

Express Mail Label No. EM 336 912 047 US

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below as Express Mail Post Office to Addressee Service addressed to:

Assistant Commissioner for Patents
BOX PATENT APPLICATION
Washington, D.C. 20231
on

MARCH 31, 1998
Date
Patricia K. Himenes
Patricia K. Himenes

DECLARATION AND POWER OF ATTORNEY FOR A UNITED STATES PATENT APPLICATION

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

As a below-named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name. I believe that I am an original and first and joint inventor of the subject matter of the invention entitled REAGENTS AND METHODS USEFUL FOR DETECTING DISEASES OF THE GASTROINTESTINAL TRACT, which is claimed and for which a patent is sought in the patent application attached hereto.

I hereby state that I have reviewed and understand the contents of the above-mentioned specification, including the claims.

I acknowledge a duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

Claim to benefit of foreign application(s):

I hereby claim foreign priority benefits under 35 U.S.C. §119 for the following foreign application(s) for patent or inventor's certificate:

NONE

The following foreign applications for patent or inventor's certificate have a filing date earlier than the filing date of the application(s) identified above:

NONE

Claim to benefit of U.S. Application(s):

I hereby claim the benefit under 35 U.S.C. §120 of the following earlier-filed United States patent application(s):

U.S. Serial No. 08/828,489 filed March 31, 1997, pending.

Insofar as the subject matter of each of the claims of this/these application(s) is not disclosed in the prior U.S. Applications in the manner required by 35 U.S.C. § 112, first paragraph, I acknowledge a duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. Which came into existence between the filing date(s) of the prior applications and the national or PCT filing date of this application.

I hereby appoint the following Attorneys and/or agents to prosecute this application and any continuation or divisional applications based hereon, and to transact all business in the Patent and Trademark Office connected therewith:

Mona Anand, Reg. No. 34,537
Regina M. Anderson, Reg. No. 35,820
Mark C. Bach, Reg. No. 34,766
Cheryl L. Becker, Reg. No. 35,441
Thomas D. Brainard, Reg. No. 32,459
Dianne Casuto, Reg. No. 40,943
Steven R. Crowley, Reg. No. 31,604
Andreas M. Danckers, Reg. No. 32,652
Michael J. Dixon, Reg. No. 32,410
Neal D. Marcus, Reg. No. 35,267
James D. McNeil, Reg. No. 26,204

Lawrence S. Pope, Reg. No. 26,791
Nicholas A. Poulos, Reg. No. 30,209
Priscilla E. Porembski, Reg. No. 33,207
Gregory W. Steele, Reg. No. 33,796
Michael J. Ward, Reg. No. 37,960
David L. Weinstein, Reg. No. 28,128
Brian L. Woodworth, Reg. No. 33,137
Frank Z. Yang, Reg. No. 35,417
Paul D. Yasger, Reg. No. 37,477
Roberta L. Robins, Reg. No. 33,208
Thomas P. McCracken, Reg. No. 38,548

Send Correspondence to:

Steven F. Weinstock
Abbott Laboratories
D-377/AP6D
100 Abbott Park Road
Abbott Park, Illinois 60064-3500

Direct telephone calls to:

Cheryl L. Becker at 847-935-1729

Name (first, middle, last): Patricia A. BILLING-MEDEL

Post Office Address: 1427 Sherwood Court, Gurnee, IL 60031

Residence: Gurnee, IL 60031

Citizenship: US

Name (first, middle, last): Maurice COHEN

Post Office Address: 2026 Deerfield Road, Highland Park, IL 60035

Residence: Highland Park, IL 60035

Citizenship: US

Name (first, middle, last): Tracey L. COLPITTS

Post Office Address: 34365 North Circle Drive, Round Lake, IL 60073

Residence: Round Lake, IL 60073

Citizenship: Canada

Name (first, middle, last): Paula N. FRIEDMAN

Post Office Address: 462 Cumnor Court, Deerfield, IL 60015

Residence: Deerfield, IL 60015

Citizenship: US

Name (first, middle, last): Julian GORDON

Post Office Address: 307 East Sheridan Road, Lake Bluff, IL 60044

Residence: Lake Bluff, IL 60044

Citizenship: US

Name (first, middle, last): Edward N. GRANADOS

Post Office Address: 19 Montgomery Lane, Vernon Hills, IL 60061

Residence: Vernon Hills, IL 60061

Citizenship: US

Name (first, middle, last): Mark HAYDEN

Post Office Address: 25059 N. Cedarwood Lane, Ingleside, IL 60041

Residence: Ingleside, IL 60041

Citizenship: US

Name (first, middle, last): Steven C. HODGES

Post Office Address: 169 Stonegate Road, Buffalo Grove, IL 60089

Residence: Buffalo Grove, IL 60089

Citizenship: US

Name (first, middle, last): Michael R. KLAS

Post Office Address: 1606 Mulberry Drive, Libertyville, IL 60048

Residence: Libertyville, IL 60048

Citizenship: US

Name (first, middle, last): Jon D. KRATOCHVIL

Post Office Address: 7101 Fifth Avenue, Kenosha, WI 53143

Residence: Kenosha, WI 53143

Citizenship: US

Name (first, middle, last): Lisa ROBERTS-RAPP

Post Office Address: 2090 Westfield Drive, Gurnee, IL 60031

Residence: Gurnee, IL 60031

Citizenship: US

Name (first, middle, last): John C. RUSSELL

Post Office Address: 8275 64th Court, Kenosha, WI 53142

Residence: Kenosha, WI 53142

Citizenship: US

Name (first, middle, last): Stephen D. STROUPE

Post Office Address: 945 Wilshire Drive, Libertyville, IL 60048

Residence: Libertyville, IL 60048

Citizenship: US

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that all statements made herein were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Patricia A. BILLING-MEDEL

Maurice COHEN

Tracey L. COLPITTS

Paula N. FRIEDMAN

Julian GORDON

Edward N. GRANADOS

Mark HAYDEN

Steven C. HODGES

Michael R. KLASS

Jon D. KRATOCHVIL

Lisa ROBERTS-RAPP

John C. RUSSELL

Stephen D. STROUPE